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1. Introduction 
1.1. Malaria: the disease and the parasite 
1.1.1. Global disease burden 
Malaria is a life-threatening infectious disease caused by protozoan parasite, Plasmodium 
falciparum (Miller et al., 2002). It is responsible for the highest amount of morbidity caused 
by any infectious disease, therefore qualifies as the most significant parasitic disease. 
According to very recent WHO (World Health Organization) statistics, malaria caused an 
estimated death of 660,000 people in 2010, majority of which are children from Africa 
(WHO, 2013) . Noteworthy, in sub Saharan Africa malaria causes death of 1-3 million people 
per year, over 75% of which are children (Breman, 2001, Snow et al., 1999). In Africa 400-
900 million children under 5 years of age living in endemic areas are the major victims of the 
disease (Breman, 2001, Miller et al., 2002). Overall, this trend raises serious concerns about 
the impact of malaria and the failure of control strategies. 
 
  !
 
 Figure 1.1 World map representing countries and territories affected by malaria, 2010. 
Orange areas represent the high risk regions affected by malaria. The zones in white represent malaria free 
areas. Territories in blue indicate the countries taking preventive measures against the reintroduction of the 
disease. Retrieved from (WHO, 2012). 
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1.1.2. Current drugs and emerging drug resistance  
 
Once detected with malaria, the individual should be immediately treated with antimalarial 
drugs within 24 hours. Delay in effective treatment can lead to the development of severe 
form of the disease causing death of the patient. 
 
Several anti-malarial drugs have been in practice so far. Methylene blue was the first 
synthetic drug with slight antimalarial activity. It could strongly inhibit the formation of 
hemozoin crystals in the food vacuole of the parasite. Combination therapy using methylene 
blue even proved to be efficacious for children below the age of five years in Africa 
(Schirmer et al., 2011). But, methylene blue can cause haemolysis in the Glucose-6-
phosphate dehydrogenase (G6PD) deficient individuals. G6PD deficiency is a disorder of the 
human erythrocyte. This mutation is prevalent among the people in the areas where malaria is 
or has been endemic (Peters and Van Noorden, 2009). For this reason, methylene blue was 
never acknowledged as a commercially available therapy for malaria and later discontinued. 
 
Quinine was also among the very first drugs developed in 17th century against malaria. This 
continued for long time as a therapy until 1940s, when chloroquine was introduced with 
lesser side effects and replaced the former (Toovey, 2004). 
 
Among the most effective and long used drugs for malaria are chloroquine and sulfadoxine-
pyrimethamine. Since its discovery in 1934, chloroquine has been extensively used in 
different parts of the world as one the most effective solution for treating uncomplicated 
malaria in patients. Choloroquine inhibits the parasites ability to form non-toxic hemozoin 
crystal from heme. As a result, the increasing accumulation of the toxic heme in the food 
vacuole causes death of the parasite (Roepe, 2009). After extensive use over a decade 
resistance against chloroquine had emerged in several parts of the world around 1980s 
(Uhlemann and Krishna, 2005). This resistance is acquired by multiple mutations in the 
PfCRT (chloroquine resistance transporter) protein that functions as a transporter on the 
parasite digestive vacuole membrane (Wellems and Plowe, 2001). The resistant parasites 
efflux chloroquine from the food vacuole and thus inhibits its function (Wellems and Plowe, 
2001, Lim et al., 1990). In many parts of the world chloroquine is no more prescribed as an 
effective antimalarial (Hempelmann, 2007).  
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Pyrimethamine–sulfadoxine combination was introduced instead of chloroquine as an 
antimalarial drug since 1993. This combination works by inhibiting the function of 
dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) in Plasmodium 
falciparum. Although this combination initially proved to be effective, resistance has already 
started growing in Southeast Asia and South America (Sibley et al., 2001). Therefore, the 
effectiveness of this combination drug is rapidly decreasing (Jelinek et al., 1999, Jelinek et 
al., 1998, Nzila et al., 2000). Point mutation in the dhfr and dhps genes of the parasite is the 
cause behind such acquired resistance (Sibley et al., 2001).  
 
The morbidity and mortality due to malaria has increased rapidly due to loss of effectiveness 
of several antimalarial drugs. In the past few years this situation has improved by the 
introduction of artemisinin - based combination therapy (ACT) (Ecker et al., 2012, Smith and 
Doerder, 1992, Kokwaro, 2009). In this therapy artemisinin is usually provided in 
combination with other antimalarials such as lumefantrine, mefloquine, amodiaquine, or 
sulfadoxine/pyrimethamine (WHO, 2012). Other possible combination is usually piperaquine 
and dihydroartemisinin (Keating, 2012, WHO, 2012). Currently, this therapeutic approach is 
the most effective way of treating uncomplicated P. falciparum malaria. ACT inhibits the 
development of resistance to any single drug component in the given combination (Kokwaro, 
2009). In spite of this, there are several reports indicating emerging drug resistance or loss of 
effectiveness of ACT since 2008 (Noedl et al., 2008, Dondorp et al., 2009, Phyo et al., 2012).  
 
Therefore, the constantly emerging resistance of the parasite against the previously effective 
antimalarial drugs makes the eradication of the disease highly challenging (Sachs and 
Malaney, 2002, Ridley, 2002, Goldberg, 2002, Kokwaro, 2009) and is disastrous on public 
health. Hence, development of new effective antimalarial therapy demands extensive amount 
of research attention. This will help us to have better understanding of the increasing 
resistance that in turn would facilitate the development of new efficacious antimalarial drugs.  
1.1.3. Plasmodium: the malaria parasite 
 
Although it was believed that only four different species of malaria parasites (P. falciparum, 
P. malarie, P. ovale and P. vivax) are capable of infecting human, Plasmodium knowlesi that 
was known to infect long-tailed (Macaca fascicularis) and pig-tailed (Macaca nemestrina) 
macaques is a recent addition onto the list (Sabbatani et al., 2010, Vythilingam et al., 2008, 
Ng et al., 2008, Cox-Singh and Singh, 2008). Nevertheless, Plasmodium falciparum is still 
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considered as the most virulent species causing the deadliest form of the disease known as 
‘malaria tropica’ that includes malignant malaria or cerebral malaria (Gupta et al., 1994). 
1.1.4. Life cycle of human malaria parasite 
 
Plasmodium falciparum has a complex life cycle divided into two phases: ‘sexual phase’ 
taking place in the mid-gut of its vector female anopheles mosquito followed by the ‘asexual 
phase’ that occurs in the human host. Infection with Plasmodium falciparum begins with the 
bite of an infected female Anopheles mosquito during its blood meal (Miller et al., 2002). 
Sporozoites from the salivary gland of the mosquito are released into the subcutaneous tissue 
of the infected person (rarely direct into the blood stream), from where they migrate to the 
liver hepatocytes (Miller et al., 2002). Research findings indicate that sporozoite travels 
through random hepatocytes before it reaches and invades a particular hepatocyte where it 
undergoes replication. Therefore, the silent infection phase lasts around 14 days (Mota et al., 
2001, Prudencio et al., 2011). Inside the hepatocyte the parasite divides and develops into 
tens of thousands of exo-erythrocytic merozoites (Cowman et al., 2012). Once the hepatocyte 
bursts the merozoites are released into the blood stream of the individual where each free 
living merozoite attaches and invades an erythrocyte. Inside the red blood cells (RBC) the 
merozoites rapidly grow and develop into ring stage (0-10 hours post invasion) followed by 
trophozoite stage (10-36 hours post invasion) and finally the schizont stage that consist of 12-
16 merozoites. The length of the intraerythrocytic stage varies among different species. For 
example, to complete a full life cycle P. falciparum needs 48 hours, establishing a non-
synchronous infection in the host. Similarly, P. vivax, and P. ovale also take 48 hours 
whereas P. malariae needs approximately 72 hours (Sylvie Manguin, 2008). Synchronous 
rupture of the infected erythrocyte leads to the clinical manifestation of the disease that is 
associated with fever and chills. During these febrile temperature episodes body temperature 
of the host can rise up to 41 ° C (Pavithra et al., 2004). The released merozoites invade 
additional erythrocyte where they undergo further rounds of replication. Amongst this pool of 
merozoites some escape and differentiate into sexual forms (female and male gametocytes). 
These gametocytes are further taken up by  female Anopheles mosquito during its blood meal 
from an infected individual. They mature into male and female gametes in the midgut of the 
mosquito. Following fertilization, the zygotes develop into ookinete and oocyst finally 
forming sporozoites. The sporozoites migrate to the salivary gland and continue infecting 
healthy individuals and thus, the cycle continues (Cowman et al., 2012). 
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Figure1.2  Life cycle of human malaria parasite.  
During the blood meal by the female anopheles mosquito the sporozoites are injected into the human body 
where they first migrate to the liver hepatocytes. After reaching the hepatocytes, the parasites undergo 
amplification producing tens and thousands of merozoites. The merozoites are released from the hepatocytes 
into the blood stream where they invade human RBC and undergo development into several stages, finally 
forming schizonts containing 14-16 merozoites. The RBC bursts open releasing these merozoites into the 
bloodstream that in turn infect new RBC. Some merozoites escape this cycle and develop into male and female 
gametocytes that are ingested by mosquito during consecutive blood meal from an infected individual and 
develop into gametes in the midgut. After fertilization following ookinete and oocyte formation the zygote 
develop into sporozoites that reach the salivary gland and can infect new individual. Retrieved from (NIAD, 
2012). 
1.2. Cell Biology of the Plasmodium falciparum infected 
erythrocyte 
 
Once hijacked by P. falciparum, the red blood cell undergoes profound morphological and 
structural changes that end up in altering the normal circulation and physical properties of the  
cell (Maier et al., 2009). The human RBC loses nucleus, mitochondria, ribosome, 
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endoplasmic reticulum (ER), and Golgi apparatus. Therefore, is completely devoid of protein 
synthesis and trafficking (Blanc et al., 2005). But surprisingly, in the RBC the parasite carries 
out different functions including replication, acquisition of nutrients, protein trafficking, and 
evasion of the host immune response (Pasini et al., 2013, Przyborski and Lanzer, 2005). In 
the intraerythrocytic stage the parasite resides inside a vacuole termed as ‘Parasitophorous 
Vacuole’ or PV. The formation of  PV is initiated by the parasite during invasion (Lingelbach 
and Joiner, 1998). The Parasitophorous Vacuolar Membrane (PVM) works as a novel 
semipermeable membrane between the erythrocyte cytoplasm and the parasite through which 
ion exchange and nutrient acquisition take place (Ansorge et al., 1996, Joiner, 1991). 
Plasmodium actively transports a range of proteins through this vacuole and beyond the PVM 
into the host RBC and vice versa (Haldar et al., 2005, Lingelbach and Przyborski, 2006). For 
example, P. falciparum exports Erythrocyte Membrane Protein-1 (PfEMP-1), a major key 
virulence protein to the surface of the infected RBC. PfEMP1 facilitates the adhesion of the 
parasite to the vessel endothelium thereby avoiding splenic clearance (McMillan et al., 2013, 
Cowman et al., 2012). These modifications of the human RBC largely contribute to the 
severe complications of Plasmodium falciparum malaria that includes fever, anaemia and in 
most severe cases coma, resulting in death of the patient (Cowman et al., 2012, Miller et al., 
2002). The proteins destined for the RBC contain a highly conserved pentameric transport 
sequence known as host targeting signal (HT) or plasmodium export element (PEXEL) 
(Ansorge et al., 1996, Marti et al., 2005, Baumeister et al., 2001, Hiller et al., 2004). 
Although protein transport is actively mediated by the parasite, it is not quite clear how in a 
molecular mechanistic level the proteins are trafficked through the PV into the RBC. 
Previously, it was believed that there is an establishment of a close contact between the 
parasite plasma membrane (PPM) and PVM that together function as a bilayer. Proteins 
destined for the RBC follows a classical secretory pathway involving vesicular transport for 
their membrane passage (Elmendorf and Haldar, 1993, Gormley et al., 1992). In contrary, 
recent research in this field proposes a ‘two-step model’ of secretion. According to this 
model, proteins emerging from ER as vesicle are first released into the lumen of PV from 
where they are transported across the PVM possibly by the involvement of protein 
conducting channels. This model to be functional requires the presence of chaperone in the 
PV and also in the host erythrocyte. The chaperone present in the PV lumen would unfold the 
protein and hold them in a ‘translocation competent state’ to pass through the possible 
translocon. On the other hand, the chaperone present in the RBC would further facilitate 
proper folding of this protein into their native functional forms (Ansorge et al., 1996). In 
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agreement with this hypothesis, using a model protein it was experimentally shown that 
proteins trafficked to the host cytoplasm are indeed first unfolded in the lumen of the PV and 
then translocated through the PVM into the RBC. Therefore, it justifies an important role of 
chaperones involved in trafficking (Gehde et al., 2009).  
 
Interestingly, Plasmodium genome encodes a significant amount of Hsps (Sargeant et al., 
2006). By a previous approach around 27 vacuolar proteins were identified, among which 34 
% were mostly chaperones (Nyalwidhe and Lingelbach, 2006). To date parasite encoded 
several Hsp40 co-chaperones have been reported to be present in the RBC (Rug and Maier, 
2011) but evidence of the presence of Hsp70 homologue was lacking. Recently, an Hsp70 
homologue known as PfHsp70-x was found to localise in the PV and RBC (Kulzer et al., 
2012). In addition, several other heat shock proteins are constitutively expressed and found 
be localized in the parasite cytoplasm, possibly involved in housekeeping. These facts 
indicate the presence of diverse chaperone machinery facilitating an evolutionary adaptation 
for better intracellular parasitism (Nyalwidhe et al., 2003). Further research is required to 
investigate the essential function of these chaperones for intraerythrocytic survival of 
Plasmodium falciparum. 
1.3. Molecular Chaperone as Heat shock proteins: the 
protein folding catalyst of the cell 
 
Protein folding in the cell is a very important biological process by which nascent 
polypeptide chain emerging from ribosome obtains its three dimensional native functional 
conformation (Alberts Bruce, 2007). The dogma known as ‘Anfinsen Dogma’ was put 
forward suggesting that the native structure of the protein is determined by its amino acid 
sequences (Anfinsen, 1972). In normal condition, spontaneous folding of protein occurs if the 
energy status and the size of the protein favour the folding (Dinner et al., 2000).  
 
But, highly crowded cellular environment and other stress often impose challenge to the 
normal protein folding process. These stress factors include heat shock (hot or cold), free 
oxygen radicals, hyperthermia, pH shift, degrading enzymes, heavy metals, ethanol, and 
clinically adverse situations like reperfusion or ischemia. Stress causing malfunction of the 
protein folding machinery results in the accumulation of toxic protein aggregates in the cell. 
These aggregates are associated with numerous diseases states like Alzheimer's disease, 
Cystic Fibrosis etc (Ellis, 2001, Luheshi et al., 2008, Dobson, 2003). To overcome these 
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obstacles cells appoint a diverse network of highly specialised group of chaperones named as 
‘Heat shock proteins’ (Hsps) (Hartl et al., 2011). This family of proteins was first noticed by 
Ritossa (1962). He observed that the introduction of heat shock resulted in an enlargement of 
special segment of Drosophila chromosome (heat shock puffs) and rapid synthesis of a new 
set of RNA. Indeed this was one of the biggest observations of the effect of environmental 
changes on gene expression (Ritossa, 1996, Ritossa, 1962) This observation eventually led to 
the discovery of Hsps much later in 1974 (Schlesinger, 1990, Tissieres et al., 1974). Hsp 
coding genes are highly conserved from yeast to human (Schlesinger, 1990). Hsps inhibit the 
formation of protein aggregates and facilitate protein folding into their native state.  
 
Proteins are highly dynamic in nature therefore the involvement of Hsp is crucial to maintain 
protein homeostasis of the cell (Hartl et al., 2011, Ellis, 2001, Smith et al., 1998, Feldman 
and Frydman, 2000). This involves a specialized machinery that determines the concentration 
of unfolded protein accumulated in cytosol or different cellular locations including 
extracytoplasmic compartments (McMillan et al., 1994). The concentration of unfolded 
proteins in these compartments induces Hsp expression (Parsell and Sauer, 1989). Cells 
recruit diverse range of heat shock proteins of different sizes. The small Hsps first get 
involved by shielding the hydrophobic region of the protein and prevent them from 
aggregation and degradation (Yon, 2001). Whereas, large Hsps or Hsp complexes comes into 
play at a later stage and capture the misfolded proteins in a cavity. This provides the protein 
an isolated environment allowing their unfolding and further correct folding into native 
functional structures (White et al., 2012, Ranford et al., 2000). There exists a highly 
orchestrated cross talk between different Hsps and various components of the cell signalling 
pathways that altogether controls the normal development and proliferation of a cell (Nollen 
and Morimoto, 2002). 
1.4. Common classes of Heat shock proteins (Hsps) 
1.4.1. Hsp 100 
In eukaryotic organisms Hsp100 group of molecular chaperones are known for their distinct 
property to reactivate proteins during stress by resolubilizing the aggregates (Zolkiewski et 
al., 2012). In E. coli, Hsp100 is known as ‘Caseinolytic peptidase B’ protein (ClpB) (Squires 
et al., 1991). In a cell, Hsp100s are detected with basal ATPase activity that is triggered by 
the induction of protein substrate delivered by co-chaperone Hsp70 (DnaK in prokaryotic 
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organisms) during cellular stress (Zeymer et al., 2013, Bosl et al., 2006, Goloubinoff et al., 
1999).  
ClpB functions via a highly specialised mechanism. Two models of action have been 
proposed so far. According to the first model, ClpB6 directly interacts with the protein 
aggregates (Barnett et al., 2005, Bosl et al., 2006). Exchange of nucleotides by nucleotide 
exchange factor (NEF) provides the necessary energy upon hydrolysis of ATP to ADP. 
Energy mediated conformational change in the structure of the ClpB6 ring results in the 
shearing of protein aggregates making its hydrophobic region highly exposed (fig 1.3) (Bosl 
et al., 2006). 
 
!!!!!!!!!!!!!!!!  
 
Figure1.3 Model of action of ClpB in collaboration with DnaK-DnaJ-GrpE  
ClpB recognises and binds to protein aggregates. Hydrolysis of ATP to ADP provides the required energy for 
the structural change of the ClpB6 complex. This results in the exposure of new hydrophobic sites in ClpB-
bound aggregates. Finally, DnaK-DnaJ-GrpE binds to the aggregates containing exposed hydrophobic domains. 
DnaK-DnaJ-GrpE mediated disaggregation of the aggregates, unfold and refold them into native functional 
forms. Adapted from (Goloubinoff et al., 1999). 
1 Introduction                    10    
! !
The other model either functions by ‘crowbar and ratchet’ mechanisms or by ‘threading 
mechanism’. According to the first mechanism, hydrolysis of ATP exerts a mechanical force 
on the bound protein aggregate resulting in their disruption (fig 1.4a) (Glover and Tkach, 
2001), (Bosl et al., 2006). Whereas, the later claims energy dependent extraction of 
individual polypeptide chains from the protein aggregates following passage through the pore 
of the chaperone central channel of the hexamer (fig 1.4b) (Lum et al., 2004, Bosl et al., 
2006).  
                 
 
                             
Figure 1.4 Model of Hsp100/ ClpB complex mediated disaggregation of protein aggregates.  
(a) In the ‘crowbar and rachet’ model disaggregation is mediated by the mechanical force on the aggregate 
induced by the conformational movement of the ClpB complex. (b) In the ‘threading mechanism’ first 
individual polypeptides are extracted from the aggregates, which are further released through the central axial 
pore of the chaperone hexamer. Modified from (Bosl et al., 2006). 
 
In both of these models released polypeptides are recognised by DnaK mediated chaperone 
machinery (DnaK-DnaJ-GrpE) by the exposed hydrophobic region on the polypeptides. 
DnaK system, further folds the polypeptides into their native states (Bosl et al., 2006, 
Goloubinoff et al., 1999) (fig.1.3). 
1.4.2. Hsp90 
 
Hsp90 is an important group of chaperone, highly conserved across all organisms and counts 
towards 1-2 % cellular proteins (Csermely et al., 1998). In eukaryotes it is found in cytosol, 
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nucleus and other organelles. Hsp90 is involved in many processes important for guarding 
imbalance in cell homeostasis during stress (Kaplan and Li, 2012, Dezwaan and Freeman, 
2008, Taipale et al., 2010). In addition, Hsp90 mediates many fundamental cellular processes 
including hormone signalling, cell survival, and cell cycle control (Wandinger et al., 2008, 
Zhao et al., 2005, Borkovich et al., 1989, Richter et al., 2010, Young et al., 2001). Most 
importantly many oncogenic proteins are client of Hsp90 qualifying it as a potential drug 
target (Mahalingam et al., 2009, Audisio et al., 2010). 
 
Hsp90 contains ~ 25 kD N-terminal ATP binding domain (NTD), a ~ 40 kD middle domain 
(MD) followed by a ~ 12 kD C-terminal domain (CTD),  responsible     for the 
dimerization of the protein. The C-terminal domain has MEEVD motif that facilitates co-
chaperone recruitment (fig 1.5) (Pearl and Prodromou, 2000, Scheufler et al., 2000, 
Prodromou et al., 1999, Chen et al., 1998, Ali et al., 2006). 
!!!!!!!!!! !  ! !
Figure1.5 Structure of Hsp90. 
(a) Schematic representation of the domain organisation of Hsp90, showing N-terminal domain (NTD), middle 
domain (MD) and C-terminal domain (CTD). (b) Crystallographic structure of Hsp90 dimer. Bound ATP 
molecules are depicted by space filling spheres. Adapted from (Ali et al., 2006) !
Hsp90 functions in collaboration with other co-chaperones like Hsp70 and Hsp70-Hsp90 
organising protein (HOP) to form large multi-chaperone complex (Wiech et al., 1993, Smith, !
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1993, Pratt and Toft, 2003). The chaperone cycle of Hsp90 progresses through three complex 
formations involving co-chaperones and substrates (Smith, 1993). The early complex is 
formed by the recognition and binding of Hsp70/Hsp40 to the substrate protein (Smith et al., 
1992, Hernandez et al., 2002, Cintron and Toft, 2006, Li et al., 2012). The cycle progresses 
with the dissociation of Hsp40 and the association of Hsp70 facilitated by adaptor co-
chaperone HOP leading to the formation of ‘intermediate complex’ where the client protein is 
transferred from Hsp70 to Hsp90 via HOP/Sti1. P23/Sba1 stabilizes the closed complex 
resulting in the dissociation of HOP and Sti1 (Smith, 1993, Chen and Smith, 1998, Johnson et 
al., 1998, Wegele et al., 2006). The final complex in the cycle is known as ‘late complex’ 
where! another peptidylprolyl isomerase (PPIase) associates with Hsp90, p23 and Sba1. 
During this complex formation Hsp90 adapts an ATPase active close conformation allowing 
client protein a chance to refold (Pratt and Toft, 2003, Johnson et al., 1994, Johnson and Toft, 
1995, McLaughlin et al., 2006, Forafonov et al., 2008). At the end of the cycle with the 
hydrolysis of ATP to ADP, p23, Sba1 and client proteins are released from the complex (Li 
et al., 2012). !
!!!!!!!!!!!!!!!!!! !! ! !
Figure1.6  Schematic representation of Hsp90 chaperone cycle.  
The cycle progresses through the formations of several intermediate stages. ‘Early complex’ formation is 
mediated by the association of the progesterone receptor (PR) and Hsp70/40 that in turn interacts with client 
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protein. In the ‘intermediate complex’ the substrate is transferred to Hsp90 via the involvement of the adaptor 
protein HOP/Sti1. As the cycle progresses HOP, Hsp70 dissociates following the stabilization of the complex by 
p23/Sba1. In the ‘late complex’ Hsp90 adapts a closed conformation bound to the p23, capturing the client 
protein inside. Hydrolysis of ATP to ADP occurs following the release of p23/Sba1 at the end of the cycle (Li et 
al., 2012).  
 
1.4.3. Hsp60 
 
Hsp60 is one of the most abundant eukaryotic proteins involved in the folding and assembly 
of a specific group of proteins in the cell (Johnson et al., 1989). This group of protein plays 
essential role during stress by their involvement in folding of ~15-30% cellular proteins 
(Johnson et al., 1989). Apart from its chaperone activity, Hsp60 also plays an important role 
in the transport and maintenance of mitochondrial DNA (Itoh et al., 2002). In eukaryotes it is 
known as eukaryotic t-complex polypeptide-1 (TCP1 complex). TCP1 complex binds to short 
nascent polypeptides, among which cytosolic protein actin and tubulin are the distinct ones 
(McCallum et al., 2000, Melki et al., 1997). In bacteria, Hsp60 homologue is called as 
‘GroES’ (Viitanen et al., 1990). Structure and function of this group of Hsp is highly 
conserved from human to bacteria (Johnson et al., 1989).  
 
Mode of action of Hsp60 has been much studied and explained in light of GroES. GroES 
mediated protein folding involves the participation of GroEL to form a multi-chaperone 
complex to fold large polypeptides (Viitanen et al., 1990). This complex is a double ring 
structure containing 14 subunits forming a large central cavity that accommodates unfolded 
protein via hydrophobic interaction. Protein folding in the cavity of GroEL is in agreement 
with the “Anfinsen cage” hypothesis that explains the folding of protein in an isolated 
cellular environment (Ellis, 1994). 
 
Each GroEL subunits have three domains: an apical domain; accommodating GroES and 
substrates, an equatorial domain; providing the ATP binding site and contacts for ring 
binding, and an intermediate domain; connecting the two rings (Ranson et al., 1998).  
 
Recently, a ‘two timer’ model was proposed towards the action of GroEL/GroES chaperone 
complex (Ueno et al., 2004). According to this model, the GroEL-substrate protein complex 
binds ATP and GroES to form the cis-ATP* complex. In this initial complex the substrate is 
caged, but the folding is still in an arrested stage. The cis-ATP* complex is further converted 
to the cis-ATP complex. Following this transition several events take place. Firstly, the 
substrate is converted to a folding competent state. The hydrolysis of ATP to ADP releases 
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phosphate (Pi). Folding of substrate polypeptide continues to the cis-ADP* complex. The cis-
ADP* complex is further transformed to the cis-ADP complex. The transition of cis-ADP* to 
cis-ADP takes the longest time in the cycle allowing folding of protein substrate in the cavity. 
The newly formed cis-ADP complex can accommodate new substrate and ATP to its 
trans ring. Binding of new substrate to the trans ring of the GroEL leads to the release of 
folded native protein from the cis ring along with the dissociation of GroES and ADP from 
the complex (fig 1.7) (Rye et al., 1999, Ueno et al., 2004).  
 
 
Figure 1.7  Two-timer model of GroEL/GroES chaperone cycle.  
Two-timer model represents two rate-limiting steps, shown by arrows (colored red and blue). GroES (blue filled 
triangle) binds to the GroEL-substrate protein-ATP complex forming the cis-ATP* complex. Transition of 
the cis-ATP* complex to the cis-ATP complex is followed by the release of the substrate in the cavity and the 
initiation of protein folding. ATP hydrolysis converts cis-ATP to cis-ADP* complex. Protein folding occurs 
between cis-ATP and cis-ADP complex. Upon transition from cis-ADP* to the cis-ADP complex and 
attachment of ATP and substrate to the trans GroEL ring leads to the release of the folded native protein. 
Modified from (Ueno et al., 2004).  
 
1.4.4. Hsp40 
 
Hsp40 is one of the large protein families in the cell that function as co-chaperones of Hsp70 
for protein folding during normal and stress conditions. Hsp40 (DnaJ in prokaryotes) is 
defined by highly conserved J domain (Laufen et al., 1999, Kakkar et al., 2012) and are 
classified in four major types depending on the domain organizations (fig 1.8) (Cheetham and 
Caplan, 1998, Rug and Maier, 2011). These include: type I, II, III and IV. Type I Hsp40 is 
identical in domain structure with that of DnaJ. It contains a signature J domain with its 
highly conserved HPD motif (~70 amino acids), followed by glycin-phenylalanine (GF) rich 
region, cysteine rich region (CRR) and C-terminal domain. Type II Hsp40 is similar in 
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domain structure when compared to type I, with only exception of CRR being absent. The 
type III and IV both contains the J domain but varies in the length and position of the HPD 
motif  (fig 1.8) (Rug and Maier, 2011). 
 
 
 
Figure 1.8  Schematic representation of the domain organisations of different types of Hsp40.  
Type I DnaJ contains the signature J-domain with a conserved HPD motif (70 amino acids).  The 
glycine/phenylalanine-rich region (GF-rich) (∼30 amino acids) is present followed by the J domain. The 
cysteine-rich region forms a zinc finger domain. At the C-terminus it contains a less conserved substrate-binding 
domain (SBD) (∼120–170 amino acids). The type II DnaJ molecules are structurally and functionally similar to 
the type I with only cysteine-rich region being absent. Type III DnaJ contains the J domain and it can be present 
anywhere on the protein molecule. Like Type III, Type IV DnaJ molecules contain the J-domain but with 
variations in the HPD motif. Possible cellular functions for the individual domains and DnaJs are mentioned. 
Modified from (Rug and Maier, 2011). 
 
As mentioned earlier Hsp40 functions as a co-chaperone of Hsp70 and facilitates complex 
formation between Hsp70 and the client proteins. Both the type I and II Hsp40s come under 
this group. Hsp40 establishes an electrostatic interaction by forming an interface between the 
J domain and ATPase domain of Hsp70, thereby accelerating the ATPase activity of the later 
(Greene et al., 1998). This is an important rate limiting step leading to the stabilization of 
Hsp70-client protein complex (Fan et al., 2003, McCarty et al., 1995, Sterrenberg et al., 
2011). The Hsp40/Hsp70 chaperone partnership is governed by ATP expanding cycles 
(Njunge et al., 2013) involving several steps (fig 1.10) (Liberek et al., 1991, Cyr et al., 1992, 
Langer et al., 1992). It is documented that Hsp40 also acts as a co-chaperone of Hsp90 
chaperone machinery and are also independently involved in many cellular processes (Tarcsa 
and Fesus, 1990) including inhibition of protein aggregation under stress (Schroder et al., 
1993). Recently, it has been shown that Hsp40 has a potential therapeutic role in the 
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prevention of polyglutamine (polyQ) diseases such as Huntington's disease (HD) (Popiel et 
al., 2012). 
 
The number of different types of Hsp40 in a cell is much higher than that of its chaperone 
partner Hsp70 (Ohtsuka and Hata, 2000). Further it has been hypothesised that Hsp70 is 
capable of interacting with variety of Hsp40s. Therefore, Hsp70 can establish a diversified 
functional partnership with different types of Hsp40 to carry out functions including protein 
folding, trafficking, and post translational membrane integration (Kampinga and Craig, 2010, 
Hegde and Keenan, 2011, Kulzer et al., 2012).  
1.4.5. Small heat shock proteins 
 
Small heat shock proteins (sHsps) are characterised by their relatively small size between 16-
30 kDa and the presence of the α-crystallin domain at the C-terminus (Shemetov et al., 2008). 
They are predominantly found in placenta, skeletal, heart, spleen and smooth muscles (Kappe 
et al., 2001) and form oligomeric complexes within the cell (van de Klundert et al., 1998). 
Small heat shock proteins might be involved in combating the stress produced in muscle 
tissues (Sugiyama et al., 2000). sHsps functions as molecular co-chaperone facilitating 
folding of client protein by larger chaperone like Hsp90 (Jakob et al., 1993, Chua et al., 
2010). Malfunction of sHsps, result in various diseases like neuromuscular disease, 
congenital disease etc (Shemetov et al., 2008, Datskevich et al., 2012).  
1.4.6. Hsp70 
 
Heat shock protein 70, also known as Hsp70 is highly essential molecular chaperones and 
folding catalyst in a cell. They are involved in a large variety of protein folding machinery. 
This is facilitated by the transient interaction of the Hsp70 with the substrate coupled with 
ATPase activity (Mayer and Bukau, 2005). 
 
Hsp70 has a molar mass of approximately 70kDa and represents ubiquitously expressed heat 
shock protein family, highly conserved among all living organisms. Some Hsp70s are 
constitutively expressed in the cell and are important for the housekeeping protein folding 
machinery whereas others come into play during cellular stress (Tavaria et al., 1996, Morano, 
2007, Silver and Noble, 2012). Hsp70s are found to be present in different cellular 
compartments to carry out some specific functions. Depending on the function and 
compartmentalisation, Hsp70s are classified into four subfamilies: cytosol, endoplasmic 
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reticulum, mitochondria, and chloroplast (Krenek et al., 2013). Several homologues of Hsp70 
proteins can be present in a cell that enable them to carry out a large variety of functions like, 
folding of nascent polypeptide chain, degradation, inhibit proteins from forming aggregates, 
intracellular signalling, and facilitating protein transport through membranes (da Silva and 
Borges, 2011). Prokaryotic version of Hsp70 is called DnaK. DnaK is expressed in the cell 
constitutively and also during stress periods (VanBogelen et al., 1997).  
 
E. coli without DnaK function are sensitive to heat stress and as a result are associated with a 
variety of physiological defects: defective chromosomal segregation, temperature sensitivity, 
poor maintenance of plasmid, and defects in cellular metabolism (Paek and Walker, 1987, 
Kusukawa and Yura, 1988, Bukau and Walker, 1989). In E. coli, chaperone function of 
DnaK occurs in collaboration with co-chaperones such as, DnaJ (prokaryotic counterpart of 
Hsp40), GrpE (nucleotide exchange factor for DnaK) (Georgopoulos and Welch, 1993, 
Straus et al., 1990). Interestingly, DnaK and DnaJ function as modulators of heat shock 
response in the cell in association with the transcription activator sigma32 subunit of RNA 
polymerase. Small increase or decrease in the level of DnaK/DnaJ controls the switch on and 
off of the heat shock response via the controlled activity of the sigma32. Therefore, 
DnaK/DnaJ functions as primary sensors in the cell detecting protein misfolding (Tomoyasu 
et al., 1998).  
1.4.6.1. Domain organisation of Hsp70 
 
As mentioned earlier, despite of their diverse function in the cell, Hsp70 molecular 
chaperones have highly conserved amino acid sequence and domain organisation (Strub et 
al., 2002, Bukau and Horwich, 1998).  Hsp70 consists of three domains:   
 
N-terminal ATPase domain: The 45 kDa ATPase domain located at the N-terminus is 
responsible for the ATPase activity of Hsp70. ATP binds to this domain and the hydrolysis of 
ATP to ADP is promoted by nucleotide exchange factor (NEF). This results in important 
conformational changes that in turn get transferred to the substrate binding domain (SBD) 
which finally determines the binding or release of the substrate from Hsp70 (fig 1.9a  and  
fig 1.9b) (McCarty et al., 1995, Strub et al., 2002, Bukau and Horwich, 1998). 
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Linker region: A highly conserved linker region is present following the ATPase domain 
that functions as a hinge between the ATPase domain and the substrate binding domain. The 
linker region facilitates inter-domain movement (fig 1.9a) (Strub et al., 2002). 
 
Substrate binding domain (SBD): Hsp70 has a 25kDa substrate binding domain for the 
interaction of client proteins. This domain provides the groove with the affinity of neutral or 
hydrophobic amino acids to accommodate client proteins. The SBD is further sub divided 
into a 15kDa β-sandwich subdomain and a C-terminal α-helical subdomain (Mayer and 
Bukau, 2005). The C-terminal α-helices serve as a “lid” for the substrate binding domain. In 
an ATP bound state, the “lid” is open and allows the binding of substrates to the SBD 
whereas, in the ADP bound state the “lid” is tightly closed capturing the substrate in the 
groove (fig 1.9a and 1.9c). 
                                                                               
  
 
!!!!!!!!!!!!!  
Figure 1.9  Domain organisation of Hsp70.  
(a) Schematic representation of the domain organisation of E.coli DnaK. The ATPase domain present on the N-
terminal end of the Hsp70 is connected to the substrate binding domain via the highly conserved linker region. 
The C-terminal substrate binding domain is further divided into helical subdomains (A-E). These subdomains 
form the β sandwich and lid segment. (b) ATPase domain of bovine Hsc70. Schematic representation of the 
secondary structure of the ATPase domain. Hsc70 in associated with inorganic phosphate, two potassium ions 
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and ADP. (c) Schematic representation of the model of substrate binding domain. Substrate binding domain of 
E. coli DnaK is associated with the client protein substrate at the hydrophobic core. H-bonds forming “latch” 
and salt bridge along with the presence of “lid” structure are indicated. (b) and (c) adapted from (Mayer and 
Bukau, 2005). 
1.4.6.2. Hsp70 chaperone cycle: an overview   
 
The Hsp70 multistep chaperone cycle involves co-chaperone Hsp40 and NEF. The steps are 
as follows: 1) The Hsp70 chaperone cycle starts with the transient interaction of client protein 
with Hsp40 by their exposed hydrophobic patches. The efficiency of Hsp40 to enhance 
ATPase activity of Hsp70 is induced by the establishment of such interactions (Kelley, 1998, 
Kelley, 1999). In certain occasion the cycle can begin with the direct interaction of Hsp70-
ATP complex with the substrate. 2) In the next step, the substrate is transferred from Hsp40 
to Hsp70. This process requires two steps, the first step is characterised by the transient 
interaction of the Hsp70-ATP complex with the J domain of the Hsp40 via the highly 
conserved HPD motif. The second step involves the subsequent transfer of the substrate from 
the Hsp40-substrate complex to the open substrate binding pocket of the Hsp70-ATP 
complex. These steps are needed to couple the ATPase activity of Hsp70 with substrate 
binding, therefore stabilizing the Hsp70-substrate complex. During substrate bound forms, 
Hsp40 accelerates the ATPase activity of Hsp70 thus inhibiting ATP hydrolysis on the free 
form of Hsp70. 3) Once the substrate is transferred to the Hsp70 and the ATP is hydrolysed 
to ADP, the affinity of Hsp70 for Hsp40 co-chaperone reduces due to the reduction in 
electrostatic interaction. As a result, Hsp40 dissociates from the complex. This indicates that 
Hsp40 works as a catalyst to transfer the client protein to Hsp70. Hydrolysis of ATP-ADP 
results in a conformational change in the ATPase domain of the Hsp70 that get transduced to 
the substrate binding domain. The ‘lid’ of the substrate binding domain obtains a ‘close 
conformation’ and tightly entraps the substrate into the cavity. 4) The cycle ends by the 
replacement of ADP with ATP by the NEF. ATP bound form of Hsp70 has high exchange 
rate and low affinity for substrate. As a result the substrate dissociates from the complex and 
the Hsp70 obtains ‘open conformation’. This is the initial state where it is bound to ATP and 
can further accommodate new client proteins to start another cycle (Bukau and Horwich, 
1998, Richter et al., 2010, Theyssen et al., 1996, Karzai and McMacken, 1996). 
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Figure1.10  Schematic representation of Hsp70 chaperone cycle.  
The Hsp70 chaperone cycle involves the participation of Hsp70 and its co-chaperone Hsp40 and the NEF. 
Hsp40 interacts with client protein via its exposed hydrophobic residues. Hsp40 further establishes a transient 
interaction with Hsp70 via its highly conserved HPD motif on the J domain. After establishment of the 
electrostatic interaction Hsp40 delivers the substrate to Hsp70 and induces the ATPase activity of Hsp70 
resulting in the stabilization of the Hsp70-substrate complex. The NEF replaces ADP with ATP and thus, the 
ADP, Hsp40, and the substrate dissociates from the complex. Hsp70 returns to its ATP bound initial stage and 
can accommodate new substrate. Adapted from (Richter et al., 2010). 
1.4.6.3. Hsp70: the central player  
 
Hsp70 plays an important role as a central chaperone to maintain the protein homeostasis of 
the cell during normal physiological condition and under stress. Hsp70 carry out its 
biological functions in the cell either independently or in association with other co-
chaperones (Mayer and Bukau, 1998, Borges and Ramos, 2005).  
 
Recently, by a quantitative proteomic approach it was demonstrated that DnaK interacts with 
~ 700 cytosolic protein, among which ~180 are aggregation prone and requires DnaK for its 
proper folding (Calloni et al., 2012). In E. coli, DnaK functions in collaboration with other 
partners like DnaJ, GrpE, GroEl/GroES. The fact is well evidenced that DnaK can bind to 
protein aggregates and can facilitate their correct folding into the native form in collaboration 
1 Introduction                    21    
! !
with DnaJ/GrpE. But, in addition it has been documented that DnaK can efficiently fulfil its 
function only if the aggregates are formed early and are relatively smaller in size. For much 
bigger aggregates either the binding site of the DnaK system needs to be highly exposed or it 
involves the catalytic activity of ClpB (Hsp100 homologue in bacteria) and ATP (Diamant et 
al., 2000). Therefore, the association of DnaK and ClpB machinery helps in disaggregating 
protein aggregates and their further folding in native forms (Rosenzweig et al., 2013). ClpB 
and DnaK chaperone system and the ratio between their cellular levels have an important role 
in inhibiting protein aggregates during heat shock (Kedzierska and Matuszewska, 2001). 
 
In the eukaryotic system the client proteins are passed from Hsp40 to Hsp70. Hsp40 as 
discussed earlier (section 1.4.6.2), also helps in the accelerating the ATPase activity of 
Hsp70, a step that is crucially important for the chaperone activity of Hsp70 (Bukau and 
Horwich, 1998). Despite of the fact that Hsp70 and Hsp90 can function independently in the 
cell, the transfer of client protein from Hsp70 to the Hsp 90 has been well studied. The 
functional interaction between Hsp70 and Hsp90 is mediated via HOP. Therefore, HOP 
works as an adaptor molecule bridging the gap between Hsp70 and Hsp90 (Smith et al., 
1993, Li et al., 2012). Once the substrate is transferred to Hsp90, Hsp70, Hsp40, and HOP 
dissociate from the chaperone complex and further folding of the client protein takes place 
via the participation of Hsp90 and p23 (fig 1.6) (Morishima et al., 2003). 
 
Therefore, it can be concluded that in both prokaryotic and eukaryotic systems the 
involvement of Hsp70/DnaK is crucial to establish functional link between individual 
chaperone pathways. Hsp70 plays an intersecting role by receiving substrate from one co-
chaperone partner (Hsp40/DnaJ) and delivering it to the other co-chaperone for the final 
folding (Hsp90/ClpB) (Richter et al., 2010).   
1.4.7. Heat Shock proteins in health and disease  
 
The fact whether heat shock proteins are the potential therapeutic agent or targets for 
potential drugs in several pathogenic diseases remains highly controversial (Pockley, 2001). 
Significant amount of study is being undertaken to understand involvement of heat shock 
proteins in disease development or prevention.  
 
In recent years, Hsps are highly acknowledged as therapeutic candidate and their induction 
show significant promise against several diseases. For instance, the role of heat shock 
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proteins in the pathogenesis of neurogenerative disorders is being extensively studied. 
Several such disorders like Alzheimer’s disease, Parkinson’s disease and Huntington’s 
disease etc, are the outcomes of Hsp dysfunction. It has been documented that the 
overexpression of several heat shock proteins including Hsp70 provided protection in model 
organism against such diseases (Mayer et al., 1991). Age related neurogenerative disorders 
known as ‘proteinopathies’ leads to the deposition of protein in several tissues. Since, 
deposition is an outcome of protein unfolding or misfolding in the event of stress, the 
involvement of heat shock protein is becoming more prominent and qualifies them as 
potential therapeutic candidates (Macario and Conway de Macario, 2000). Another example 
is ‘Vitiligo’. It is an autoimmune disorder causing the destruction of melanocytes, leading to 
progressive depigmentation. In a recent study using mouse model it has been shown that the 
delivery of iHsp70, a modified head inducible Hsp70 could attribute to significant inhibition 
of depigmentation (Mosenson et al., 2013). Aging is also related to the loss of Hsp function, 
and induction of Hsp70 proved to be effective in increasing life expectancy in model 
organisms like yeast or Drosophila (Tatar et al., 1997). Induction of Hsp70 leads to the 
efficient recovery from a large number of other cases including diabetes and ischemic heart 
disease (Soti et al., 2005).  
 
In contrast to all these facts, Hsps are also exploited for development of several types of 
cancers, where the inhibition of their function is necessary for therapy. Besides the protein 
folding role, heat shock proteins are largely involved in protein trafficking and regulation of 
transcription. Crucial cytoprotective role of heat shock proteins makes them essential for the 
survival of cancer cells. Androgen receptor (AR), a transcription factor has a significant 
contribution towards the development of several cancers, most importantly prostate cancer. 
ARs are found to be associated with several Hsps and are upregulated during cancers 
(Hessenkemper and Baniahmad, 2013). For instance, Hsp90 plays an important role in signal 
transduction via its interaction with several transcription factors and protein kinases 
(Rutherford and Zuker, 1994). Hsp90 maintains AR at a high affinity conformation and the 
loss of function of the former in the cell renders AR less active (Fang et al., 1996). Therefore, 
many emerging drugs against prostate cancer target Hsp90 and AR associated Hsps 
(Hessenkemper and Baniahmad, 2013). Several other Hsps like Hsp70 and Hsp27 are present 
at very high levels in cancer cells and further increased by cancer chemotherapy. It has been 
postulated that these group of Hsps are involved in the development of cancer and confer 
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protection to cancer cells against chemotherapy. Therefore, inhibition of these Hsps has also 
emerged as a novel anticancer therapy (Garrido et al., 2006). 
 
Additionally, Hsps are often exploited during the onset of pathogenesis caused by invading 
microorganisms. Molecular chaperones are often used by several disease causing bacteria for 
their adaptation in the host. Many of these expose Hsps on their cell surface that induces a 
huge immune response during several diseases like leprosy, tuberculosis, Chagas’s disease, 
legionnaire’s disease, chlamydial infections, lyme disease, and Q fever. Unfortunately, in 
many occasions due to the high level of conservation between Hsps from host and bacterial 
origin, cells develop autoimmunity causing diseases like rheumatoid arthritis, lupus 
erythematodes, multiple sclerosis, diabetes etc (Lamb et al., 1989, Pockley, 2002). Several 
pathogens produce heat shock proteins during the invasion of host cells that have become 
targets for drug and vaccine development (Newport, 1991). The role of heat shock proteins in 
the development of infection and parasitic diseases is being highly scrutinised (Macario, 
1995). Parasite exploits a range of heat shock protein for better adaptation and infectivity 
within the host cell. They produce Hsps in response to stress and exploit them for various 
purposes ranging from adaptation, differentiation and protein trafficking to establish 
pathogenicity (Silva et al., 1998). For example, apicomplexan parasite Toxoplasma gondii 
expresses Hsp70 for the development of bradyzoites to tachyzoites. Hsp70 as a vaccine was 
shown to protect experimental animal model from Toxoplasma challenge (Makino et al., 
2011). On the other hand Hsp90 function in Leishmania is essential for the morphological 
differentiation of the parasite (Wiesgigl and Clos, 2001). Hsp90 is also important for 
adaptation of Toxoplasma gondii and Trypanosomatids in their hosts (Angel et al., 2012). 
   
Plasmodium falciparum expresses a wide range of heat shock proteins for better adaptation in 
the host. It has recently been documented that chaperones of parasitic origin are upregulated 
in malaria patients and that the expression profile is correlated with different stages of 
parasite life cycle (Pallavi et al., 2010). Cytoplasmic Hsp90 has been reported to be 
indispensible for the survival of Plasmodium in the human RBC (Banumathy et al., 2003). 
Elevated temperature during the course of fever has been shown to augment parasite 
development and infectivity. This is mostly occurs due to the upregulation of Hsp90 and its 
co-chaperone complex. Inhibition of Hsp90 by geldanamycin (GA) inhibited temperature 
dependent development of the intraerythrocytic parasite (Pavithra et al., 2004). Hsps in the 
parasite might be involved in interesting roles, ranging from the protection against stress in 
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the host cell (elevated temperature, oxidative stress, degrading enzymes, immune system) to 
the establishment of virulence (Polla, 1991). It has been hypothesised that Plasmodium codes 
different chaperones (Hsp70/Hsp40 homologues) for the trafficking of parasite virulence 
protein (PfEMP1) to the RBC membrane (Kulzer et al., 2012). It can be speculated that the 
challenges encountered by Plasmodium has led to the evolutionary selection of a diverse 
group of chaperone for better adaptation (Shonhai et al., 2011). Therefore, the different 
chaperone networks are important weapons for the parasite to combat insults encountered in 
the host. Nevertheless, the essential role of chaperone in the establishment of adaptation and 
virulence qualifies them as potential drug candidates. Since heat shock proteins are highly 
conserved among different organisms, cautious assessment needs to be taken into 
consideration for the development of new drugs to avoid cross reactivity between the 
pathogen and the host (Newport, 1991). 
1.5. Molecular chaperones: role in the adaptation of 
Plasmodium falciparum within the human host 
 
The lifecycle of Plasmodium, as explained earlier is divided into two phases; sexual phase, 
that takes place in the poikilothermic mosquito vector and an asexual phase, occurring in the 
warm blooded human host (fig 1.2). Plasmodium falciparum during its life cycle comes 
across a wide range of environmental challenges that is associated with its migration from the 
mosquito vector to the human host. During the passage from poikilothermic mosquito vector 
to the warm blooded human host it encounters a temperature shift from 25 ° C to 37 ° C. 
Most importantly the body temperature of the host can rise up to 41° C during the course of 
fever episodes which is a characteristic of human malaria. As mentioned earlier such elevated 
temperature facilitates parasite development inside the human RBC, a key stage in 
Plasmodium life cycle. This observation supports the notion that temperature is an important 
environmental factor for the development and infectivity of the malaria parasite in human 
(Pavithra et al., 2004).  
 
In almost all organisms, heat shock proteins provide defence to the cell under stressful 
conditions. It is therefore suspected that heat shock proteins play an important role in the 
adaptation of the parasite in the human host. Plasmodium falciparum codes for many heat 
shock proteins belonging to the families of Hsp90, Hsp70, Hsp60 and Hsp40 (Watanabe, 
1997, Das et al., 1997, Bonnefoy et al., 1994, Kumar et al., 1991, Banumathy et al., 2003). 
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For example, one of the P. falciparum Hsp70s known as PfHsp70-1 has been shown to 
supress thermosensitivity of E. coli DnaK. This indicates a possible cytoprotective role of this 
protein in the human malaria parasite (Shonhai et al., 2005). Parasite growth is terminated by 
blocking PfHsp90 and qualifies it as an essential protein for parasite survival (Banumathy et 
al., 2003, Kumar et al., 2003). On the other hand, an Hsp40 homologue known as the ‘ring-
infected erythrocyte surface antigen’ (RESA) has been found to be involved in conferring 
resistance to the parasite during elevated temperature in the host (Silva et al., 2005). 
Therefore, it is interesting to note that Plasmodium adapts to several challenges encountered 
within the host and establishes pathogenesis by recruiting diverse chaperone network 
(Pavithra et al., 2007). In many aspects direct biochemical evidences, supporting the 
importance of these chaperones are still missing. Therefore, further research on several 
parasitic chaperones would help us to better understand the parasite biology in order to 
design efficacious antimalarial drugs. 
1.6. Major heat shock proteins in Plasmodium falciparum 
1.6.1. Plasmodium falciparum Hsp90 (PfHsp90) 
 
Plasmodium codes only one PfHsp90 (PF3D7_0708400), expressed throughout all 
intraerythrocytic stages of the life cycle (Bonnefoy et al., 1994, Khachane et al., 2005, 
Acharya et al., 2007). PfHsp90 has retained a conserved domain structure and shares 64 % 
sequence identity to its human homologue. N-terminal ATP binding domain is highly 
conserved in PfHsp90 (Acharya et al., 2007, Shonhai, 2010). The dimerization domain helps 
in the establishment of functional dimeric structure of the protein. It also contains EEVD 
motif at its C- terminus, characteristic of cytosolic chaperones and might be involved in the 
interaction with co-chaperones (i.e. Hsp70 and HOP) (Kumar et al., 2007). In fact, due to its 
essential role for the intraerythrocytic survival, it is the most well studied chaperone in P. 
falciparum.                                     
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Figure 1.11 Schematic representation of domain organisation of PfHsp90.  
PfHsp90 contains a highly conserved ATPase domain at the N-terminus (pink). In addition to the linker region 
(red) it also possesses calmodulin binding domain (brown), leucine zipper motif (green) and a dimerization 
domain (yellow) present towards the C- terminus. At the extreme C-terminus it contains a highly conserved 
EEVD motif (blue) characteristic of cytosolic Hsp90. This motif plays important role in the interaction with 
Hsp70/HOP. Adapted from (Acharya et al., 2007). 
 
As previously mentioned Hsp90 is essential for the development of the parasite in the mature 
human erythrocyte. Inhibition of PfHsp90 pathway by geldanamycin arrested the growth of 
the parasite at the ring stage (Pavithra et al., 2004, Banumathy et al., 2003). Geldanamycin  
(Hsp90 inhibitor and a benzoquinone ansamycin antibiotic) functions by inhibiting the 
interaction of Hsp90 with its co-chaperone Hsp70 and thereby, rendering the PfHsp90 
machinery non-functional. Therefore, the arrest of parasite development resulting from the 
inhibition of Hsp90 function indicates the passive or active involvement of other co-
chaperones (Banumathy et al., 2003). In agreement with this notion, PfHsp90 has been found 
to associate with other molecular co-chaperones in vitro or in vivo (Acharya et al., 2007). The 
co-precipitation of PfHsp90 with PfHsp70-1 indicates functional partnership between both 
(Banumathy et al., 2003). A p23 homologue was identified in Plasmodium, which is highly 
conserved among this species and a relatively abundant cytosolic protein expressed through 
ring to trophozoite stages of the parasite. Therefore, it might be involved in the replication of 
the parasite within the human RBC in collaboration with other chaperones like PfHsp90 
(Wiser, 2003, Kumar et al., 2003). A HOP homologue was recently characterised in 
Plasmodium and was found to co-localise and co-precipitate with PfHsp90 indicating a 
functional interaction between them similar to other eukaryotic system (Gitau et al., 2012).  
PfPP5 (a co-chaperone of Hsp90) was also co-immunoprecipitated with PfHsp90 (Dobson et 
al., 2001, Dobson et al., 1999, Acharya et al., 2007). Calcineurin is a protein that is needed by 
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Hsp90 for folding. In Plasmodium, calcineurin was found to be closely associated with 
PfHsp90 and the interaction could be strongly inhibited by cyclosporine A (CsA) and 
probably explains the reason behind the CsA sensitivity to malaria (Dobson et al., 1999). 
Association with all these co-chaperones indicates an obvious involvement of Hsp90 
machinery in the intraerythrocytic stages of Plasmodium. 
 
Therefore, it can be concluded that PfHsp90 is a potential drug target and inhibition of 
PfHsp90 function could overcome the resistance of Plasmodium to current antimalarial drugs 
(Acharya et al., 2007). Presently, drugs against PfHsp90 are going through phase III clinical 
trial (Angel et al., 2012). 
1.6.2. Plasmodium falciparum Hsp60 (PfHsp60) 
 
There is very limited amount of information available about Hsp60 homologue in 
Plasmodium falciparum. PfHsp60 (PF3D7_1015600) is expressed in all intraerythrocytic 
stages (Das et al., 1997). A study reported, a heat dependent increase in the cellular mRNA 
level for Hsp60 (Syin and Goldman, 1996). Although a three-fold increase was observed in 
the total mRNA level of PfHsp60, there was no increase in the total protein content, 
indicating a possible involvement of PfHsp60 in the translational level. PfHsp60 was also 
found to co-immunoprecipitate with several other proteins suggesting possible interactions 
(Das et al., 1997).  
1.6.3. Plasmodium falciparum small heat shock proteins 
 
As previously described, sHsps plays an important role in the disaggregation and proper 
folding of denatured proteins in the cell (Jakob et al., 1993). Plasmodium falciparum genome 
possesses only two genes coding for small heat shock proteins (PF3D7_0816500 and 
PF3D7_1304500). PF3D7_0816500 codes for a small heat shock protein of 20kDa (Hsp20). 
The gene expression profile reveals that there is not much stage dependent change in the 
expression level of this protein in intraerythrocytic stages of P. falciparum. Although the 
parasite specific role of this protein is yet to be determined, there are predictions that this 
could be a possible Bag1 co-chaperone of P. falciparum as it shares homology with the Bag1 
gene from its apicomplexan relative, T. gondii. On the other hand, PF3D7_1304500 gene 
codes for a 25kDa putative protein. The expression profile of the gene in the intraerythrocytic 
stage of the parasite demonstrates several fold increase in the protein level during the 
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trophozoite stage. But, the actual role of this protein in the parasite is still unknown 
(Aurrecoechea et al., 2009). 
1.6.4. Plasmodium falciparum Hsp40 (PfHsp40) 
 
Plasmodium genome codes for 43 Hsp40 genes in total. Very few Hsp40s from Plasmodium 
falciparum have human homologue except for those involved in fundamental cellular 
processes (Botha et al., 2007). The pool of Hsp40 from Plasmodium is further classified into 
different types according to the DnaJ canonical classification system. Out of the 43 Hsp40s, 
31 Hsp40s contain a signature J domain with a conserved HPD motif. We further classify the 
Hsp40s in two subgroups: exported and non-exported Hsp40. 
1.6.4.1 Exported PfHsp40s 
 
Amongst the 43 Hsp40s, 18 contain a Plasmodium export element ‘PEXEL’ motif and can be 
exported. But, only five of them were found to be exported to the host cell till date (Hiller et 
al., 2004, Silva et al., 2005, Bhattacharjee et al., 2008, Kulzer et al., 2010). PF3D7_0113700, 
PF3D7_0201800, PF3D7_0501100.1 code for exported type II PfHsp40s, (Rug and Maier, 
2011). Both the PF3D7_0113700 and PF3D7_0501100.1 PfHsp40s were found to localize in 
the infected RBC and associates with mobile structures in the RBC cytosol named as ‘J dots’ 
(Kulzer et al., 2010). PF3D7_0113700 was proved to be essential for the survival of 
Plasmodium (Maier et al., 2008). Several Type IV exported PfHsp40s are trafficked to the 
RBC cytosol, thereby could be involved in the remodelling of erythrocyte. RESA is one of 
the most extensively studied exported type IV PfHsp40s (PFA0110w) from Plasmodium 
origin. RESA is initially localized in the dense granule and plays an important role during 
invasion. After being released in the forming PV it gets transported through PVM into the 
RBC cytosol and finally gets associated with spectrin present on the RBC membrane (Foley 
et al., 1990, Da Silva et al., 1994). There is a huge amount of conflicting data about the 
timing and extent of RESA influencing RBC cytoskeleton. But, the important role of this 
protein in the protection of cytoskeleton during high temperature fever episodes remains 
unquestioned (Rug and Maier, 2011). Another highly important exported type IV PfHsp40 is 
PF3D7_1039100. It is thought to be involved in the knob formation on the infected 
erythrocyte. Knobs are formed as a result of membrane remodeling induced by the parasite, 
and provide anchoring point for the major virulence factor PfEMP-1. Knockout of 
PF3D7_1039100 from the parasite genome largely affects the ability of the parasite to form 
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knobs (Maier et al., 2008) impairing their ability to adhere to the endothelium (LaCount et 
al., 2005). 
1.6.4.2. Non-exported PfHsp40s 
 
We predict that the non-exported cytosolic Hsp40s might be involved in house keeping 
function and cytoprotection of the cell. They function either independently or in association 
with Hsp70 chaperone machinery (Rug and Maier, 2011). Indeed heat shock mediated 
upregulation of the mRNA and protein level was observed for a type I cytosolic PfHsp40 
(PF3D7_0409400) (Watanabe, 1997). The J domain from this PfHsp40 could reverse the 
thermosensitivity of E. coli strain lacking its DnaJ by establishing a possible interaction with 
DnaK (Nicoll et al., 2007). In addition, it could facilitate the chaperone activity of PfHsp70-1 
(cytosolic, heat inducible Hsp70 from Plasmodium) indicating its possible interaction with 
the later in vivo (Misra and Ramachandran, 2009). Another type I cytosolic Hsp40 
(PF3D7_1437900) was also found to be heat inducible and co-localized with PfHsp70-1 in 
the cytosol of the parasite upon heat shock (Botha et al., 2011). This also indicates a 
housekeeping and cytoprotective role in vivo.  This Hsp40 candidate was also able to enhance 
ATPase activity of PfHsp70-1, which could further be inhibited by small molecules. On the 
other hand PfJ4 (PF3D7_1211400), a heat inducible type II PfHsp40 co-localized, co-
immunoprecipitated with PfHsp70-1 and demonstrated thermosensitivity (Nicoll et al., 2007, 
Pesce et al., 2008).  Another type II cytosolic PfHsp40 (PF3D7_0213100) is likely to be 
involved in cytoprotection. Interaction of this protein with PfHsp70-1 has been predicted 
(Botha et al., 2007). Although, this prediction indicates a possible co-chaperone partnership 
of this particular PfHsp40s with PfHsp70-1 to provide cytoprotection to the parasite, direct 
research data supporting this notion is still lacking.  
The facts mentioned above, all together indicate a very important role of a diverse group of 
PfHsp40s either in the cytoprotection or pathogenesis of the parasite. The PEXEL positive 
Hsp40 crosses the parasite plasma membrane (PPM), PV, PVM and contribute mostly to the 
establishment of pathogenesis in the host. Whereas, the non-PEXEL cytosolic ones might be 
involved in the cytoprotection of the parasite during thermal stress period. Therefore, all 
these functions qualify PfHsp40s as potential drug candidates.  
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1.6.5. Plasmodium falciparum Hsp70 (PfHsp70) 
 
Plasmodium genome codes for 6 Hsp70 genes and cellular localisations of these proteins are 
either already shown or predicted (Table 1) (Shonhai, 2010).  
 
Amongst all, PfHsp70-1 (PF3D7_0818900) is highly abundant and constitutively expressed 
during all intraerythrocytic stages of the parasite. PfHsp70-1 is localised in the parasite 
cytosol (Kumar et al., 1991). In fact it is the most extensively studied candidate from all the 
Hsp70s identified so far (Refer to section 1.7.4.1 for details). 
 
PfHsp70-2 (PF3D7_0917900) is a homologue of the ER resident Grp78 and BiP. PfHsp70-2 
has conserved nuclear localization signal and is localized to ER like structures in 
Plasmodium, mediated by N-terminal leader sequence and C-terminal ER-retention signal 
(Kumar et al., 1991, Lanzer et al., 2006, Shonhai et al., 2007, Shonhai, 2010). It has also been 
found to be present in the Maurer’s cleft (Vincensini et al., 2005). 
PfHsp70-3 (PF3D7_1134000) is a mitochondrial homologue and also found in Maurer’s cleft 
(Lanzer et al., 2006, Shonhai, 2010, Vincensini et al., 2005). It has a conserved nuclear 
localization signal (Shonhai, 2010). This Hsp70 homologue was also detected in the PV 
(Nyalwidhe and Lingelbach, 2006, Shonhai, 2010).  
PfHsp70-x (PF3D7_0831700) shares high sequence identity with PfHsp70-1 and contains an 
EEVN domain suggesting its role as a cytosolic chaperone (Shonhai, 2010). But, in contrast 
to this prediction recent work has demonstrated the trafficking of PfHsp70-x to the PV and 
cytosol of the infected erythrocyte mediated by a short segment of eight amino acid 
sequences present directly after the predicted signal sequence. This is the first report of a 
parasite encoded Hsp70 to be trafficked to the host cell. This suggests a possible involvement 
of PfHsp70-x in trafficking of a number of parasite encoded proteins favoring pathogenesis. 
In addition, this indicates a possible collaboration of PfHsp70-x with parasite coded Hsp40s 
either in the host cytosol or in the PV (Kulzer et al., 2012).  
 
The last two Hsp70 homologues PfHsp70-y (PF3D7_1344200) and PfHsp70-z 
(PF3D7_0708800) have a relatively conserved ATPase domain, but the substrate binding 
domains do not show any conservation. These Hsps do not have nuclear localization signal. 
They neither have the threonine residue like the DnaK, crucial for phosphorylation nor a 
proper linker region. Therefore, these two PfHsp70s might be involved in functions that is 
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not typical of Hsp70. PfHsp70-y might be involved in functioning as an ER-based NEF of the 
Hsp110/Grp170 family of protein whereas, PfHsp70-z might act as cytosolic Hsp110/Grp170 
(Shonhai, 2010). 
Name/PlasmoDB 
annotation 
Molecular 
weight 
(kDa) 
Signal 
sequence/special 
features 
Predicted cellular 
localization 
Expression 
phase 
PfHsp70-1/ 
PF3D7_0818900 
74 C-terminal EEVD 
motif, GGMP motif 
Cytoplasm Erythrocytic 
stage 
PfHsp70-2/ 
PF3D7_0917900 
73 Carboxy terminal ER 
sequence/homologue of 
Bip/Grp78 
ER Exo-
erythrocytic 
stage 
PfHsp70-3 / 
PF3D7_1134000 
73 Mitochondrial transit 
sequence/ homologue of 
mtHsp70 
Mitochondria      
(not confirmed) 
Unknown 
PfHsp70-x/ 
PF3D7_0831700 
76 Predicted signal peptide 
followed by eight amino 
acid sequence 
Parasite 
cytosol/PV/RBC 
cytosol 
Erythrocytic 
stage 
PfHsp70-y/ 
PF3D7_1344200 
108 Carboxy terminal ER 
sequence 
ER     
(not confirmed) 
Unknown 
PfHsp70-z/ 
PF3D7_0708800 
100 Homologue of 
cytoplasmic hsp105 
Cytoplasm        
(not confirmed) 
Unknown  
 
Table 1. Six different Hsp70s from Plasmodium falciparum. 
This table summarizes molecular weight, special features, cellular localizations, and expression phases of 
individual PfHsp70 of P. falciparum. Adapted from (Shonhai et al., 2007, Kulzer et al., 2012). 
1.6.5.1. Plasmodium falciparum Hsp70-1 (PfHsp70-1): findings, chaperone 
properties and physiological importance 
 
PfHsp70-1 has received an extensive amount of research interest in the last decades. As 
mentioned earlier, cytosolic Pfhsp70-1 is one of the most abundant proteins expressed by 
Plasmodium and is expressed throughout all intraerythrocytic stages (Shonhai, 2010). Stress 
introduced to cultured parasite in human red blood cell induced upregulation in the level of 
PfHsp70-1, indicating a cytoprotective role (Kumar et al., 1991). PfHsp70-1 could reverse 
the thermosensitivity of E. coli having compromised DnaK function, therefore suggesting its 
in vivo chaperone function (Matambo et al., 2004, Shonhai et al., 2005). PfHsp70-1 has 
conserved substrate binding domain allowing it to interact with protein aggregates or 
degradation prone substrates. In support to this hypothesis it has been demonstrated that 
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PfHsp70-1 could efficiently inhibit the heat induced aggregation of malate dehydrogenase 
(MDH) in vitro (Shonhai et al., 2008).  
 
In other biological systems Hsp70 functions in collaboration with Hsp90 where Hsp90 
receives substrate from Hsp70. PfHsp70-1 possess a C-terminal EEVD motif, responsible for 
the establishment of interaction with Hsp90 via the adaptor co- chaperone HOP (Shonhai et 
al., 2007). Therefore, such a functional interaction between Hsp70 and Hsp90 in Plasmodium 
system cannot be overlooked. In fact, PfHsp70-1 was detected in a complex with PfHsp90 
during co-immunoprecipitation and proposes a possible functional partnership between them 
(Banumathy et al., 2003, Banumathy et al., 2002). In a recent study, a HOP homologue has 
been identified and characterised in Plasmodium. The PfHOP (PF3D7_1434300) co-localised 
with PfHsp70-1 and PfHsp90 and was detected in a common complex (Gitau et al., 2012). 
Hence, these data suggests a functional partnership between PfHsp70-1 and PfHsp90 via 
PfHOP. Since, PfHsp90 is essential for parasite survival, the interaction of PfHsp70-1 with 
the former demands high research attention.  It also indirectly implicates PfHsp70-1 as a 
potential drug target.  
 
Another important co-chaperone of Hsp70 is Hsp40. As described earlier Plasmodium codes 
for 43 Hsp40 homologues among which type I and type II members possess J domain with 
highly conserved HPD motif and therefore qualify as a co-chaperones of cytosolic PfHsp70-
1. In support to this hypothesis several PfHsp40 were found to interact with PfHsp70-1 (as 
detailed under section 1.7.4).  
 !
Figure 1.12 Schematic representation of the domain organisation of PfHsp70-1.  
PfHsp70-1 is highly conserved in its domain organisation. It possesses a 45kDa N-terminal ATPase domain 
(black) divided into two subdomains. The ATPase domain is connected to the substrate-binding domain by a 
highly conserved linker region (black line). The substrate binding domain (blue) is formed of β and α-helices. 
The β provides the hydrophobic pocket for the substrate binding whereas α-helices work as lid entrapping the 
substrate. PfHsp70-1 has a C-terminal EEVD motif (green) characteristic of cytosolic Hsp70s to interact with 
co- chaperones. Modified from (Fan et al., 2003). 
  
In addition to the mentioned Hsp40s another putative type II non PEXEL Hsp40 from 
Plasmodium (PF3D7_0213100) is predicted to be the cytosolic co-chaperone of PfHsp70-1 
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(Pavithra et al., 2007), but till date there is no direct biochemical evidence supporting this 
partnership (Rug and Maier, 2011). 
 
Small molecule inhibitor for the interaction of PfHsp70-1 with either its potential co-
chaperones (Hsp40/Hsp90) or substrate could emerge as a promising approach towards drug 
development against malaria.  
1.6.5.2. PfHsp70-1 as a potential drug candidate  
 
Hsp70 brings different chaperone networks into functional collaboration in a cell. A small 
molecule inhibitor, immunosupressant 15-deoxysperguallin (DSG) has been proposed as an 
antimalarial agent that targets PfHsp70-1 and is undergoing phase II clinical trial. DSG is 
known to bind PfHsp70-1 (Ramya et al., 2007) and is thought to inhibit its function in two 
possible ways. Firstly, DSG attaches to the EEVD motif at the C-terminus of the protein and 
thus inhibits the interaction with PfHsp90. Since, PfHsp90 is predicted to receive substrate 
from PfHsp70-1 like in other eukaryotic organisms, this inhibition of interaction render 
PfHsp90 chaperone machinery non-functional, leading to the death of the parasite (Shonhai, 
2010). The other possible way that DSG could function is by interrupting the interaction 
between PfHsp70-1 and its co-chaperone, PfHsp40 via the C-terminal EEVD motif (Demand 
et al., 1998). By a recent approach several molecules were screened to assess their potential 
to inhibit chaperone function of PfHsp70-1. A few promising candidates emerged from this 
screen that could inhibit the protein aggregation suppression activity of purified PfHsp70-1 in 
vitro in a concentration dependent manner. These small molecules were also found to inhibit 
parasite growth. Therefore, this compound justifies the potential of PfHsp70-1 as a drug 
target. On the other hand, they could prove to be important molecular probes for the study of 
PfHsp70-1 chaperone function (Cockburn et al., 2011). As previously mentioned, the 
functional interaction of PfHsp70-1 in the parasite with either PfHsp40 or PfHsp90 co-
chaperone is predicted. Such partnership might be involved in cytoprotection and trafficking 
of proteins to establish pathogenesis and virulence. Therefore, the functional partnership 
between PfHsp70-1 and their chaperone counterpart is crucial for the stress management of 
the cell and is of high priority (Botha et al., 2007). The inhibition of such crucial function 
might interrupt several processes including cytoprotection, protein trafficking, and actin 
polymerisation (Tardieux et al., 1998). Although Hsp70s are conserved between organisms, 
PfHsp70-1 has some unique features. The SBD of PfHsp70-1 shares very less amino acid 
identity with that of its human homologue (Hsc70). In addition, PfHsp70-1 has high basal 
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ATPase activity in comparison to that of Hsc70. Therefore the PfHsp70-1 function can be 
inhibited by limiting the cellular level of ATP, without affecting the function of Hsc70 
(Matambo et al., 2004). Due to the growing resistance of Plasmodium to commercially 
available antimalarials, further screening and identification of small molecule inhibitors of 
PfHsp70-1 co-chaperone/substrate interaction could prove to be a promising approach 
towards the development of new efficacious drugs against malaria. 
1.7. Strategy to generate PfHsp70-1 and PfHsp40 
knockdown cell lines using dominant negative protein 
combined with destabilization domain approach 
 
The study of essential genes by classical knockout approaches is hindered with several 
challenges in Plasmodium system. Firstly, the intraerythrocytic stage of plasmodium is 
haploid therefore knocking out essential gene would result in parasite death. RNA 
interference (RNAi) is another frequently used approach for gene knockout in other parasitic 
organism like Trypanosoma brucei in combination with Tetracyclin Repressor (TetRep) 
based system (Wirtz and Clayton, 1995, Bastin et al., 2000, Pino et al., 2012). But, P. 
falciparum does not code for the crucial enzymes of the RNAi pathways and previous 
attempt to establish RNAi in Plasmodium falciparum failed (Baum et al., 2009). This 
indicates that the effective application of RNAi is yet to be proven in Plasmodium falciparum 
(Agop-Nersesian et al., 2008). Another inducible gene expression system, where the Tet 
Repressor (TetRep) is fused to a nonendogenous activating domain (TATi) was established in 
close apicomplexan Toxoplasma gondii (Meissner et al., 2002). This tool was found to be 
highly effective to study the functional importance of several essential candidate genes in T. 
gondii (Meissner et al., 2002, Buguliskis et al., 2010, Plattner et al., 2008). This artificial 
transactivator was also be used in P. falciparum to regulate gene expression from episomal 
plasmid (Meissner et al., 2005). Unfortunately, this system also failed to generate conditional 
knockout of genes because of less transactivation activity (Pino et al., 2012). FLP recognition 
target (FRT)-specific/FLP recombinase system has been reported to be used with some 
success at specific stages of the parasite, but this system is irreversible (O'Neill et al., 2011, 
van Schaijk et al., 2010, Combe et al., 2009).  
 
Hence, during this study we used a different strategy to identify the functional importance of 
PfHsp70-1 in the intraerythrocytic stage of the Plasmodium.  We wanted to inhibit the 
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function of the endogenous PfHsp70-1/Hsp40 by episomal over expression of the dominant 
negative (DN) version of the protein. Therefore, we expected the dominant negative proteins 
to shield the effect of wild type endogenous ones in a competitive manner by capturing all 
possible co-chaperone and client substrates. DN version can bind to all interacting co-
chaperone/substrate proteins without being catalytically active. This would result in blocking 
the access of the endogenous PfHsp70-1/Hsp40 to their respective substrates, rendering their 
cellular function silent. Similar work was carried out in E. coli by introducing a dominant 
negative mutation in the DnaK, resulting in visible phenotypic outcome (Buchberger et al., 
1994). This strategy has been extensively been adapted to study the function of a number of 
protein families. Nevertheless, it is most applicable for proteins that require interaction with 
several ligands within the cell to form protein multimers to be functional (Sheppard, 1994). 
This approach has been established in Toxoplasma gondii (Herm-Gotz et al., 2007, Kremer et 
al., 2013) and also in Plasmodium falciparum (Jain et al., 2013, Bongfen et al., 2012, 
DeSimone et al., 2009) to study the function of several genes.  
 
We further combined this approach with destabilization domain strategy. In this system the 
protein of interests (POIs) are further fused to destabilisation domains. There are several dds 
reported till date (dd-FKBP, dd-ecDHFR), (Armstrong and Goldberg, 2007, Dvorin et al., 
2010, Iwamoto et al., 2010), but their mode of action is somehow similar. These domains are 
unstable when expressed in the cell and target the whole fusion protein to proteosomal 
degradation pathway. Upon addition of a small cell permeable ligand (either shield-1 or 
trimethoprim (TMP) depending on the dd used) the protein is stabilised and can carry out its 
biological function (fig 1.13). Thus, a tuneable dose dependent regulation of the protein level 
is possible in vivo. Recently, the destabilization domain strategy has been successfully 
applied to assess the importance of a number of proteins in different organisms including 
Trypanosoma cruzi, Leishmania major, Toxoplasma gondii, Plasmodium falciparum and also 
in murine model (Ma et al., 2012, Madeira da Silva et al., 2009, Herm-Gotz et al., 2007, Jain 
et al., 2013, Dvorin et al., 2010, Armstrong and Goldberg, 2007, Iwamoto et al., 2010). 
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Figure 1.13 Schematic representation of dd based control of protein stability by shield-1/TMP.  
(a) In absence of the ligand the fusion protein is unstable and rapidly degraded by the proteasome. b) Cell 
permeable ligand binds to the dd domain and stabilises the fusion protein that can carry out its function. !
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1.8. Objective !
Plasmodium falciparum is the causative agent of malaria and responsible for the death of 
approximately 6 million people worldwide. It mostly affects children under five years of age. 
The severity of the disease is an outcome of the replication of the parasite in the human 
erythrocyte. Interestingly, research findings indicate an enhanced replication and infectivity 
of the parasite during the febrile temperature episodes, that is characteristic of malaria. The 
heat-mediated development is facilitated by molecular chaperones. This specialised group of 
heat shock proteins (Hsps) provide cytoprotection to the parasite during its diverse life cycle 
from mosquito to human. Hsps play essential role in maintaining protein homeostasis during 
stress and other cellular insults encountered in the host.  
 
There is growing evidence that PfHsp70-1, a heat inducible, cytosolic chaperone is important 
for the intraerythrocytic survival of Plasmodium. In other organisms, Hsp70 works as a 
central chaperone and accomplish its role in tight collaboration with other co-chaperones like 
Hsp40 and Hsp90. Thus, existence of such a partnership cannot be overlooked in 
Plasmodium. But, till date there is very limited direct in vivo biochemical evidence available 
to prove this notion. In fact, our knowledge about the parasite specific function of PfHsp70-1 
in the intraerythrocytic life cycle of Plasmodium falciparum is scarce.  
 
Therefore, the aim of this project was to further elucidate the crucial parasite specific 
importance of PfHsp70-1. For this purpose, we wanted to generate PfHsp70-1 and PfHsp40 
knockdown parasite lines to assess the contribution of these chaperones towards the 
intraerythrocytic life cycle of P. falciparum. We aimed to accomplish this by overexpression 
of the dominant negative versions of the candidate proteins, fused to ligand-controlled 
destabilisation domains (Armstrong and Goldberg, 2007, Iwamoto et al., 2010). By this 
approach we wanted to establish a tunable conditional knockdown of the endogenous wild 
type proteins by inhibiting their cellular functions. To our knowledge, this is the first attempt 
to use such a system to study Hsps in P. falciparum. The outcome would have helped us to 
define the essential role of PfHsp70-1 and PfHsp40 during the intraerythrocytic life cycle of 
the parasite. The findings would have finally contributed towards the validation of these 
candidate proteins as potential drug targets for malaria in the future.  
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2. Materials & Methods 
2.1. Materials 
2.1.1. Instrumentation !
Instrument Manufacturer  
 
5810 R refrigerated centrifuge 
 
Eppendorf 
Agarose gel chambers 
 
Gibco BRL 
Analytical balance 2414 
 
Sartorius 
Autoclave (Varioklav) 
 
Thermo scientific 
Biofuge fresco centrifuge 
 
Heraeus 
Blotting chambers 
 
Phase 
Film developing cassette  
 
Rego 
Gel doc system Intas 
Gene pulser II Biorad 
Ice machine (AF-20) Scotsman 
Incubator B5060-EC Heraeus 
Incubator C16 Labotect 
Shaking incubator (G25) New Brunswick Scientific Co 
Laminar flow Herasafe Heraeus 
Mikro 22R refrigerated centrifuge Hettich 
pH meter Greisinger electronic GmbH 
Power Pac basic power supply Biorad 
Precision balance 1205 MP Satorius 
Roller mixer NeoLab 
T-personal PCR cycler Biometra 
Thermoblock Stuart Scientific 
Thermomixer 5436 Eppendorf 
Vista viosion microscope VWR 
Vortexer vortex-genie 2 Scientific industries 
Waterbath Köttermann 
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2.1.2. Consumables   !
Material Provider 
Centrifuge tubes PC Beckman 
Cryotubes Sarstedt 
Culture flasks Greiner 
Electroporation cuvettes BioRad 
SDS sample loading tips VWR 
Glass ware Schott 
Medical X-ray films RX NIF Fuji 
Microscope slides VWR 
Nitrocellulose membrane Schleicher & Schuell 
Pasteur pipettes Brand GmBH 
Petri dishes VWR/ Greiner 
Pipette tips Sarstedt / Greiner 
Plastic consumables Sarstedt / Eppendorf / Greiner 
Reaction tubes (0.2 ml, 0.5 ml, 1.5ml, 2.0 ml, 15 
ml, 50 ml ) 
Sarstedt / Eppendorf 
Whatman paper Schleicher & Schuell  
2.1.3. Chemicals / reagents  !
Chemicals  Provider 
1kb+ DNA ladder Invitrogen 
1,4-Dithio-DL-threitol (DTT) Roth 
Agar Roth 
Agarose (molecular biology grade)  Eurogentec / Peqlab 
Ammonium peroxodisulphate (APS) Roth 
Ampicillin  Roth 
Bovine serum albumin fraction V (BSA) PAA 
Bromophenol blue Amersham Biosciences 
Calcium chloride Roth 
Chloroform Roth 
Citrate phosphate dextrose solution (CPD) Sigma 
Dimethyl sulphoxide (DMSO) Roth 
Deoxyribonucleotide Mix (peq Gold dNTP mix) Peqlab 
2 Materials and Methods       40 
! !
Ethanol p.a. (EtOH) Roth 
Ethidium bromide (EtBr) Sigma 
Ethylendiamintetra-acetic acis (EDTA) Roth 
Glacial acetic acid Roth 
Glycerol anhydrous Applichem 
Hoechst 3325 Molecular probes 
Hydrochloric acid (37%) Roth 
Hydrogen peroxide (H2O2) Merck 
Isopropanol Mercl 
LB-agar (Lennox) Roth 
Luminol  Applichem 
Magnesium chloride (MgCl2) Roth 
Magnesium sulphate (MgSO4) Roth 
Methanol (MetOH) Roth 
NNN′N-tetramethyleneethylenediamine 
(TEMED) 
 
Roth 
o-cresolsulfonephthalein (Cresol Red) Sigma Aldrich 
p-Coumaric acid Roth 
PageRuler Prestained Protein Ladder  
(10-170kDa) (Cat# 26616) 
 
Thermo Scientific 
Pepton Roth 
Phenylmethylsulfonylfluoride (PMSF) Serva  
Protease Inhibitor Cocktail Set III Calbiochem 
Rotiphorese ®Gel 30 Roth 
Shield-1  Clontech 
Skimmed milk powder Roth 
SOB – medium Roth 
Sodium acetate (C2H3NaO2, NaOAc) Roth 
Sodium chloride (NaCl) Roth 
Sodium docecyl sulphate (SDS) Applichem 
Sodium hydroxide (NaOH) Merck 
Sucrose Roth 
Trimethioprim (TMP) Sigma 
Tris  Applichem 
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Water (sterile, pyrogen-free) Roth 
Yeast extract Roth 
2.1.4. Enzymes  !
Enzymes Provider  
Alkaline phosphatase, Calf intestinal (CIP) New England Biolabs 
DNase Applichem 
KOD Hot start DNA Polymerase Novagen 
RNase Applichem 
SuperScriptTMIII one-step RT-PCR system Invitrogen 
T4 DNA Ligase Invitrogen 
Taq DNA polymerase New England Biolabs 
2.1.5. Molecular biology kits  !
Kits Provider 
Gel extraction kit Seqlab 
PCR purification kit Seqlab 
Peq GOLD plasmid miniprep kit I  Peqlab 
Plasmid Maxi kit Qiagen 
2.1.6. Cell culture materials !
Materials Provider 
AlbuMAXII Invitrogen 
Blasticidin S Invitrogen 
D-Sorbitol Roth 
Gelafundin B. Braun 
Gentamycin PAA 
Giemsa Merck 
Human erythrocyte concentrate A (Rh+) and O 
(Rh+) 
 
Blood bank, University Hospital Marburg 
Human Plasma A (Rh+) Blood bank, University Hospital Marburg 
Hypoxanthine CC Pro 
Neomycin solution Sigma 
RPMI 1640 Gibco 
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RPMI 1640 PAA 
WR99210 Jacobus Pharmaceuticals 
2.1.7. Antibodies  !
Primary antibodies 
Mouse α-GFP monoclonal Roche Diagnostic  
Mouse α-Glycophorin A/B monoclonal Sigma Aldrich 
Mouse α-PfHsp70-1 monoclonal T. Blisnick, Pasteur Institute, Paris, France 
Rabbit α-Pf Aldolase polyclonal This working group 
Rabbit α-HA polyclonal Rockland 
Rabbit α-FKBP12 polyclonal Abcam  
Secondary antibodies 
Goat α-mouse HRP DAKO 
Goat α-Rabbit HRP DAKO 
2.1.8. Cells and organisms !
Strain Genotype Reference 
E. coli TOP 10 DH10B™ Invitrogen 
P. falciparum clone 3D7 The clone was obtained by 
limiting dilution of the 
original NF54 (Isolated near 
Schipol Airport, Amsterdam, 
Netherlands) 
The Walter and Eliza 
Institute of Medical 
Research, Melbourne, 
Australia 
2.1.9. Buffers and solutions 
2.1.9.1. Used for protein work !
Buffers and solutions Composition 
Ammonium peroxodisulphate (APS) 10% in ddH2O 
Blocking solution- IFA 3%  bovine serum albumin in PBS pH7.4 
Blocking solution-western blot 3% skim milk powder in PBS pH7.4 
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Developer (X-Ray film) 6.4 mM Metol 
80 mM Hydroquinone 
571 mM sodium sulfite (Na2SO3) 
452 mM sodium carbonate (Na2CO3) 
34 mM Potassium bromide (KBr) 
 
ECL developing solution 5 mM luminol 
0.8 mM p-coumaric acid 
200 mM Tris-HCl pH8.5 
 
Electrophoresis buffer (5X) 124 mM Tris 
960 mM glycine 
0.5 % SDS 
 
Phosphate Buffer Saline (PBS) 140 mM Sodium chloride (NaCl) 
2.7 mM Potassium chloride (KCl) 
1.4 mM mono-potassium phosphate 
(KH2PO4) 
0.8 M di-sodium phosphate (Na2HPO4) 
 
SDS sample buffer (2X) 100 mM Tris/HCl pH6.8 
5mM EDTA 
20% Glycerol (v/v) 
4% SDS 
0.2 % bromophenol blue 
100 mM DTT 
 
Seperating buffer (4X) 1.5 mM Tris-HCl pH8.8 
0.4% SDS (w/v) 
 
Stacking buffer (4X) 500 mM Tris-HCl pH6.8 
0.4% SDS (w/v) 
 
Western blot transfer buffer 48 mM Tris-HCl pH9.5 
39 mM glycine 
0.04% SDS (w/v) 
20 % MetOH (v/v) 
2.1.9.2. Molecular biology solutions !
Buffers and solutions 
 
Composition 
Colony mix (6ml) 1ml Cresol Red solution 
600 µl reaction buffer (10X) 
120 µl dNTPs (10mM) 
4.28 ml sterile water 
DNA extraction buffer A 100mM Sodium Chloride (NaCl) 
50mM Sodium Acetate (C2H3NaO2, NaOAc) 
1 mM EDTA 
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DNA loading dye (6X) 1 % bromophenol blue 
30% glycerol (v/v) 
50 mM Tris-HCl pH8.0 
5 mM EDTA 
 
TAE (50X) 2 M Tris 
2 M acetic acid 
50 mM EDTA 
2.1.9.3. Bacteriological media !
Media 
 
Composition 
LB (Luria-Bertani) agar 35 gm / LB agar 
 
SOC media SOB medium 
20 mM glucose 
 
SOB medium 20 gm /L peptone 
5 gm /L yeast extract 
10mM sodium chloride (NaCl) 
2.5mM potassium chloride (KCl) 
20mM magnesium Chloride (MgCl2) 
 
Superbroth Medium, pH7.0 35 gm/ L tryptone 
20 gm / L yeast extract 
5 gm / L sodium chloride (NaCl) 
5 ml / L sodium hydroxide (NaOH) 
2.1.9.4. Plasmodium cell culture solutions !
Blasticidin S Hydrochloride Stock solution (10 mg /ml) was diluted to a 
working concentration (5 µg / ml) 
 
Cytomix (100 ml) 6 ml 2M potassium chloride (KCl) 
7.5 µl 2M calcium chloride (CaCl2) 
1 ml stock solution III 
10 ml stock solution II 
500 µl 1M magnesium Chloride (MgCl2) 
 
Cytomix stock solutions I. 10M potassium hydroxide (KOH) 
II. 250 mM HEPES, 20mM EGTA, 
pH7.6 (5.96 gm/100 ml HEPES, 
0.76 gm /100 ml EGTA, pH7.6 
with stock solution I) 
III. 1 M phosphate buffer pH7.6 (8.66 
ml 1M dipotassium phosphate, 
1.34 ml 1M monopotassium 
phosphate)  
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Freezing solution 28 % glycerol (v/v) 
3% d-sorbitol (w/v) 
0.65 % sodium chloride (NaCl) (w/v) 
 
Thawing solutions  I. 12 % sodium chloride (w/v) 
solution 
II. 1.6 % sodium chloride (w/v) 
solution 
III. 0.9 % sodium chloride (w/v) 
solution 
 
WR 99210 20 mM stock (8.6 mgs/1ml DMSO) diluted 
to a working concentration of 20µM with 
RPMI 1640 
Final working concentration 2.5nM  
2.1.10. Basic Plasmids used in this study !
Plasmid Provider 
pARL2-GFP mut2 This working group 
pARL-BSD This working group 
pCHD-3/4-Hsp86-FKBP-YFP Prof. Daniel E. Goldberg, (Armstrong and 
Goldberg, 2007) 
 
pT8-dd-MycTgMLC1-HX Prof. D. Soldati-Fabre 
pJDD41 Prof. Thomas J Wandless 
2.1.11. Synthetic oligonucleotides 
All oligonucleotides were synthesized by Europhins MWG operon. Restriction sites are 
underlined. 
Vector Primers 
pARL_F 
 
5 CGT  TAA TAA TAA ATA CAC GCA G 
pARL_R 
 
5 CAG TTA TAA ATA CAA TCA ATT GG 
GFP+54_R 5 GTG CCC ATT AAC ATC ACC ATC 
 
 
Primers to amplify the wild type (WT) and dominant negative (DN) PfHsp70-1 
 
Hsp70_F  5 CC GCG CGC ATG GCT AGT GCA AAA GGT TCA 
AAA C 
 
Hsp70_R 5 CC CCC GGG TTA ATC AAC TTC TTC AAC TGT 
TGG TC 
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Hsp70_E187K_F 5 GAG AAT TAT TAA TAA ACC TAC TGC AGC TGC 
 
Hsp70_E187K_R 
 
5 GTA GGT TTA TTA ATA ATT CTC ATA AC 
Hsp70_TA_F 5 CC GCG CGC TA ATG GCT AGT GCA AAA GGT 
TCA AAA C 
 
Hsp70_323_R 
 
5 CCT GAT TTA ACA GTG AAT GGC C 
Hsp70_878_R 
 
5 GCT TGT GTA GAT GAT GAT AAA GTA CG 
Hsp70_1508_R 5 GCC GTA ACG TTT AAG ATA CCG 
 
 
Primers to amplify the WT and DN PfHsp40 
 
Hsp40_F 5 CC GCG CGC ATG GGG AAG GAT TAT TAT TCA 
ATA TTA GG 
 
Hsp40_R 5 CC CCC GGG TTA GAA TGT ATT TGC CAA TGT 
TTC TC 
 
HSP40_D34N_F 
 
5 GAT GTG GCA TCC TAA TAA ACA TAA TGA C 
HSP40_D34N_R 5 GAT TTC TCG TCA TTA TGT TTA TTA GGA TGC 
 
Hsp40_ AvrII_F_P 5 CC  CCT AGG ATG GGG AAG GAT TAT TAT TCA 
ATA TTA GG    
  
Hsp40_BssHII_R_2 5 CC  GCG CGC   GAA TGT ATT TGC CAA TGT TTC 
TC 
 
 
Primers to amplify 3XHA  
 
3XHA_F 
 
5 CC CTC GAG ATG TAC CCG TAC GAC GTC C 
3XHA_R 5 CC CCT AGG GAG CTC GGC ATA ATC TGG AAG 
 
 
Primers to amplify GFP 
 
GFP_AvrII_F 5 CC CCT AGG ATG AGT AAA GGA GAA GAA CTT 
TTC 
 
GFP_BssHII_R 
 
5 CC GCG CGC TTT GTA TAG TTC ATC CAT GCC 
GFP_BssHII_TA_F_P 5 CC GCG CGC TA ATG AGT AAA GGA GAA GAA 
CTT TTC 
 
GFP_XmaI_R_P 5 CC CCC GGG TTT GTA TAG TTC ATC CAT GCC 
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Primers to amplify dd-FKBP 
 
FKBP_F 5 CC CCT AGG ATG ACT GCA GGA GTG CAG GTG 
 
FKBP_R 5 CC GCG CGC TTC CGG TTT TAG AAG CTC CAC 
ATC 
 
 
Primers to amplify ecDHFR 
 
ecDHFR_AvrII _F_P 5 CC CCT AGG ATC AGT CTG ATT GCG GCG TTA GC 
 
ecDHFR_BssHII_R_P 5 CC GCG CGC GCA ATA GCT GTG AGA GTT  
CTG C 
 
ecDHFR_BssHII_F_P 5 CC GCG CGC ATC AGT CTG ATT GCG GCG  
TTA GC      
 
ecDHFR_XmaI_R_P 5 CC CCC GGG GCA ATA GCT GTG AGA GTT  
CTG C 
 
 
Primers to amplify DD29 
 
DD29_AvrII_F_P 
 
5 CC CCT AGG ATG GGA GTG CAG GTG G 
DD29_BssHII_R_P 5 CC GCG CGC TCA TTC CAG TTT TAG AAG CTC 
 
DD29_BssHII_F_P 
 
5 CC GCG CGC ATG GGA GTG CAG GTG G 
DD29_KpnI_R_P 5 CC GGT ACC TCA TTC CAG TTT TAG AAG CTC 
 
 
Primers for the cloning of PfHsp70-1 native promoter  
 
Hsp70_5'_F1 
 
5 GATGCTATTAAAAGCGGAATATTTTAC 
Hsp70_5'_R1 
 
5 GGTTTTGAACCTTTTGCACTAGCC 
Hsp70_5'_NotI_F2 5 CC GC GGCC GC TTT ATA TAT ATA CGC AAA 
ATT ATG AAA ATC CAC 
 
Hsp70_5'_XhoI_R2 5 GG CTC GAG TTT TTC TTA ATT CTT TTG 
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2.1.12. Softwares and databases  !
Software Provider 
 
PlasmoDB http://plasmodb.org/plasmo/ 
PlasmoDB: A genomic for Plasmodium falciparum 
(version 9.1) 
 
NEBcutter V2.0 
 
http://tools.neb.com/NEBcutter2/ (New England BioLabs) 
 
Oligoproperties 
 
http://www.basic.northwestern.edu/biotools/oligocalc.html 
Blast 
 
http://blast.ncbi.nlm.nih.gov/Blast.cgi 
Clustlw 
 
http://www.ebi.ac.uk/Tools/msa/clustalw2/ 
4peaks Mekentosj.com 
 
2.2. Methods 
2.2.1. Molecular biology techniques 
2.2.1.1. DNA based techniques 
2.2.1.1.2. Quantification of DNA samples 
Concentration of DNA was measured using NanoDrop (NanoDrop Technologies, Wilmigton, 
USA). For this 1 µl of DNA was loaded onto the nanodrop and the quantification was done 
following manufacturers protocol. The ratio of absorbancse at 260 nm and 280 nm was 
calculated to assess the purity of DNA (~ 1.8 for pure DNA). TE or dH2O served as blank. 
2.2.1.1.3. In vitro amplification of DNA and cDNA 
DNA templates were amplified in vitro, either from genomic DNA or from pre-existing 
plasmid by Polymerase Chain Reaction (PCR) (Mullis et al., 1986). For the in vitro 
amplification of the DNA template, either Taq polymerase or Hot start KOD polymerase 
were used following the manufacturer’s protocol. Amplification of cDNA was carried out by 
Reverse Transcription PCR (RT-PCR) using ribonucleic acid (RNA) as template. First one 
step RT-PCR was performed using Superscript III reverse transcriptase kit (Invitrogen) as per 
manufacturer’s instruction. Further standard PCR was carried out using the resulting cDNA 
as a template to achieve double stranded DNA. The reaction set up and cycle condition for 
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the PCR was optimized depending on the length of the DNA to be amplified and the melting 
temperatures of the primers.  
2.2.1.1.3.1. Standard PCR reaction setup  !
Reagents & buffers 
 
Amount 
Template DNA 1.0 µl (taken directly from the genomic or  
            plasmid DNA stock) 
 
Forward primer (50 pmol/ µl) 1.0 µl (final concentration 1.0 pmol/µl) 
 
Reverse primer (50 pmol/ µl) 1.0 µl (final concentration 1.0 pmol/µl) 
 
KOD Hot Start DNA Polymerase (1U/µl) 1.0 µl  (1U) 
 
10X PCR Buffer for KOD Hot Start DNA 
Polymerase 
 
5.0 µl (final concentration 1X) 
dNTPs (10 mM each) 5.0 µl (final concentration 0.2 mM) 
 
MgSO4 (25 mM) 3.0 µl (final concentration 1.5 mM) 
 
PCR Grade Water 33.0 µl 
 
Total Volume 50.0 µl 
2.2.1.1.3.2. Standard colony PCR cycling conditions !
Initial denaturation  94°C 5 minutes 
 
 
35 cycles 
94°C 
50°C 
68°C 
30 seconds 
50 seconds 
30 seconds per kb 
 
Final extension 68°C 10 minutes 
 
Storage  4°C Hold 
 
2.2.1.1.4. Generation of dominant negative mutations  
2.2.1.1.4.1. Dominant negative mutation of PfHsp70-1  
To generate dominant negative version of PfHsp70-1 (PF3D7_0818900), we replaced the 
Glutamic acid (E) at amino acid position 187 with a lysine (K) residue by the method of 
overlapping extension PCR as explained under section 2.2.1.1.5. The E187K mutation should 
inhibit the coupling of the substrate binding with the ATPase activity of the PfHsp70-1. 
Although the mutated protein binds and occupies the possible substrates of the endogenous 
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PfHsp70-1, cannot accomplish its function in the cell, and is therefore dominant negative. It 
has already been shown in E. coli that E171 is essential for the coupling of substrate binding 
and ATPase activity of DnaK (Hsp70 homologue in E. coli). Mutation to K (Lysine) 
compromises the chaperone function of DnaK, (Buchberger et al., 1994). Alignment of the 
amino acid sequences of DnaK and PfHsp70-1 was done (fig S.1). 
2.2.1.1.4.2. Dominant negative mutation of PfHsp40  
The highly conserved HPD motif in the J domain of PfHsp40 (PF3D7_0213100) was mutated 
to the HPN (D34N) motif. It is well known that the conservation of the HPD motif is highly 
important for the interaction of the Hsp40 with Hsp70. Mutation of this domain abolishes the 
interaction with Hsp70, thereby inhibiting the stimulation of its ATPase activity by Hsp40 
(Cheetham and Caplan, 1998, Hennessy et al., 2000). It has been experimentally shown that 
DnaJ (Hsp40 homologue in E. coli) with aspartic acid (D) in the HPD motif mutated to 
Asparagine (N) could no longer bind to DnaK with comparable affinity between wild type 
DnaJ and DnaK. Therefore, confirmed that such mutation disrupts the train for a functional 
Hsp70-Hsp40 interaction (Hennessy et al., 2005). During this work the desired mutation was 
incorporated into the HPD motif of PfHsp40 by the method of overlapping extension PCR as 
explained under section 2.2.1.1.5.  
2.2.1.1.5. Overlapping Extension PCR 
Overlapping extension PCR method was used to incorporate point mutation into a DNA 
template. The DNA template was first amplified in two parts using two different sets of 
primers. The 3′ fragment of the DNA was amplified using two primers; one annealing to the 
extreme 3′ end and other annealing at the middle of the template DNA (fig 2.1c). Whereas, 
the 5′ fragment of the DNA was amplified using another set of primers; one annealing at the 
middle and the other annealing at the extreme 5′ end of the template DNA (fig 2.1b). Both the 
primers that annealed to the opposite strands at the middle of the template in these two 
individual PCR reactions share few complimentary nucleotide bases therefore complimentary 
to each other. Among the complimentary region one nucleotide base is altered in the primer 
compared to that of the original template (fig 2.1f). This nucleotide base was altered 
depending on the mutation required, and will be incorporated in the resulting final PCR 
product. Mutagenesis in a nucleotide base will alter the codon that will eventually end up in 
coding for a different amino acid. After the PCR reaction both the resulting 3′ and 5′ 
fragments were purified by gel extraction and were used together as templates for the final 
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overlapping extension PCR (fig 2.1d and fig 2.1e). In the denaturation step of the overlapping 
extension PCR both the strands from each template denature. The single strand resulting from 
both the 3′ and 5′ fragments have a complimentary region as mentioned earlier. Therefore the 
strand anneal to each other utilizing the complimentary overhangs (fig. 2.1f). Furthermore, 
polymerase adds on dNTP to complete the strands towards the 3′ and 5′ ends and results in 
the full length double stranded DNA. Once the double stranded DNA is formed the PCR 
cycle progresses as normal, amplifying copies of the DNA carrying the desired mutation (fig 
2.1g). 
 
Figure 2.1 Schematic illustration of overlapping extension PCR. 
(a) The wild type template containing the base to be mutated (shown in green). (b) PCR for the amplification of 
the 5’ part of the DNA. The reverse primer binding in the middle of the template contains the desired mutation 
(shown in red). (c) PCR for the amplification of the 3’ part of the DNA. The forward primer binding in the 
middle of the template contains the desired mutation (shown in red). (d) Amplified 5’ part of the DNA 
containing the desired mutation (shown in red). (e) Amplified 3’ part of the DNA containing the desired 
mutation (shown in red). (f) Overlapping extension PCR, where both 5’ and 3’ products obtained from 
individual PCR are mixed. After initial denaturation both the templates anneal to each other using the 
complementary regions. DNA polymerase fills the gap on both direction and completes the formation of the full 
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length DNA molecule. Finally, 5’ forward and 3’ reverse primers amplify the DNA template containing the 
desired mutation. (g) Final product carrying the desired mutation (shown in green).  
2.2.1.1.6. Agarose gel electrophoresis for the separation of nucleic acid 
DNA and RNA molecules were separated depending on their respected sizes via agarose gel 
electrophoresis as described by Sambrook et al., (2001) (Sambrook J, 2001) . Concentration 
of the agarose gels varied from 0.8-1.5% depending on the size of the nucleic acids to be 
separated. For larger DNA or RNA lower percentage of agarose was used allowing the 
molecule to pass through the relatively bigger pores in the agarose matrix. Whereas, for much 
smaller nucleic acids high percentage of agarose was used leading to the formation of small 
pore size in the matrix that serves as better sieve for the small molecules. Agarose gels were 
prepared by dissolving the appropriate amount of agarose in 1XTAE buffer. Ethidium 
Bromide (EtBr) was added to a final concentration of 0.3ng/ml to the melted agarose. 
Ethidium bromide is extensively used to make DNA or RNA molecule visible. It intercalates 
into the major groove of nucleic acids and fluoresces when the samples are exposed to the 
UV light. Once the gel was casted samples were mixed with 6X loading dye to a 1X final 
concentration and were loaded onto the wells followed by electrophoresis at 90V in 1X TAE 
buffer. 1KB+ DNA ladder (Invitrogen) was loaded alongside for size determination of the 
separated bands resulting from the samples. Images were captured using the IX Imager 
(INTAS, Gottingen). 
2.2.1.1.7. Extraction and purification of DNA 
To purify DNA from contaminants like enzyme and buffers, the bands were carefully excised 
from the agarose gel post electrophoresis. Further, the DNA was extracted and purified from 
the gel using Gel Extraction Kit (Seqlab) following the manufacturer’s protocol. After 
purification the DNA was eluted from the column using appropriate amount of TE or 
autoclaved dH2O. After the PCR, if a single specific DNA band was observed in the gel, the 
product was directly purified from the reaction mixture using PCR purification kit (Seqlab) 
and was eluted with appropriate amount of TE or autoclaved dH2O. 
2.2.1.1.8. Ethanol precipitation of DNA 
Ethanol precipitation was carried out to purify and concentrate DNA samples. Therefore, the 
DNA samples were mixed with 0.1 volume of 3M NaAc (pH5.2) and 3 volume of 100 % 
EtOH following storage at -20 °C for the duration of 1 hour to overnight for better 
precipitation. The following day the samples were centrifuged at 13000 rpm for 30 minutes at 
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4 °C. Following centrifugation the supernatant was carefully discarded and the pellet was 
washed with 500 µl of 70% EtHO followed by another centrifugation at 13000 rpm for 10 
minutes at 4 °C. The resulting pellet was air dried and the DNA was redissolved in 
appropriate volume of TE or autoclaved dH2O. 
2.2.1.1.9. Restriction digestion of DNA 
Digestion of DNA was carried out using specific restriction endonucleases. Restriction 
endonucleases recognise specific cleavage sites on the DNA, also known as restriction sites. 
The size of the restriction sites usually varies from 4-8 nucleotide bases depending on 
individual enzyme. Digestion of templates or plasmid DNAs were carried out using 10U of 
enzymes/~ 0.2-3.0ng of DNA in an appropriate buffer as recommended by the manufacturer. 
The optimum temperature for the reaction was determined depending on the enzyme used. 
Usually, 2 hours were allowed for the digestion of linear DNA molecules, whereas 6-8 hours 
were allowed plasmids. Two different restriction enzymes were selected for digestion of 
individual template and plasmid DNA. Primers to amplify these templates were designed in 
such a way that they contained these restriction sites and therefore the restriction sites were 
incorporated at the 5′ and 3′ ends of the resulting DNA. Use of two different restriction sites 
guided orientation specific ligation of these inserts into the multiple cloning sites (MCS) of 
the plasmids. In order to avoid re-circularization of the plasmid DNA, the digested vectors 
were treated with 1µl of alkaline phosphatase (CIP) to remove the terminal phosphate groups 
at the 5′ end of the linearized plasmids.  
2.2.1.1.10. Ligation 
Prior to ligation insert and vector were digested using compatible restriction enzymes in the 
appropriate buffer and temperature. Although, a molar ratio of 3:1 (insert: plasmid) was used 
to set up ligation, some exception were done and the molar ratio was adjusted according to 
the size, concentration and quality of the purified products (insert and vector). Usually, 
ligation was carried out in a total volume of 30 µl with 1U of T4 DNA ligase in a suitable 
buffer as recommended by the manufacturer. Ligation was set up overnight at 16 °C water 
bath. Negative controls were set up alongside using two different ligation reactions; one 
without the insert and the other without the T4 ligase. Following the overnight ligation the 
DNA from each reaction was precipitated using 100% EtOH and 3M NaAc as explained 
earlier under section 2.2.1.1.8. The precipitated DNA was re-dissolved in 10 µl of water and 
was used for transformation into electrocompetent E. coli cells.  
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2.2.1.1.11. Plasmid preparation 
Extraction and purification of plasmid DNA was carried out using Mini or Midiprep kit 
(Seqlab, Qiagen) according to the manufacturer’s protocol. Maxi preparation was done with 
an initial bacterial culture of 400 ml, whereas for miniprep initial volume of culture was 3-6 
ml. The protocol for the maxi preparation was slightly optimized. Basic principle of the 
extraction and purification of plasmid DNA underlines the alkaline lysis of bacteria using 
ionic detergent SDS in the lysis buffer (buffer II in the miniprep kit). SDS with a high pH 
lyses the bacteria and denatures proteins and contaminating chromosomal DNA. Plasmid 
DNA is also released as a result of lysis, but is non-separable because of its circular nature. 
Plasmid DNA binds to the ion exchange resin of the column provided with the kit. The 
column was washed several times with wash buffer following elution of the bound DNA with 
high salt buffer. The eluted DNA was precipitated using isopropanol and was further washed 
with 70% ethanol. After the final ethanol wash the DNA pellet was air-dried and re dissolved 
in 1.5 ml of TE buffer. In contrast, during mini preparation the DNA binds to silica matrix in 
the column in the presence of high salt buffer. After several washes the bound plasmid DNA 
was eluted with appropriate amount of TE buffer. 
2.2.1.1.12. Sequencing of DNA !
After purification, plasmid DNA samples were sequenced by Seqlab to ensure correct 
ligation and also absence of any mutation in the coding nucleotide regions. For this purpose 
600-700ng plasmid DNA mixed with 200 pmol appropriate primer was sent to Seqlab. For 
each construct one set of primers (forward and reverse primer) was used: one binding to the 
insert and the other to the vector. Sometimes depending on the length of DNA multiple 
primers were used to cover the entire length of the insert DNA.  After obtaining the 
sequencing report from Seqlab the sequence was aligned with the original sequence using 
EMBL-EBL ClustalW2 online software.  
2.2.1.2. Bacteriological methods 
2.2.1.2.1. Preparation of electrocompetent E. coli cells 
TOP 10 cells were inoculated from the stock into 10 ml superbroth and were allowed to grow 
overnight at 37 º C shaking incubator. The following morning 6 ml from the overnight culture 
was added to 600 ml of superbroth and was allowed to grow for another 4 hours and 30 
minutes in the 37 º C shaking incubator. Following incubation, the culture was cooled down 
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on ice and was centrifuged at 6000 rpm for 10 minutes. The pellet was washed three times 
with 600 ml of autoclaved ddH2O and three times with 600 ml of 10 % glycerol (v/v in 
ddH2O). Centrifugation between each wash was carried out at 6000 RPM for 15 minutes at 4 
º C. After the final wash the pellet obtained from 600 ml initial culture was dissolved in 1.5 
ml of 10 % glycerol (v/v in ddH2O) on ice in the cold room. The cell suspension was 
aliquoted in several 1.5 ml eppendorf tubes (100 µl in each) and shock frozen in liquid 
nitrogen. The cells were finally stored at -80 º C for future use. 
2.2.1.2.2. Liquid and solid bacteria cultures 
Electrocompetent E. coli TOP10 cells transformed with plasmid DNA were grown in super 
broth containing appropriate antibiotic at 37°C shaking incubator overnight. For plating the 
bacterial culture on solid media, LB agar (Roth) was made with appropriate antibiotics.  
2.2.1.2.3. Transformation of E. coli  
For transformation of plasmid DNA electrocompetent E. coli Top10 cells were used unless 
stated otherwise. As mentioned earlier, the DNA from ligation was precipitated and was 
redissolved in 10 µl of dH2O. For retransformation of plasmid DNA 3-10 µl of DNA was 
used depending on the concentration of the samples. The DNA was mixed well with 50µl of 
TOP10 cells on ice and immediately transferred to chilled electroporation cuvettes. 
Electroporation was carried out at 2kV, 25µF and 200Ω. Immediately after electroporation 
the cells were mixed with 1ml of prewarmed SOC medium following incubation for 45 
minutes at 37°C shaking incubator. The cultures were then plated on several dilutions ranging 
from 100 µl to 900 µl on LB agar plate containing appropriate antibiotics. The plates were 
further transferred to 37°C incubator and incubated overnight for the growth of bacterial 
colonies.  
2.2.1.2.4. Colony PCR 
Since blue-white selection using LacZ could not be used to identify the recombinant bacterial 
colonies, colony PCR method was adapted. After allowing overnight incubation of the 
bacterial agar plate at 37°C, single colonies were picked up from the plate and were first 
streaked on a prewarmed LB agar replica plate (numbered at the back). The same colony was 
further inoculated in 25µl colony mixture. The colony mixture contained appropriate primer 
pair along with premixed Taq polymerase, Taq reaction buffer (including Mg), dNTPs and 
loading dye. The duration of the extension step of the PCR was adjusted according to the 
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length of the template to be amplified. Following colony PCR samples were loaded on 
agarose gel to detect the amplified DNA product of the expected size in order to confirm 
successful cloning of the insert into the vector. 
2.2.1.2.4.1. Standard colony PCR reaction setup  !
Reagents & buffers Amount 
Colony Mix 23.5 µl 
 
Forward primer 0.5 µl (final concentration 1.0 pmol/µl) 
 
Reverse primer 0.5 µl (final concentration 1.0 pmol/µl) 
 
Taq polymerase  0.5 µl 
 
Colony  Inoculate with a pipette tip  
 
Final volume  25 µl 
2.2.1.2.4.2. Standard colony PCR cycling conditions !
Initial denaturation  94°C 5 minutes 
 
 
35 cycles 
94°C 
50°C 
72°C 
30 seconds 
50 seconds 
60 seconds per kb 
 
Final extension 72°C 10 minute 
 
Storage  4°C Hold 
  
2.2.2. Generation of transfection plasmids for this study 
2.2.2.1. Generation of dd-FKBP based constructs  (Armstrong and Goldberg, 2007)  
2.2.2.1.1. Generation of PfHsp70-1 (WT/DN) and GFP control constructs 
The coding sequence of the WT PfHsp70-1 (PF3D7_0818900) was amplified using Hsp70_F 
and Hsp70_R primers from 3D7 genomic DNA for the generation of the wild type Hsp70-1 
construct. Whereas, for the generation of the dominant negative constructs DNPfHsp70-1 
insert was amplified using Hsp70-1_F, Hsp70_E187K_R, Hsp70_E187K_F and Hsp70_R, 
primers by the method of overlapping extension PCR using 3D7 genomic DNA as the initial 
template as explained earlier under section 2.2.1.1.5. Following successful amplification and 
purification, the inserts were digested by BssHII and XmaI restriction enzymes. Digested and 
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purified fragments were cloned into pARL2-GFP vector pre-digested with BssHII and XmaI. 
Plasmids resulting from this ligation were amplified by miniprep and confirmed by test 
digestion and sequencing. The same plasmids were further used to subclone the dd-FKBP or 
control GFP on the N-terminus of the PfHsp70-1 (WT/DN) ORFs between AvrII and BssHII 
restriction sites. For this reason the ORF of FKBP was amplified from pre-existing plasmid 
(contained the FKBP insert) as template by FKBP_F and FKBP_R primers. The control GFP 
template was amplified from pARL2-GFP plasmid using GFP_AvrII_F_P and 
GFP_BssHII_R_P. Following PCR amplification and purification, both the FKBP and GFP 
templates were digested with AvrII and BssHII restriction enzymes. Purified templates were 
cloned between AvrII and BssHII sites into the predigested plasmids (already containing the 
WT/DN PfHsp70-1 insert). The constructs resulting from this ligation were amplified by 
miniprep and confirmed by test digestion and sequencing. The generated constructs were 
used to clone the 3XHA tag at the N-terminus of FKBP or GFP between XhoI and AvrII 
restriction sites. The 3XHA tag was amplified using a pre-existing plasmid (contained the 
3XHA tag) as template by 3XHA_F and 3XHA_R primers. Purified templates were cloned 
between XhoI and AvrII sites into the predigested plasmids (already containing the 
FKBP/GFP and WT/DN PfHsp70-1 inserts). The final transfection construct resulting from 
this ligation were amplified by miniprep and were confirmed by test digestion and 
sequencing. Finally, plasmids were amplified by maxiprep and were used for transfection. All 
the resulting plasmids are schematically illustrated in fig 2.2. 
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Figure 2.2 Schematic illustration of dd-FKBP based WT/DN PfHsp70-1 and GFP control plasmids.  
(a) Construct coding for wild type (WT) PfHsp70-1 fussed to the dd-FKBP domain at the N-terminus. (b) 
Construct coding for dominant negative (DN) PfHsp70-1 (E187K) fussed to dd-FKBP at the N-terminus. (c) 
Construct coding for WTPfHsp70-1, where the dd-FKBP at the N-terminus is replaced with control GFP. (d) 
Construct coding for DNPfHsp70-1, where dd-FKBP at the N-terminus is replaced with control GFP. 3XHA tag 
was cloned in all constructs at the extreme N-terminus between XhoI and AvrII for the purpose of detection of 
the fusion proteins. All constructs were generated using pARL2-GFP plasmid backbone. Colour codes 
representing each coding region are shown in the inset. Relative sizes of different inserts are not in scale.  
 
2.2.2.1.2 Generation of PfHsp40 (WT/DN) and GFP control constructs 
The Hsp40 (PF3D7_0213100) gene contains several introns. Therefore, reverse transcriptase 
PCR was carried out using RNA. The coding region of the WTPfHsp40 was amplified using 
Hsp40_F and Hsp40_R primers from the cDNA. On the other hand, for the generation of 
dominant negative PfHsp40 constructs, the DNPfHsp40 insert was amplified using Hsp40_F, 
Hsp40_D34N_R, Hsp40_D34N_F and Hsp40_R primers by the method of overlapping 
extension PCR using wild type PfHsp40 as a template as detailed earlier under section 
2.2.1.1.5. Following successful amplification and purification of the templates, digestions 
were carried out using BssHII and XmaI restriction enzymes. Digested and purified 
fragments were cloned into pARL2-GFP vector predigested with BssHII and XmaI. 
Constructs resulting from this ligation were amplified by miniprep and confirmed by test 
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digestion and sequencing.  The construct was further used to subclone the dd-FKBP or 
control GFP on the N-terminus of the PfHsp40s (WT/DN) between AvrII and BssHII 
restriction sites. For this reason the ORF of FKBP was amplified from pre-existing plasmid 
(contained the FKBP insert) as template by FKBP_F and FKBP_R primers. The control GFP 
template was amplified from pARL-2GFP plasmid using GFP_AvrII_F_P and 
GFP_BssHII_R_P. Following PCR amplification and purification, both the FKBP and GFP 
templates were digested with AvrII and BssHII restriction enzymes. Purified templates were 
then cloned between AvrII and BssHII sites into the predigested plasmid (already containing 
the WT/DN PfHsp40 inserts). The constructs resulting from this ligation were amplified by 
miniprep and confirmed by test digestion and sequencing. The generated constructs were 
further used to clone the 3XHA tag at the N-terminus of FKBP or GFP between XhoI and 
AvrII restriction sites. The 3XHA tag was amplified from pre-existing plasmid (contained the 
3XHA tag) as template by 3XHA_F and 3XHA_R primers. Purified templates were cloned 
between XhoI and AvrII sites into the pre-digested plasmid (already containing the 
FKBP/GFP and WT/DN PfHsp40 inserts). The final transfection constructs resulting from 
this ligation were amplified by miniprep and were confirmed by test digestion and 
sequencing. After confirmation plasmid DNAs were amplified by maxi preparation and used 
for transfection. All the resulting plasmids are schematically illustrated in fig 2.3. 
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Figure 2.3 Schematic illustration of dd-FKBP based WT/DN PfHsp40 and GFP control plasmids.  
(a) Construct coding for wild type (WT) PfHsp40 fussed to the dd-FKBP domain at the C-terminus. (b) 
Construct coding for dominant negative (DN) PfHsp40 (D34N) fussed to dd-FKBP at the C-terminus. (c) 
Construct coding for WT PfHsp40, where the C-terminus dd-FKBP is replaced with control GFP. (d) Construct 
coding for DN PfHsp40, where dd-FKBP at the C-terminus is replaced with control GFP. 3XHA tag was cloned 
in all constructs at the extreme N-terminus between XhoI and AvrII for the purpose of detection of the fusion 
proteins. All constructs were generated using pARL2-GFP plasmid backbone. Colour codes representing each 
coding region are shown in the inset. Relative sizes of different inserts are not in scale. 
2.2.2.2. Generation of dd-ecDHFR based constructs (Iwamoto et al., 2010) 
            
2.2.2.2.1. Generation of PfHsp70-1 (WT/DN) and GFP control constructs 
For the generation of the dd-ecDHFR based constructs, the 3XHA tag was amplified from a 
pre-existing plasmid (contained the 3XHA tag) as a template using 3XHA_F and 3XHA_R 
primers. Digested and purified 3XHA tag was cloned between XhoI and AvrII sites into the 
predigested pARL-BSD plasmid. The construct resulting from this ligation was amplified by 
miniprep and confirmed by test digestion and sequencing. The resulting plasmid containing 
the 3XHA tag was further used for further cloning of dd-ecDHFR. Therefore, ORF of dd-
ecDHFR was amplified by ecDHFR_AvrII_F_P and ecDHFR_BssHII_R_P from a plasmid 
containing the dd-ecDHFR domain kindly provided by Prof Thomas J Wandless. After 
amplification the dd-ecDHFR insert was digested with AvrII and BssHII, following 
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purification and cloning into pARL-BSD (containing the HA tag) predigested with the 
compatible restriction endonucleases. The resulting constructs were amplified by miniprep 
and was confirmed by test digestion and sequencing. The sequencing revealed two bases 
missing at the end of the dd-ecDHFR insert. Since the template ends with a pair of ‘GC’ and 
followed by a ‘GCGCGC’ (BssHII restriction site), BssHII recognised GC of the template as 
the start of the restriction site and the other GC at the middle of the actual restriction site as 
the end instead of the last GC of the BssHII site. As a consequence the resulting construct 
had a pair of ‘GC’ missing at the end. This ends up in shifting the reading frame of the 
multiple cloning sites. The inserts that needed to be cloned to the C-terminus of the dd-
ecDHFR ORFs are GFP and WT/DN PfHsp70-1. Therefore, to solve this frame shift an extra 
‘TA’ was planned to be incorporated between the BssHII restriction sites and start codon 
(ATG) of the following inserts. Therefore, the forward primers to amplify GFP or WT/DN 
PfHsp70 were designed accordingly to incorporate two extra nucleotide bases TA at the 
beginning of the ORF. WT/DN PfHsp70-1 was amplified from pre-existing construct (fig. 
2.2a and fig. 2.2b) using Hsp70_TA_F and Hsp70_R primers. Likewise, the GFP fragment 
was amplified from a pre-existing construct (fig. 2.2c) using GFP_BssHII_TA_F and 
GFP_XmaI_R_P. After successful amplification, the inserts were digested with appropriate 
enzymes and were cloned between the BssHII and XmaI restriction sites of the pre-digested 
vector (containing 3XHA-dd-ecDHFR) for the generation of the final transfection construct. 
The resulting constructs were amplified by miniprep and was confirmed by restriction 
digestion and sequencing. Sequencing revealed that the ORF was back in frame by the 
successful insertion of the additional TA before the open reading frame (ORF) of the WT/DN 
PfHsp70-1 and GFP. These final constructs were further propagated by maxi preparation and 
were used for transfection. All the resulting plasmids are schematically illustrated in fig 2.4. 
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Figure 2.4 Schematic illustration of dd-ecDHFR based WT/DN PfHsp70-1 and GFP control plasmids.  
(a) Construct coding for wild type (WT) PfHsp70-1 fussed to the dd-ecDHFR domain at the N-terminus. (b) 
Construct coding for dominant negative (DN) PfHsp70-1 (E187K) fussed to dd-ecDHFR at the N-terminus. (c) 
Control construct coding for GFP, fussed to dd-ecDHFR at the N-terminus. 3XHA tag was cloned in all 
constructs at the extreme N-terminus between XhoI and AvrII for the purpose of the fusion proteins. All 
constructs were generated using pARL-BSD plasmid backbone. Colour codes representing each coding region 
are shown in the inset. Relative sizes of different inserts are not in scale. 
2.2.2.2.2. Generation of PfHsp40 (WT/DN) and GFP control constructs 
For the generation of the dd-ecDHFR based WT/DN PfHsp40 and control GFP construct 
WT/DN PfHsp40 ORFs were amplified from two pre-existing plasmids (fig. 2.3a and 
fig.2.3b) using Hsp40_AvrII_F_P and Hsp40_BssHII_R_P. Whereas, the ORF of the GFP 
was amplified from another construct (fig. 2.2c) using GFP_AvrII_F and GFP_BssHII_R 
primers. The amplified inserts were purified and digested with AvrII and BssHII restriction 
endonucleases. The digested and purified inserts were then cloned into digested pARL-BSD 
plasmid (containing the 3XHA between XhoI and AvrII) between AvrII and BssHII 
restriction sites. The constructs resulting from this ligation were amplified by miniprep and 
confirmed by test digestion and sequencing. Unlike the dd-ecDHFR based PfHsp70-1 
constructs as mentioned earlier, the dd-ecDHFR was cloned to the C-terminus of the protein 
of interests (POIs) in these constructs. Therefore, dd-ecDHFR was amplified from a plasmid 
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(fig. 2.4a) using ecDHFR_BssHII_F_P and ecDHFR_XmaI_R_P. Following digestion with 
the appropriate enzymes and purification, the dd-ecDHFR insert was cloned between BssHII 
and XmaI restriction sites of the predigested pARL-BSD (containing the 3XHA-
WT/DNPfHsp40 or GFP). The resulting constructs were amplified by miniprep and were 
confirmed by restriction digestion and sequencing. The resulting plasmids were multiplied 
and purified by maxi preparation and were used for transfection. All the resulting plasmids 
are schematically illustrated in fig 2.5.  
 
Figure 2.5 Schematic illustration of dd-ecDHFR based WT/DN PfHsp40 and GFP control plasmids.  
(a) Construct coding for wild type (WT) PfHsp40 fussed to the dd-ecDHFR domain at the C-terminus. (b) 
Construct coding for dominant negative (DN) PfHsp40 (D34N) fussed to dd-ecDHFR at the C-terminus. (c) 
Control construct coding for GFP, fussed to dd-ecDHFR at the C-terminus. 3XHA tag was cloned in all 
constructs at the extreme N-terminus between XhoI and AvrII for the purpose of detection of the fusion 
proteins. All constructs were generated using pARL-BSD plasmid backbone. Colour codes representing each 
coding region are shown in the inset. Relative sizes of different inserts are not in scale. 
2.2.2.3. Generation of DD29 based constructs (Chu et al., 2008) !!!!!!!!!!!!!!!! 
2.2.2.3.1. Generation of PfHsp70-1 (WT/DN) and GFP control constructs 
For the generation of the DD29 based WT/DNPfHsp70-1 constructs pre-existing dd-
FKBP_WT/DN transfection plasmids (fig. 2.2a and fig. 2.2b) were used. These plasmids had 
hDHFR cassette in the backbone. The plasmids also contained an N-terminus 3XHA 
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(between XhoI/AvrII) followed by dd-FKBP (between AvrII/BssHII) and WT or DNHsp70-1 
(between BssHII and XmaI) as mentioned earlier. DD29 ORF was amplified by 
DD29_AvrII_F_P and DD29_BssHII_R_P from PJDD41 plasmid (containing the DD29 
coding region) kindly provided by Prof Thomas J Wandless. Following amplification, the 
DD29 insert was digested by AvrII and BssHII restriction endonucleases. The plasmids 
coding for 3XHA-dd-FKBP_WT/DNPfHsp70-1 (fig.2.2a and fig.2.2b) were digested with 
AvrII and BssHII restriction endonucleases to swap the dd-FKBP with DD29 insert. After 
digestion the plasmids were purified. DD29 was cloned between the AvrII and BssHII 
restriction sites of the digested plasmids. The resulting plasmids from this ligation were 
amplified by mini preparation and were confirmed by test digestion and sequencing. As the 
dd_FKBP in these two plasmids was replaced successfully with DD29 the resulting plasmids 
had 3XHA at the N-terminus (between XhoI/AvrII) followed by DD29 (between AvrII/ 
BssHII) and WT or DNPfHsp70-1 (between BssHII/XmaI) (fig.2.6a and fig.2.6b). Therefore, 
the DD29 based WT/DNPfHsp70-1 transfection was generated by this one step ligation. For 
the generation of the control GFP construct a different strategy was employed. In neither of 
the PfHsp70-1 constructs (DN and WT), the PfHsp70-1 insert could be swapped with GFP 
insert using BssHII and XmaI. The reason being that DD29 contained an XmaI restriction site 
within its ORF. For this reason, pARL2-GFP plasmid was used for the generation of 3XHA-
DD29-GFP plasmid. The 3XHA was first amplified from one of the pre existing plasmids 
using 3XHA_F and 3XHA_R primers. Purified insert was digested using XhoI and AvrII 
restriction endonucleases and purified. Digested and purified 3XHA tag was cloned between 
the XhoI and AvrII restriction sites in predigested and purified pARL2-GFP plasmid. 
Construct resulting from this ligation was amplified by miniprerp and confirmed by test 
digestion and sequencing. Further, ORF coding for DD29 was amplified from PJDD41 
plasmid using DD29_AvrII_F_P and DD29_BssHII_R_P. The primers deleted the stop 
codon at the end of the amplified insert. After PCR amplification the insert was digested with 
AvrII and BssHII restriction enzymes following purification. The purified DD29 insert was 
cloned in frame to the C-terminus of 3XHA in the pARL2-GFP plasmid in between the AvrII 
and BssHII restriction sites. The resulting construct was amplified and was confirmed by test 
digestion and sequencing. An advantage of using the pARL2-GFP plasmid for cloning was 
that it already contained a GFP in frame to the C-terminus of the cloned DD29 between KpnI 
and XmaI restriction sites. Therefore, the construction 3XHA-DD29-GFP plasmid was 
complete. The plasmids were further amplified following purification by maxi preparation 
and used for transfection. All the resulting plasmids are schematically illustrated in fig 2.6. 
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Figure 2.6 Schematic illustration of DD29 based WT/DN PfHsp70-1 and GFP control plasmids.  
(a) Construct coding for wild type (WT) PfHsp70-1 fussed to the DD29 domain at the N-terminus. (b) Construct 
coding for dominant negative (DN) PfHsp70-1 (E187K) fussed to DD29 at the N-terminus. (c) Control 
construct coding for GFP fussed to the DD29 domain at the N-terminus. Unlike in the WT and DN PfHsp70-1 
coding constructs, GFP was cloned between KpnI and XmaI restriction sites. 3XHA tag was cloned in all 
constructs at the extreme N-terminus between XhoI and AvrII for the purpose of the detection of the fusion 
proteins. All constructs were generated using pARL2-GFP plasmid backbone. Colour codes representing each 
coding region are shown in the inset. Relative sizes of different inserts are not in scale. 
2.2.2.3.2. Generation of PfHsp40 (WT/DN) and GFP control constructs 
For the generation of the DD29 based WT/DNPfHsp40 constructs a pre-existing plasmid 
kindly provided by Sabrina Heiny was used. This plasmid unlike pARL2-GFP had a 
blasticidin (BSD) selection cassette instead of hDHFR. The DD29 was amplified from 
PJDD41 plasmid using DD29_BssHII_F_P and DD29_KpnI_R_P. The PCR product was 
purified and the insert was digested with BssHII and KpnI restriction enzymes. The purified 
insert was cloned between BssHII and KpnI restriction sites in the predigested plasmid 
(obtained from Sabrina Heiny). After successful ligation the resulting plasmid was amplified 
following confirmation by test digestion and sequencing. This plasmid already contained an 
ORF of GFP in frame at the N-terminus of the cloned DD29 between AvrII and BssHII 
restriction sites. Therefore, to clone the 3XHA tag the plasmid was further digested with 
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XhoI and AvrII restriction endonucleases. Simultaneously, the 3XHA insert was amplified 
from pre-existing plasmid using 3XHA_F and 3XHA_R primers. After PCR the insert was 
digested with XhoI and AvrII restriction enzymes following purification. The purified insert 
was cloned in frame to the N-terminus of the GFP between XhoI and AvrII restriction sites in 
the predigested plasmid (already containing GFP and DD29). The resulting construct from 
this ligation was amplified following confirmation by test digestion and sequencing. This 
construct was used as GFP-dd-ecDHFR control transfection construct. The GFP construct 
was further used for the cloning of WT and DNPfHsp40 inserts. The ORF of the WTPfHsp40 
(PF3D7_0213100) and DNPfHsp40 was amplified from pre-existing dd-FKBP based 
WT/DN-Hsp40 constructs (fig.2.3a and fig.2.3b) using Hsp40_AvrII_F and 
Hsp40_BssHII_R_P primers. The inserts were digested using AvrII and BssHII restriction 
endonucleases. The purified inserts were cloned between the AvrII and BssHII restriction 
sites in the predigested GFP control construct (fig.2.7c), thus replacing the GFP by either 
WTPfHsp40 or DNPfHsp40. Both the resulting plasmids were amplified following 
confirmation by test digestion and sequencing. Finally, all the dd-ecDHFR based 
WT/DNPfHsp40 and control GFP plasmids were amplified and used for transfection. All the 
resulting plasmids are schematically illustrated in fig 2.7. 
     
Figure 2.7 Schematic illustration of DD29 based WT/DN PfHsp40 and GFP control plasmids.  
(a) Construct coding for wild type (WT) PfHsp40 fussed to the DD29 domain at the C-terminus. (b) Construct 
coding for dominant negative (DN) PfHsp40 (D34N) fussed to DD29 at the C-terminus. (c) Control construct 
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coding for GFP fussed to the DD29 domain at the C-terminus. 3XHA tag was cloned in all constructs at the 
extreme N-terminus between XhoI and AvrII for the purpose of detection of the fusion proteins. All constructs 
were generated using pARL-BSD plasmid backbone. Colour codes representing each coding region are shown 
in the inset. Relative sizes of different inserts are not in scale. 
2.2.2.4. Importance of tagging the destabilisation domains (dds) to the N -
terminus of the PfHsp70-1 whereas, the same is ligated to the C-terminus of 
the PfHsp40 
In all the plasmids coding for either wild type of dominant negative PfHsp70-1 the 
GFP/FKBP/dd-ecDHFR/DD29 was fused to the N-terminus of the protein to be studied. 
Since, the C-terminal EEVD motif of PfHsp70-1 is important for interaction with partner 
proteins (Shonhai et al., 2007) we avoided tagging the C-terminus that could interfere with 
the in vivo normal functional interaction of the fusion proteins. 
On the other hand, in all the plasmids coding for either wild type or dominant negative 
PfHsp40 the GFP/FKBP/dd-ecDHFR/DD29 was ligated to the C-terminus of the candidate 
proteins. PfHsp40 contains a highly conserved HPD motif located in the J domain towards 
the N-terminus. The HPD tripeptide is the signature domain of the Hsp40 family of proteins 
and facilitates interaction with the ATPase domain of Hsp70 by binding to an acidic cleft 
(Fan et al., 2003). Therefore, we avoided tagging at the N-terminus that could interfere with 
the in vivo normal functional interaction of PfHsp40 with PfHsp70-1. 
2.2.2.5. Cloning of PfHsp70-1 promoter into pARL2-GFP vector 
During this study pARL2-GFP plasmid was mostly used as a backbone to generate all 
plasmids for transfection. pARL2-GFP possesses a CRT promoter, which is weaker in nature 
when compared to the native Hsp70 promoter of the Plasmodium falciparum. Therefore, 
CRT promoter was replaced with Hsp70 promoter to generate a pARL2-GFP plasmid, where 
expression of the fusion protein could be driven from Hsp70-1 promoter. This provides the 
opportunity to place PfHsp70 insert in frame next to its native promoter. This makes 
comparative study with transgenic parasite line more realistic as both the endogenous wild 
type and episomal dominant negative PfHsp70-1 is under the control of their native promoter. 
Promoter region is always highly AT rich making it challenging to design primer for this 
region.  Therefore, first the larger fragment of the 5 ′ promoter region was amplified by the 
initial PCR reaction using 3D7 genomic DNA as template. For this PCR, Hsp70_5'_F1 
forward primer (annealing 1749 bp upstream the 5′ UTR of the PfHsp70-1 ORF) and 
Hsp70_5'_R1 primer (annealing 2 bp downstream from the start codon of Hsp70_1 ORF) 
were used. At the end of the PCR reaction the PCR product was found to be at the right size 
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on agarose gel. The desired DNA band was excised from the agarose gel following 
purification by the gel extraction kit (following manufacturer’s protocol). The amplified 
product from the initial PCR reaction was further used as template for the second PCR 
reaction. This minimizes the chances of unspecific annealing of the primers as a single 
isolated template is used, instead of the whole 3D7 genomic DNA. Hsp70_5'_NotI_F2 
forward primer (annealing 1520 bp upstream the 5 ′ UTR) and Hsp70_5'_XhoI_R2 reverse 
primer (annealing 18 bp upstream the 5 ′ UTR) were used. The PCR product was found to be 
at the right size on agarose gel and was further purified by gel extraction kit (following 
manufacturer’s protocol). The purified insert was digested with NotI and XhoI restriction 
endonucleases. The digested insert was purified by PCR purification kit (following 
manufacturer’s instructions). Simultaneously, pARL2-GFP plasmid was also digested with 
NotI and XhoI restriction endonucleases that resulted in the excision of the CRT promoter. 
The digested plasmid was loaded on agarose gel following purification by gel extraction kit 
(following manufacturer’s protocol). The insert (Hsp70-1 promoter) was finally cloned 
between the NotI and XhoI restriction sites in the pre-digested pARL2-GFP plasmid. The 
resulting plasmid was amplified following confirmation by test digestion and sequencing. 
Upon confirming the successful swapping of the CRT promoter with the PfHsp70-1 promoter 
the plasmid was amplified and used for transfection.  
2.2.3. Parasite cultivation 
2.2.3.1. Routine culture of Plasmodium falciparum, synchronisation and 
enrichment of the infected erythrocytes  
Plasmodium falciparum was cultured in human A+ blood and was maintained at a 
haematocrit of 4% in RPMI cell culture media. The RPMI was supplemented with 10% A+ 
human serum, 20µg/ml gentamycin or neomycin (0.1mg/ml), and 200µg hypoxanthine as 
described by Trager and Jensen (1976) (Trager and Jensen, 1976). Culture of the parasite was 
either maintained in a T75 cell culture flask or plates with 35 ml of RPMI at 37°C gas 
incubator with a constant supply of 5% CO2 and 5% O2.  
D-sorbitol was used to synchronise parasites at ring stage (Lambros and Vanderberg, 1979). 
Late stage parasite (trophozoite or schizont) leads to increased permeability of the 
erythrocytes. Therefore, treatment with 5% d-sorbitol for 10 minutes at 37°C results in an 
osmotic imbalance in the late stage infected erythrocyte that finally leads to cell lysis. 
Whereas, RBCs infected with ring stage of Plasmodium falciparum do not have such 
2 Materials and Methods       69 
! !
increased permeability and therefore can survive this treatment. After treatment the pellet 
(which should contain only ring infected erythrocytes) was washed 1X with cell culture 
RPMI media and was immediately plated with 35ml of media. 
Enrichment of trophozoite - infected erythrocytes was achieved by the method of gelafundin 
flotation as described by Pasvol et al., (1978) (Pasvol et al., 1978). Once the infected blood 
pellet was prepared from the whole culture, it was incubated with 7 ml of gelafundin solution 
for 10 minutes at 37°C. Following incubation the supernatant was carefully collected in a 
new tube and was centrifuged at 3000 rpm for 2 minutes. The pellet was further mixed with 
10 fold volume of RPMI cell culture media and a slide was made from the cell suspension in 
order to calculate the parasitemia. Following the determination of the parasitemia, the culture 
was diluted by the addition of fresh blood to achieve the required parasitemia. 35 ml of RPMI 
was added and the culture was returned to 37°C incubator. 
2.2.3.2. Culture of Toxoplasma gondii 
The RH strain of Toxoplasma Gondii was cultured in Human Foreskin Fibroblast (HFF) with 
Dulbecco’s Modified Eagle Medium (DMEM) at 37 °C gas incubator (5% CO2). The 
parasites grow and replicate intracellular. Upon rupture of the HFF cells, the free tachyzoites 
(extracellular parasites) invade new host cells. Once all the HFFs are utilised by the parasites, 
appropriate amount of media (containing the free tachyzoites) was transferred to a new flask 
containing HFFs. Thus, the free tachyzoites could further invade new host cells and the 
culture could be continued. 
2.2.4. Culture of Human Foreskin Fibroblast (HFF) cell line 
The HFFs are adherent cells that can be visualized under a 10X objective of a light 
microscope. The media was changed twice a week. The cells were first washed 1X with 
DMEM medium (without FCS) following supplementation with fresh DMEM. The HFFs 
were diluted once they were confluent. For dilution and subculture of the HFFs, first the 
supernatant was discarded following 1X wash with DMEM (without FCS). The HFFs were 
detached from the surface of the flask by trypsinisation. For this, the cell monolayer was 
incubated shortly with 1X trypsin/EDTA solution. After this short incubation period trypsin 
was removed and the flask containing the HFFs was incubated for additional 10 minutes at 37 
°C for efficient detachment of the cells. Detachment of the cells was confirmed by checking 
flask under the microscope. The cells were collected by centrifugation. Finally appropriate 
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amount of HFFs were seeded into a new flask supplemented with DMEM and transferred to 
the 37 °C gas incubator (5% CO2). 
2.2.4. Transfection of parasite lines  !
2.2.4.1. Transient transfection of Toxoplasma gondii (Soldati and Boothroyd, 1993) 
For Transient transfection of Toxoplasma gondii 50-100µg of plasmid DNA was linearized 
by NotI endonuclease one day prior to the transfection. The DNA was precipitated overnight 
with 100 % EtOH and 3M NaAc as described previously. On the day of transfection the 
precipitated DNA pellet was further washed with 70% EtOH and dried on 50 °C. The dried 
DNA pellet was resuspended in 50 µl of cytomix and incubated at 50 °C until the pellet was 
completely dissolved. Simultaneously, 3 X 107 extracellular parasites (Tachyzoites) were 
collected by centrifugation. The parasite pellet obtained, was dissolved in 500 µl of cytomix 
following the addition of the plasmid DNA. The mixture was transferred to electroporation 
cuvette and electroporated at 2000 V, 25 Ω and 50µF.  Post pulse the mixture was 
immediately transferred to a 6 well plate containing high density of HFFs and further 
incubated for one day at 37 °C gas incubator (5% CO2). On the next day Xanthin (50µg/ml) 
and Mycophenolic acid (25µg/ml) was added to the well for selection. Medium supplemented 
with Xanthin (50µg/ml) and Mycophenolic acid (25µg/ml) was changed on alternative days. 
Once the parasites were extracellular they were used for the study. 
2.2.4.2. Transfection of Plasmodium falciparum (Crabb et al., 1997) 
Plasmodium falciparum was cultured in human O+ RBC and supplemented with gibco cell 
culture medium 24 hours prior to transfection. For transfection approximately 100µg plasmid 
DNA was precipitated overnight using 100 % EtOH and 3M NaAc as explained earlier. On 
the day of transfection the DNA pellet obtained from precipitation was washed 1X with 70% 
EtOH and was dried at 50 °C.  The dried DNA pellet was redissolved in 30 µl of TE buffer 
(pH7.6) at 50 °C. Simultaneously a thin blood smear was prepared from the culture in order 
to determine the stage and parasitemia. Transfection of Plasmodium was mostly carried out at 
ring stage with a parasitemia of 5-10 %. After determination of the desired stage and optimal 
parasitemia, the whole culture was centrifuged at 3000 rpm for 2 minutes. The pellet obtained 
from the parasitized RBC was used for transfection. Prior to transfection 385 µl of cytomix 
and 200 µl of iRBC (from the RBC pellet) was mixed with the DNA suspension (30 µl) by 
gentle tapping. The entire mixture was transferred to an electroporation cuvette (0.2 cm gap) 
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and was electroporated at 0.310kV and 950µF (high capacitance). Usually the time constant 
was found to vary between 8-12 msec. Post pulse the cells were transferred to a T25 cell 
culture flask or plate containing 12 ml of pre-warmed gibco cell culture medium 
(supplemented with 0.25% AlbuMAX II, 5% human serum, hypoxanthine and gentamycin / 
neomycin). In addition, 400 µl of fresh O+ human erythrocyte was added to the medium and 
the cells were transferred to the 37°C gas incubator. 4 hours post transfection appropriate 
selection drug was added to the culture. During this work, WR 99210 was added to a final 
concentration of 2.5 nM, whereas Blasticidin (BSD) was used at a final concentration of 
4µg/ml. From the following day a thin slide was made from the blood and was observed 
under 100X objective of the light microscope. The media was changed daily until no live 
parasite could be seen. Once all parasites were found to be dead, only twice a week used 
medium was replaced with fresh medium supplemented with appropriate drug. The culture 
was passaged with 200µl fresh O+ human erythrocyte after 14 days. Once the parasite started 
to reappear at least 3-4 vials of transfected parasite were immediately frozen as back up 
(following the freezing protocol) and were stored at -80°C. Once few such vials were stored 
experiments were carried out with the transgenic lines.  
Noteworthy, all the plasmids coding for the fusion proteins tagged to dd-ecDHFR were 
transfected into Plasmepsin I (PM1 KO) cell lines during this work. PM1 KO 3D7 line 
contained a human DHFR (hDHFR) integrated into the gene of the parasite (Liu et al., 2005). 
The stabilising ligand, TMP used in this study is toxic to wild type 3D7, but the presence of 
hDHFR confers resistance to the parasite against TMP. 
2.2.5. DNA extraction from infected erythrocyte 
To confirm that the transgenic parasite line is expressing the right plasmid, the plasmid DNA 
was extracted from each transgenic line. In order to carry out DNA extraction the whole 
culture was lysed by 0.1% saponin solution in a total volume of 10 ml with PBS (PIC and 
PMSF supplemented) as mentioned under section 2.2.8.1.1. After lysis the parasite pellet was 
dissolved in 200 µl PBS (pH7.4) following the addition of 200µl 2x sample buffer A. 100 µl 
20 % SDS was added to the sample and mixed by inverting the tube. The DNA was further 
extracted by phenol-chloroform treatment. Following the phenol-chloroform treatment the 
top most layer containing the DNA was collected carefully in a separate tube and was 
precipitated by ethanol. The ethanol precipitated DNA was re-dissolved in 500 µl of TE 
buffer (pH8.0) and the phenol-chloroform extraction was repeated. After this treatment the 
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top most layer was collected and was subjected to chloroform extraction to remove residual 
phenol. The resulting top phase was further carefully transferred to a new tube and plasmid 
DNA was precipitated by ethanol precipitation. The DNA pellet was finally dissolved in 
appropriate amount (50-100 µl) of TE buffer (pH8.0). Finally the plasmid DNA was digested 
with appropriate restriction endonucleases and visualised on agarose gel against 1 Kb+ DNA 
ladder. 
2.2.6. Cryopreservation 
In order to maintain long-term storage of transgenic parasite line, parasite cultures at ring 
stage with at least 3% parasitemia, was centrifuged at 3000 RMP for 2 minutes. The pellet 
was mixed with equal amount (volume/volume) of freezing solution. The mixture was 
immediately transferred to a labelled cryopreservation tube and was shock frozen at liquid 
nitrogen for 10 minutes. Following freezing the tubes were stored at -80 °C for few days 
before being transferred to liquid nitrogen. 
2.2.7. Thawing of cryopreserved infected RBC 
In order to thaw frozen transgenic parasite line and bring them back to culture, the frozen 
cells were taken out from the liquid nitrogen and were first allowed to thaw at room 
temperature (RT). Once the frozen aliquots were completely thawed, they were transferred to 
a 15ml falcon tube. To this 200 µl of thawing solution I (200µl/1ml of frozen iRBC) was 
added drop-wise with constant shaking following incubation for 3 minutes at RT. After 3 min 
of incubation 5ml of the thawing solution II was added drop-wise with constant shaking 
followed by an additional incubation for 3 minutes at RT. At last 5 ml of thawing solution III 
was added drop-wise with shaking and was incubated for 3 minutes at RT. The mixture was 
finally centrifuged at 3000 rpm for 2 minutes. The pellet was washed 1X with gibco cell 
culture media (supplemented with 0.25 % AlbuMAXII, 5 % human serum, hypoxanthine). 
Post washing the pellet was plated in a T25 cell culture flask/ plate with 12 ml gibco media 
and fresh A+/O+ human RBC (300-400 µl). The following day appropriate selection drug was 
added. The cells were observed regularly under the microscope for the reappearance of the 
live parasite.  
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2.2.8. Methods with infected erythrocytes 
2.2.8.1. Protein biochemical methods 
2.2.8.1.1. Saponin lysis of infected erythrocytes 
To gather pool of free parasite with intact parasite membrane saponin lysis of infected 
erythrocyte was carried out. Saponin is a non-ionic detergent and believed to interact with 
cholesterol in lipid bilayers and liposomes (Beaumelle et al., 1987). During treatment with 
saponin the erythrocyte plasma membrane along with the parasitophorous vacuolar 
membrane (PVM) are permeabilise, but the parasite membrane stays intact. Infected blood 
pellet (mixed or gelafundin enriched culture) was treated with 0.1% of saponin solution in a 
total volume of 10 ml PBS (pH7.4, supplemented with PIC and PMSF) for 6 minutes on ice. 
After the incubation period the intact parasites were collected by centrifugation at 5000 rpm 
for 4 minutes at 4 °C. The pellet was washed with PBS until no haemoglobin was left and the 
supernatant turned colourless. Supernatant was discarded (contained soluble content of the 
PV and the host RBC cytosol) and the pellet contained the intact parasites. Since during this 
thesis work cytosolic protein contents from the parasite were studied, we were not interested 
in the content of the RBC and PV. Further, the parasite pellet was dissolved in appropriate 
amount of 2X SDS sample buffer (PIC and PMSF supplemented) and boiled at 95 °C for 10 
minutes prior to be analysed by SDS-PAGE. In some cases depending on the experiments the 
resulting pellet from the saponin lysis was further lysed by Tris lysis buffer and centrifuged at 
18000 rpm for 20 minutes at 4 °C. The pellet resulting from the centrifugation contained the 
parasite plasma membrane whereas the supernatant contained the cytosolic protein from the 
parasite. The supernatant was carefully transferred to a new tube. The supernatant (cytosolic 
fraction) and the pellet (membrane fraction) were mixed separately with appropriate amount 
of 2X SDS sample buffer and boiled at 95 °C for 10 minutes. Finally, the samples were 
analysed by SDS-PAGE. 
2.2.8.1.2. Experiment with Shield-1 or TMP 
To determine whether shield-1 or TMP has any effect on the stabilization of the fusion 
protein, appropriate transgenic parasite lines were treated without or with different 
concentration of shield-1 or TMP. Individual Plasmodium falciparum transgenic line was 
treated with D-sorbitol and synchronised at ring stage. Under the light microscope the 
resulting parasitemia of the culture was determined. The parasetimia was further adjusted to 
0.4 % by adding fresh A+ human blood. 200 µl of infected blood (0.4 % parasetimia) was 
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seeded in each well with 5 ml of gibco cell culture media supplemented with appropriate 
selection drug. Individual well was treated without or with increasing concentration of shield-
1 (0.5-1.5 µM) / TMP (5.0-15.0 µM). TMP stock was maintained at a concentration of 
100mM in 100 % EtOH, which was further diluted by adding cell culture media to the 
desired working concentration. The shield-1 was diluted directly into the cell culture media to 
obtain the desired working concentration. The media was changed every day supplemented 
with drug and +/- shield-1/TMP until 72 hours. After 72 hours the parasitemia of the culture 
from individual well was determined. Following determination of the parasitemia cells from 
each well was pelleted and was treated with saponin separately as explained earlier. The 
pellets obtained from saponin lysis were dissolved in appropriate amount of 2X SDS sample 
buffer and boiled for 10 minutes at 95 °C prior to SDS-PAGE. Equal amount of parasite 
equivalence were loaded in each well of the SDS-PAGE for comparative study. 
Transgenic Toxoplasma gondii was treated with +/- shield-1. Shield-1 was added to a final 
concentration of 0.5 µM into the media in a T25 cell culture flask on free tachyzoites. At the 
same time another T25 flask with free tachyzoites was maintained without shield-1 as 
negative control. After 24 hours of incubation +/- shield-1, parasites from both the flasks 
were collected in 15 ml falcon tubes and 10 µl of cell suspension was loaded onto 
haemocytometer chamber for counting. The suspensions were centrifuged at 3000 RPM for 5 
minutes to obtain cell pellet. The pellets were finally dissolved in appropriate amount 2X 
SDS sample buffer (supplemented with PIC and PMSF) to achieve similar cell equivalence. 
Finally, 3x107 parasite equivalence was loaded in each well of the SDS-PAGE for 
comparative analysis. 
2.2.8.1.3. Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis or SDS-
PAGE  
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)!(Laemmli, 1970) 
was carried out to separate individual protein according to their molecular weight from a pull 
of cytosolic protein. Proteins are usually neutrally charged but the application of SDS imparts 
an overall negative charge to the protein molecules. As a result, the negatively charged 
proteins run towards the positive pole under electric field and get separated according to their 
molecular weight. Presence of dithiothreitol (DTT) to the SDS PAGE sample buffer reduces 
disulphide bonds thereby supporting protein denaturation. During electrophoresis the gel 
matrix serves as a molecular sieve. The smaller proteins more easily pass through the pores, 
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therefore migrate longer distance in the gel. Whereas, the larger ones cannot migrate easily 
hence remain close to the points of their origin. Therefore, the proteins would have 
differentially migrated according to their sizes that result in the separation of different size 
proteins at different levels in the gel matrix. During this work prior to analysis the samples 
were mixed with appropriate amount of 2X SDS-PAGE sample buffer (supplemented with 
fresh DTT) and boiled for 10 minutes at 95 °C. The samples were loaded onto the gel 
alongside a prestained protein marker (Thermo Scientific) for the determination of the size of 
individual protein band. The percentage of the SDS-PAGE separating gel was determined 
depending on the expected size of protein. Usually 10-12% gel was used. Concentration of 
the gel was increased further if small molecular weight protein was being studied.  
2.2.8.1.4. Semi-dry immunoblotting  
Semi-dry immunoblotting (Towbin et al., 1979) method was used for the detection of specific 
proteins using antibody directed against them. For this reason first proteins needed to be 
transferred onto nitrocellulose membrane from the gel matrix after SDS-PAGE. Following 
SDS-PAGE the gel unit was carefully dismantled and the stacking gel was cut out. The 
separating gel was then carefully placed on an equally sized nitrocellulose membrane pre 
soaked in transfer buffer (supplemented with fresh 20% MetOH). 3 soaked whatman papers 
cut to the same size was also placed on each side of the gel. The sandwich was then placed 
carefully onto the chamber and any air bubble formed between the layers was removed by 
pressing the sandwich with a roller in order to confirm efficient transfer. The chamber was 
closed and transfer was carried out at a constant current of 1mA/cm2 for 1 hour. Following 
transfer, the membrane was removed from the chamber. The transfer of protein was 
confirmed as the prestained protein marker got transferred onto the nitrocellulose membrane. 
The membrane was further blocked with 3% milk in PBS (pH7.4) for 1 hour at room 
temperature. After blocking, the membrane was incubated with 1ºantibody solution (diluted 
accordingly in 3% blocking solution) overnight at 4 ºC. The following day blot was washed 3 
times with PBS (pH7.4) followed by the incubation in the 2ºantibody solution (diluted 
accordingly in 3% blocking buffer) for 2 hours at room temperature. After two hours of 
incubation the membrane was washed 3 times with PBS (pH7.4). The blot was finally 
incubated for 60 seconds in ECL solution (supplemented with 0.02% H2O2) followed by 
exposer to the medical X-ray film in the dark room and developed. 
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2.2.8.2. Fluorescence Microscopy 
2.2.8.2.1. Live cell imaging 
1 ml of cell culture suspension containing GFP expressing transgenic parasite, was directly 
taken from the cell culture plate and was incubated shortly with Hoechst 33258 (10µg/ml) 
following imaging under the microscope. Images of the GFP parasites were obtained using a 
Zeiss Axio Observer inverse epifluorescence microscope system. Appropriate filter sets were 
used for imaging which was equipped with Axiovision 4 software. In order to minimise 
bleaching exposure time of the samples were adjusted accordingly allowing proper 
visualisation of the details. 
2.2.8.2.2. Image restoration 
After capturing individual image from the live parasites under different channels of the 
microscope, the images were imported to Image J64 (version 1.39u: available at 
http://rsb.info.nih.gov/ij). The images were further converted to 8-bit greyscale following 
background substraction, and overlay with ImageJ plugin RGB merge. To create figures for 
the data TIF files were imported to Microsoft powerpoint. After making the final images they 
were saved as JPEG files. During this work no image was ever subjected to gamma 
adjustment. At the same time all data presented in this work are in agreement with the 
recommendation of   Rossner and Yamada (2004) (Rossner and Yamada, 2004). 
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3. Results 
 
Several postulations towards the function of PfHsp70-1, (PF3D7_0818900) in Plasmodium 
falciparum has been put forward till date, but direct biochemical evidence supporting the 
essential role of this protein for intraerythrocyitc survival of the parasite is still missing. At 
the same time, it was also predicted that a cytosolic Hsp40 homologue, PfHsp40 
(PF3D7_0213100) might be a possible co-chaperone of PfHsp70-1 (Rug and Maier, 2011, 
Botha et al., 2007, Shonhai et al., 2007) but, no study has so far documented any in vivo 
experimental evidence of such partnership. Therefore, our aim was to define the essential 
roles of these two proteins by their conditional knockdown in blood stage P. falciparum. 
Classical knockout of essential genes in Plasmodium during intraerythrocytic haploid stage is 
difficult to achieve. Therefore, we sought to adapt dominant negative system combined with 
destabilization domains (dd) strategy to obtain regulatable overexpression of dominant 
negative alleles of the endogenous proteins. The dd system has recently been developed 
where a destabilisation domain (dd) is fused either to the N- or C- terminus of the proteins of 
interest. The destabilisation domain tagged fusion protein is unstable and therefore should be 
detected by the cellular machinery leading to the proteosomal degradation. The stability can 
be reverted by the addition of stabilising ligands and thereby degradation is mitigated. The 
system has been successfully adapted to study function of several proteins in Plasmodium 
and apicomplexan relative Toxoplasma gondii (Banaszynski et al., 2006, Armstrong and 
Goldberg, 2007, Herm-Gotz et al., 2007). 
 
During this study, we tried to use the system to overexpress dominant negative versions of 
PfHsp70-1 and PfHsp40 driven from episomal plasmid, keeping the wild type genes intact at 
their respective loci. We expected the dominant negative versions to override the native 
endogenous protein functions in a competitive manner by occupying their cellular ligands. 
Although the fusion proteins interacts with the cellular ligands, they cannot carry out the 
necessary biological functions in the cell as they are catalytically dead. This would have 
helped us to establish a conditional knockdown of the endogenous proteins by inhibiting their 
essential cellular function. Further, the resulting phenotype could be studied to assess the 
parasite specific importance of PfHsp70-1 and PfHsp40 for intraerythrocytic survival of 
Plasmodium.  
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3.1 dd-FKBP based approaches  !
3.1.1 Dominant negative system coupled with dd-FKBP to 
establish conditional knockdown of PfHsp70-1 in 
intraerythrocytic Plasmodium falciparum 
3.1.1.1 Validation of the episomal expression of the correct fusion proteins  
 
Plasmids coding for WTPfHsp70-1 (PF3D7_0818900), DNPfHsp70-1 were generated as 
explained under section 2.2. Post transfection with the plasmids, the parasites were cultured 
under drug pressure (WR99210) for 2-3 weeks for selection of plasmid-carrying transgenic 
parasite lines. To confirm the expression of the fusion proteins, free parasites were isolated 
from infected RBCs (iRBC) by saponin lysis. Following several washes of the parasite 
pellets, soluble protein extracts were obtained by cell lysis (described under section 2.2). 
SDS-PAGE and western blot were carried out to validate the expression of the right fusion 
proteins in the parasites. The signals were detected at the correct molecular mass with anti-
HA antibody and thereby confirmed the episomal expression of the right fusion proteins (fig 
3.1b and fig 3.1d). Noteworthy, during this initial experiment all transgenic parasite lines 
were maintained without shield-1.  
 
 
Figure 3.1 Schematic illustrations and detection of of WT/DNPfHsp70-1 fusion proteins.  
(a) Schematic illustration of the wild type (WT) PfHsp70-1 fusion protein. Full length WTPfHsp70-1 is shown 
in dark orange and the N-terminal dd-FKBP domain is shown in red. 3XHA tag on the extreme N-terminus is 
shown in blue. (b) Western blot with anti-HA antibody on the whole cell extract from parasite transfected with 
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the dd-FKBP-WTPfHsp70-1 plasmid shows the expression of the correct molecular mass fusion protein at ~ 
92kDa. (c) Schematic illustration of the dominant negative (DN) PfHsp70-1 fusion protein. Full length 
DNPfHsp70-1 is shown in light orange with gradient and contains the E187K mutation. N-terminal dd-FKBP 
and 3XHA tag are shown in red and blue simultaneously. (d) Western blot with anti-HA antibody on the whole 
cell extract from parasite transfected with the dd-FKBP-DNPfHsp70-1 plasmid shows the expression of the 
fusion protein at right molecular mass of ~ 92kDa. No protein was detected in the 3D7 (negative control) lanes 
(3.1b and 3.1d). 1x107 parasite cell equivalents were used for analysis. 
3.1.1.2 Wild type PfHsp70-1 could be destabilised by N-terminal fusion of 
dd-FKBP and addition of shield-1 yielded further increase in the fusion 
protein level in the intraerythocytic stages of P. falciparum 
 
Cell lines expressing dd-FKBP-PfHsp70-1 (fig 3.2a) were cultured with or without 1.0µM 
shield-1 for 72 hours. Post treatment with or without shield-1 free parasites were isolated by 
saponin lysis. Following several washes of the parasite pellets, soluble protein extracts were 
obtained by cell lysis (described under section 2.2). Samples were analysed by SDS-PAGE 
and western blot to determine the effect of shield-1 on the stabilization of the fusion proteins.  
 
In the extracts from cells expression dd-FKBP-PfHsp70-1, the fusion protein could be 
detected at the expected size of ~92kDa in the absence of the shield-1 by western blot with 
rabbit anti-HA and mouse anti-PfHsp70-1 antibodies (fig 3.1b and fig 3. 2b). This indicated 
that dd-FKBP domain could not mediate complete degradation of the fusion protein since 
some protein could still be detected in the absence of shield-1. As expected, on the other hand 
in the presence of 1.0µM shield-1 there was a noticeable increase in the level of the fusion 
protein as shown by anti-PfHsp70 (fig 2b) and anti-HA antibody (fig 2c). Noteworthy, in the 
western blot with anti-PfHsp70-1 antibody from cell lines expressing WTPfHsp70-1, the 
level of endogenous PfHsp70-1 was much higher in magnitude in comparison to that of the 
fusion proteins in both the lanes (+/- shield-1) (fig 3. 2b). Western blot with anti-glycophorin 
antibody served as loading control (fig 3. 2d). 
 
To conclude, we could see shield-1 dependent regulation of the episomally expressed 
WTPfHsp70-1 protein but the level of the fusion protein was lower by several orders of 
magnitude compared to that of the endogenous PfHsp70-1. We further wanted to test whether 
level of the dominant negative PfHsp70-1 can be controlled in the same way. 
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Figure 3.2 Analysis of dd-FKBP mediated destabilisation and the effect of Shield-1 on the suppression of 
the destabilisation of PfHsp70-1 fusion protein.  
(a) Schematic representation of dd-FKBP-PfHsp70-1 fusion protein. (b) and (c) Western blot analysis from the 
whole cell extract of cells expressing WTPfHsp70-1 N-terminally tagged to dd-FKBP, that grew with or without 
1.0µM shield-1 for 72 hours. (b) Without shield-1 the fusion protein could be detected at the correct size of ~92 
kDa with anti-PfHsp70 antibody. Addition of 1.0µM of shield-1 to the same parasite line shows increase in the 
level of the fusion protein as detected with stronger signal intensity compared to that without shield-1. 
Endogenous PfHsp70-1 was detected with much stronger signal intensity than compared to that of the fusion 
proteins in both the lanes (+/- shield-1). (c) The fusion proteins were detected from the same samples at the 
expected molecular mass of ~92 kDa with anti-HA antibody. The intensity of the band was shown to be at least 
two time stronger in the cells treated with shield-1 that the untreated ones. (d) Glycophorin level was assessed as 
loading control with anti-glycophorin A antibody, and indicted equal loading of samples in both the lanes (+/- 
shield-1). 1x107 cell equivalents were used for all the western blot analysis. Similar results were obtained in 
three independent experiments.  
3.1.1.3 Dominant negative PfHsp70-1 could not be destabilised by N-
terminal fusion of dd-FKBP and addition of shield-1 did not yield any 
further increase in the fusion protein level in the intraerythocytic stages of 
P. falciparum 
 
Here we wanted to assess whether shield-1 dependent regulation of the level of DNPfHsp70-
1 can be obtained. For this reason, cell lines expressing dd-FKBP-DNPfHsp70-1 (fig 3.3a) 
were cultured with or without 1.0µM shield-1 for 72 hours. Post treatment with or without 
shield-1, free parasites were isolated by saponin lysis. Following several washes of the 
parasite pellets, soluble protein extracts were obtained by cell lysis (described under section 
2.2). Samples were analysed by SDS-PAGE and western blot to determine the effect of 
shield-1 on the stabilization of the fusion proteins.  
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In the absence of the shield-1 fusion protein could be detected with anti-PfHsp70-1 antibody 
at the correct molecular mass of ~ 92 kDa, representing the fact that dd-FKBP failed to 
mediate degradation of dd-FKBP-DNPfHsp70-1 fusion protein (fig 3.1d, fig 3.3b and fig 
3.3c). Further, we wanted to find out whether addition of shield-1 has any effect on protein 
level. Therefore parasites were treated with 1.0µM and 1.5µM shield-1 for 72 hours. No 
further increase in the level of fusion proteins was seen from the whole cell extract by 
western blot with anti-PfHsp70-1 and anti-HA antibody (fig 3.3b and fig 3.3c). Noteworthy, 
the level of endogenous PfHsp70-1 was found to be higher in comparison to that of the 
dominant negative fusion proteins in both the lanes (fig 3.3a). The cells expressing 
DNPfHsp70-1 exhibited normal developmental stages indicating the absence of any 
dominant negative effect in the parasites. Western blot with anti-glycophorin A antibody 
served as loading control (fig 3.3d). 
 
Therefore, from this experiment we could conclude that shield-1 dependent regulation of the 
episomally expressed DNPfHsp70-1 protein level was not possible. At the same time the 
level of dominant negative protein was lower than compared to that of the wild type. In 
addition, expression of the dominant negative PfHsp70-1 did not affect normal growth and 
development of the parasite. Being unsuccessful to establish a dominant negative phenotype 
in the parasite line, we further wanted to try this system for PfHsp40 (PF3D7_0213100). 
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Figure 3.3 Analysis of dd-FKBP mediated destabilisation and the effect of Shield-1 on suppression of the 
destabilisation of DNPfHsp70-1 fusion protein.  
(a) Schematic representation of dd-FKBP-DNPfHsp70-1 fusion protein. The dominant negative PfHsp70-1 
contains an E187K mutation. (b) and (c) Western blot analysis from the whole extract of cells expressing DN 
PfHsp70-1 N-terminally tagged to dd-FKBP, that grew with or without shield-1 for 72 hours. (b) Without 
shield-1 the fusion protein could be detected at the correct size of ~92 kDa with anti-PfHsp70-1 antibody. 
Maintenance of the same parasite line in shield-1 ranging upto 1.5µM does not yeild any increase in the level of 
fusion proteins. Fusion protein not detected in the 3D7 control lane confirming the specificity of the antibody. 
Endogenous PfHsp70-1 was detected at least with tow time stronger signal intensity than compared to that of 
the dominant negative protein in all the lanes (+/- shield-1). (c) The fusion proteins were detected from the same 
samples at the expected size of ~92kDa with anti-HA antibody and no increase in the level of the fusion protein 
was observed by shield-1 treatment (1.0-1.5µM). (c) Glycophorin level was assessed as loading control with 
anti-glycophorin A antibody, and indicated equal loading of samples in all the lanes (+/- shield-1 and control 
lane). 1x107 cell equivalents were used for all the western blot analysis. Similar results were obtained in three 
independent experiments.  
 
3.1.2 Dominant negative system coupled with dd-FKBP to 
establish conditional knockdown of PfHsp40 in intraerythrocytic 
Plasmodium falciparum !
PfHsp40 (PF3D7_0213100) was predicted to be a potential cytosolic co-chaperone of the 
PfHsp70-1. Therefore, we aimed to overexpress a dominant negative (DN) version of 
PfHsp40 to define its importance in the parasite. In the DNPfHsp40 the conserved HPD motif 
in the J domain is mutated to HPN motif (fig 3.4b) (explained under section 2.2). Such 
mutagenesis hinders the functional interaction with PfHsp70-1(Hennessy et al., 2005). The 
loss of such interaction should inhibit the transfer of client protein and stimulation of ATPase 
activity of PfHsp70-1 by PfHsp40. This should adversely effect the chaperoning of substrate 
by PfHsp70-1. In our belief, this should be reflected by the defective phenotype of the 
parasite during the intraerythrocytic stages, considering PfHsp40 plays an essential role as a 
co-chaperone.  
3.1.2.1 Validation of the episomal expression of the fusion proteins 
 
Plasmids coding for PfHsp40 and DNPfHsp40 were generated as explained under section 2.2. 
Post transfection of 3D7 line with these plasmids the parasites were cultured under drug 
pressure (WR99210) for 2-3 weeks for selection of plasmid-carrying transgenic parasite 
lines. To confirm the expression of the fusion proteins, free parasites were isolated from 
infected RBCs (iRBC) by saponin lysis. Following several washes of the parasite pellets, 
soluble protein extracts were obtained by cell lysis (described under section 2.2). SDS-PAGE 
and western blot were carried out to validate the expression of the right fusion proteins in the 
parasites. The signals were detected at the correct molecular mass with anti-HA antibody and 
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thereby confirmed the episomal expression of the right fusion proteins (fig 3.4b and fig 3.4d). 
Noteworthy, during this initial experiment all transgenic parasite lines were maintained 
without shield-1.  
      
 
Figure 3.4 Schematic illustrations and the detection of WT/DNPfHsp40 fusion proteins.  
(a) Schematic illustration of the wild type (WT) PfHsp40 fusion protein. Full length WTPfHsp40 is shown in 
dark olive green and the N-terminal 3XHA tag is shown in blue. The dd-FKBP domain is fused to the C-
terminus of the protein and shown in red. (b) Western blot with anti-HA antibody on the whole cell extract from 
parasite transfected with the dd-FKBP-WTPfHsp40 plasmid shows the expression of the right molecular mass 
fusion protein at ~ 56kDa. (c) Schematic illustration of the dominant negative (DN) PfHsp40 fusion protein. 
Full length DNPfHsp40 is shown in light olive green with gradient and possess a D34N. The N-terminal 3XHA 
tag is shown in blue. The dd-FKBP domain is fused to the C-terminus of the protein and shown in red. (d) 
Western blot with anti-HA antibody on the whole cell extract from parasite transfected with the dd-FKBP-
DNPfHsp40 confirms the expression of the right molecular mass fusion protein at ~ 56kDa. No protein was 
detected in the 3D7 (negative control) lanes (3.4b and 3.4d). 1x107 cell equivalents were used for all the western 
blot analysis. 
 
3.1.2.2 Wild type PfHsp40 could not be destabilised by N-terminal fusion of 
dd-FKBP and addition of shield-1 did not yield any further increase in the 
fusion protein level in the intraerythocytic stages of P. falciparum 
 
We started with WTPfHsp40 to assess whether protein level can be regulated in a shield-1 
dependent manner. For this, cell lines expressing dd-FKBP-WTPfHsp40 (fig 3.5a) were 
cultured with or without increasing concentrations of shield-1 ranging upto 1.0µM for 72 
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hours. Post treatment with or without shield-1 free parasites were isolated by saponin lysis. 
Following several washes of the parasite pellets, soluble protein extracts were obtained by 
cell lysis (described under section 2.2). Samples were analysed by SDS-PAGE and western 
blot to determine the effect of shield-1 on the stabilization of the fusion proteins.  
 
In the absence of shield-1 the wild type fusion protein could be detected at expected 
molecular mass of ~56 kDa by western blot with anti-HA antibody from the whole extract 
obtained from WTPfHsp40-dd-FKBP expressing parasite line (fig 3.4a and fig 3.5b). On the 
other hand by the addition of either 0.5 µM or 1.0 µM shield-1 no further stabilization of 
fusion protein could be seen since the level of the fusion protein remained same with no 
noticeable increase (fig 3.5b). Due to the unavailability of a specific anti-PfHsp40 antibody, 
the level of endogenous PfHsp40 could not be determined. This restricted us to compare the 
level of episomally expressed WTPfHsp40 with that of the endogenous version. Western blot 
with anti-glycophorin antibody served as loading control and confirmed equal loading of 
samples in all the lanes (fig 3.5c). 
 
Hence, from this experiment we could summarise that fusion of dd-FKBP to PfHsp40 failed 
to direct fusion protein to degradation. Additionally, shield-1 dependent regulation of the 
episomally expressed WTPfHsp40 fusion protein was not possible. Therefore, we further 
wanted to test whether the stabilization of dominant negative PfHsp40 could be regulated by 
shield-1.    
 
 
Figure 3.5 Analysis of dd-FKBP mediated destabilisation and the effect of Shield-1 on suppression of the 
destabilisation of WTPfHsp40 fusion protein.  
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(a) Schematic representation of WTPfHsp40-dd-FKBP fusion protein. (b) Western blot analysis from the whole 
extract of cells expressing WT PfHsp40, C- terminally tagged dd-FKBP maintained with or without shield-1 for 
72 hours. Without shield-1 the fusion protein was detected with anti-HA antibody at the correct molecular mass 
of ~56kDa with strong signal intensity. Maintenance of the same parasite line in shield-1 ranging from 0.5-
1.0µM did not yield any increase in the level of the fusion proteins (c) Glycophorin level was assessed as 
loading control with anti-glycophorin A antibody, and indicted equal loading of samples in all the lanes (+/- 
shield-1). 1x107 cell equivalents were used for all the western blot analysis. Similar results were obtained in 
three independent experiments. 
3.1.2.3 Dominant negative PfHsp40 could not be destabilised by N-terminal 
fusion of dd-FKBP and addition of shield-1 did not yield further increase in 
the fusion protein level in the intraerythocytic stages of P. falciparum 
 
We further wanted to figure out whether dominant negative PfHsp40 fusion protein could be 
regulated in a shield-1 dependent manner. For this reason, cell line expressing dd-FKBP-
DNPfHsp40 (fig 3.6a) was cultured with or without increasing concentrations of shield-1 
ranging upto 1.0µM for 72 hours. Post treatment, with or without shield-1 free parasites were 
isolated by saponin lysis. Following several washes of the parasite pellets, soluble protein 
extracts were obtained by cell lysis (described under section 2.2). Samples were analysed by 
SDS-PAGE and western blot to determine the effect of shield-1 on the stabilization of the 
fusion proteins.  
 
In the absence of shield-1 the dominant negative fusion protein could be detected at expected 
molecular mass of ~56 kDa by western blot with anti-HA antibody from the whole extract 
obtained from DNPfHsp40-dd-FKBP expressing parasite line (fig 3.4d and fig 3.6b). On the 
other hand by the addition of either 0.5µM or 1.0µM shield-1 no further stabilization of 
fusion protein could be achieved since the level of the fusion protein remained same with no 
noticeable increase (fig 3.6b). The cells expressing DNPfHsp40 exhibited normal 
developmental stages indicating the absence of any dominant negative effect in the parasites. 
As mentioned earlier due to the unavailability of a specific anti-PfHsp40 antibody, the level 
of endogenous PfHsp40 could not be determined. This restricted us to compare the level of 
episomally expressed DNPfHsp40 with that of its endogenous counterpart. This is why we 
could not determine whether the level of the endogenous protein is higher than that of the 
episomal dominant negative version, responsible nullifying any dominant negative effect. 
Western blot with anti-glycophorin antibody served as loading control and confirmed equal 
loading of samples in all the lanes (fig 3.6c). 
 
Altogether, from this experiment we could summarise that dd-FKBP could not mediate 
degradation of the fusion proteins. In addition, regulation of DNPfHsp40 protein level by 
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shield-1 was also not possible and the expression a dominant negative version of the PfHsp40 
did not affect the normal growth and development of the parasite.  
 
From the experiments carried out so far we could only regulate the level of dd-FKBP-
WTPfHsp70-1 fusion protein. Other than this, none of the dd-FKBP tagged candidate 
proteins could be regulated by shield-1.  Therefore, at this point we wanted to validate the 
efficacy of the system by using a positive control. 
 
 
 
Figure 3.6 Analysis of dd-FKBP mediated destabilisation and the effect of Shield-1 on suppression of the 
destabilisation of DNPfHsp40 fusion protein. 
(a) Schematic representation of DNPfHsp40-dd-FKBP fusion protein. (b) Western blot analysis from the whole 
extract of cells expressing DNPfHsp40 tagged to the dd-FKBP on the C-terminus that grew with or without 
shield-1 for 72 hours. Without shield-1 the fusion protein could be detected with anti-HA antibody at the correct 
molecular mass of ~56 kDa with strong signal intensity. Maintenance of the same parasite line in shield-1 
ranging upto 0.5-1.0µM does not yield any increase in the level of the fusion proteins. (c) Glycophorin level was 
assessed as loading control with anti-glycophorin A antibody, and confirmed equal loading of samples in all the 
lanes (+/- shield-1). 1x107 cell equivalents were used for all the western blot analyses. Similar results were 
obtained in three independent experiments. 
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3.1.3 Robust destabilisation of Toxoplasma gondii myosin light 
chain 1 (MLC1) could be achieved, when fused dd-FKBP on the 
N-terminus and stability could be reverted by the addition of 
shield-1 
 
Since we failed to regulate the level of almost all dd-FKBP tagged candidate proteins (except 
wild type PfHsp70-1) by shield-1, we wanted to further test the system by using a positive 
control. This would help us to figure out any technical or handling error involved. At the 
same time effectiveness of the shield-1 could be tested, as it is susceptible to degradation by 
repeated freeze thaw and inappropriate handling. For this reason, a plasmid (DD-Myc-
TgMLC1-HXGPRT) coding for Toxoplasma gondii Myocin light chain (MLC1) fused to dd-
FKBP on the N-terminus (fig 3.7a) was used. The plasmid was kindly provided by Prof. 
Dominique Soldati-favre. It served as a positive control, since the level of DD-Myc-TgMLC1 
fusion protein could be efficiently regulated by shield-1 at Prof. Soldati-favre’s group.  
 
For this reason, we transfected T. gondii with the reporter plasmid (described under section 
2.2.4.1). Post transfection, parasites expression the MLC1 tagged to dd-FKBP were treated 
with or without 0.5µM shield-1 for 24 hours. Post treatment with or without shield-1, free 
parasite pellets were collected from each individual experiments. Following several washes 
of the parasite pellets, soluble protein extracts were obtained by boiling the pellets in SDS-
PAGE sample buffer (described under section 2.2). Finally, samples were analysed by SDS-
PAGE and western blot to determine the effect of shield-1 on the stabilization of the fusion 
proteins.  
 
In the absence of shield-1 the fusion protein could barely be detected by western blot with 
anti-FKBP antibody from the whole cell extract obtained from DD-Myc-TgMLC1 expressing 
parasite line (fig 3.7b). Longer exposure of the same resulted in stronger signal depicting 
residual amount of fusion protein in the absence of the shield-1 (fig 3.7c).  However, on the 
other hand, treatment of the parasites with 0.5µM shield-1 resulted in a clear and robust 
increase in the level of fusion protein as detected at the expected molar mass of ~40kDa (fig 
3.7b and fig 3.7c). Amount of actin served as loading control and confirmed equal loading of 
samples in both the lanes (fig 3.7d). 
 
This experiment confirmed that the episomal level of TgMLC1 fused to dd-FKBP could be 
efficiently regulated by shield-1. This proved that the dd-FKBP domain can mediate efficient 
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degradation of the fusion protein and that can further be supressed by the addition of shield-1 
in our experimental set up.  At the same time the outcome also validated the effectiveness of 
shield-1 used for previous experiments. 
 
 
 
 
Figure 3.7 Analysis of dd-FKBP mediated destabilisation and the effect of Shield-1 on further suppression 
of the destabilisation of MycMLC1 fusion protein.  
(a) Schematic representation of dd-FKBP-Myc-MLC1 fusion protein. Toxoplasma gondii MLC1 is shown in 
dark yellow and fused to the myc tag on the N-terminus (shown in blue). The dd-FKBP domain is shown in red 
and is fused to the N-terminus of myc-MLC1 (b) Western blot with anti-FKBP antibody from the whole extract 
of parasites expressing MLC1 tagged to dd-FKBP on the N-terminus, that grew with or without shield-1 for 24 
hours. Without shield-1 the fusion protein was almost completely degraded and could barely be detected. 
Maintenance of the same parasite line in shield-1 at a concentration of 0.5µM shows rapid increase in the 
protein level by several magnitudes (c) same blot exposed for a duration of 30 seconds, shows residual amount 
of protein without shield-1. With shield-1 protein level is significantly increased. (d) Actin level was assessed as 
loading control and confirmed equal loading of samples in both the lanes (+/- shield-1). 5x107 cell equivalents 
were used for all the western blot analysis. Similar results were obtained in three independent experiments. 
  
We also attempted to test a positive control of the dd-FKBP system in Plasmodium 
falciparum. For this study, the control plasmid was kindly provided by Prof. Daniel E. 
Goldberg. It contained a yellow fluorescent protein (YFP) fused the dd-FKBP to the N-
terminus under strong hsp86 promoter. The stabilization of the level of the fusion protein 
could be efficiently controlled by Shield-1 as documented earlier (Armstrong and Goldberg, 
2007). Therefore, the plasmid was transfected into 3D7 parasite line (as explained under 
section 2.2). Unfortunately, no transgenic parasite line could be generated inspite of repeated 
transfection during the time frame of this work.  
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Therefore, taking into account the outcomes from all the dd-FKBP based approaches we can 
summarize that dose dependent regulation of almost no dd-FKBP tagged fusion proteins 
could not be achieved. Only wild type PfHsp70-1 fusion protein level could be regulated by 
shield-1. At the same time, the level of Toxoplasma gondii MLC1 (positive control) could be 
regulated (Table 2). Therefore, we further sought to employ a different destabilization 
domain derived from E. coli dihydrofolate reductase (ecDHFR) (Iwamoto et al., 2010) to 
achieve conditional tuneable regulation of protein level in the parasite.  
 
Construct Regulation by shield-1 
 
HA- dd-FKBP- PfWTHsp70-1 ✔ 
HA- dd-FKBP- PfDNHsp70-1 ✗ 
HA- WTPfHsp40- dd-FKBP ✗ 
HA- WTPfHsp40- dd-FKBP ✗ 
dd-FKBP-Myc-TgMLC1 (control) ✔ 
 
Table 2. Summary of all the candidate and control proteins studied and their regulation conferred by 
shield-1 
 
3.2 dd-ecDHFR based approaches  
 
Recently it was reported that reported that E. coli dihydrofolate reductase (ecDHFR) derived 
destabilization domain (dd-ecDHFR) confers better instability to a tagged protein, leading to 
the rapid degradation by proteasome in the absence of a stabilizing ligand (Iwamoto et al., 
2010). Trimethoprim (TMP) is cell permeable high-affinity ligand for ecDHFR and stabilizes 
fusion proteins in a dose-dependent manner.  
Although, ecDHFR-derived dd functions in a similar fashion as compared to that of the dd-
FKBP, there are some significant advantages of using this system (Rakhit et al., 2011). The 
most noteworthy advantage is that ecDHFR based dd, when fused to the C-terminus of the 
protein, is more efficient in destabilizing the fusion protein in compared to that of the dd-
FKBP. In addition, the ligand TMP is commercially available, inexpensive, and possesses 
good pharmacological characteristics. Therefore, due to these advantages we further adapted 
this system to establish conditional knockdown of PfHsp70-1 and Pfhsp40.  
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3.2.1 Dominant negative system coupled with dd-ecDHFR to 
establish conditional knockdown of PfHsp70-1 in 
intraerythrocytic P. falciparum 
3.2.1.1 Generation of cell lines expressing WT/DN PfHsp70-1 and GFP, N- 
terminally fused to dd-ecDHFR  
 
Plasmids coding for PfHsp70-1, DNPfHsp70-1 and GFP fused to the dd-ecDHFR on the N-
terminus, were generated as explained under section 2.2. Unlike in the dd-FKBP approach, 
the transfection of these plasmids was carried out into Plasmepsin I knockout (PM1 KO) 
parasite line where human DHFR (hDHFR) is integrated into the endogenous locus. Presence 
of hDHFR in 3D7 (PM1 KO) line confers resistance against TMP, which is otherwise toxic 
to the wild type 3D7. This parasite line was always cultured in the presence of 10.0nM 
WR99210. Post transfection, parasites were cultured under drug pressure (BSD) for 2-3 
weeks for selection of plasmid carrying parasites. 
3.2.1.2 Wild type PfHsp70-1 could not be destabilised by N-terminal fusion 
of dd-ecDHFR and addition of TMP did not yield further increase in the 
level of fusion protein in the intraerythocytic stages of P. falciparum 
 
Cell lines expressing dd-ecDHFR-PfHsp70-1 (fig 3.8a) were cultured without or with 
increasing concentrations of TMP ranging upto 15.0µM for 72 hours. Post treatment, with or 
without TMP free parasites were isolated by saponin lysis. Following several washes of the 
parasite pellets, soluble protein extracts were obtained by cell lysis (described under section 
2.2). Samples were analysed by SDS-PAGE and western blot to determine the effect of TMP 
on the stabilization of the fusion protein.  
 
In the absence of the TMP, the fusion protein could be detected with anti-PfHsp70-1 antibody 
at the correct molecular mass of ~ 95kDa represents the inefficiency of dd-ecDHFR to direct 
degradation of DNPfHsp70-1 fusion protein (fig 3.8b). Further, we wanted to verify whether 
addition of TMP had any effect on fusion protein level. Therefore, same parasites were 
treated with increasing concentrations of TMP ranging from 5.0 - 15.0µM for 72 hours. 
Unfortunately, no further increase in the level of fusion proteins were seen from the whole 
cell extract by western blot with anti-PfHsp70-1 antibody (fig 3.8b). At the same time, an 
additional weak signal was detected in al the lanes at ~ 80kDa. This could be a possible 
degradation product generated during sample preparation. Noteworthy, the endogenous 
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PfHsp70-1 level was found to be higher than compared to that of the fusion proteins in all the 
lanes (fig 3.8b). Western blot with anti-glycophorin A antibody served as loading control (fig 
3.8c). 
 
Therefore, from this experiment we could conclude that dd-ecDHFR could not mediate 
degradation of the WTPfHsp70-1 fusion protein and further TMP dependent regulation of 
protein level was not possible. At the same time, the level of episomal fusion protein was 
lower than that of its endogenous version. Therefore, we further tried to use this system for 
the dominant negative version of the PfHsp70-1 and to assess whether a TMP dependent 
regulation could be achieved.  
 
 
 
 
Figure 3.8 Analysis of dd-ecDHFR mediated destabilisation and the effect of Shield-1 on further 
suppression of the destabilisation of WTPfHsp70-1 fusion protein.  
(a) Schematic representation of dd-ecDHFR-WTPfHsp70-1 fusion protein. The wild type PfHsp70-1 is shown 
in dark orange. The dd-ecDHFR domain is shown in grey and is fused to the N- terminus of the candidate 
protein. The HA tag is shown in blue at the extreme N-terminus of the fusion protein (b) Western blot analysis 
from the whole extract of cells expressing WTPfHsp70-1 tagged to dd-ecDHFR on the N-terminus, that grew 
with or without TMP for 72 hours. Without TMP the fusion protein could be detected at the expected molecular 
mass of ~95kDa with anti-PfHsp70-1 antibody. Maintenance of the same parasite line with TMP ranging upto 
15.0 µM did not yield any increase in the level of the fusion proteins. Endogenous PfHsp70-1 was detected at 
least with equal or tow time stronger signal intensity than compared to that of the fusion proteins in all the lanes 
(+/- TMP). A weak signal is detected at ~80kDa that can be a possible degradation product (c) Glycophorin 
level was assessed as loading control with anti-glycophorin A antibody, and indicted equal loading of samples 
in all the lanes (+/- TMP). 1x107 cell equivalents were used for all the western blot analysis. Similar results were 
obtained in three independent experiments 
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3.2.1.3 Dominant negative PfHsp70-1 could not be destabilised by N-
terminal fusion of dd-ecDHFR and addition of TMP did not yield further 
increase in the level of fusion protein in the intraerythocytic stages of P. 
falciparum 
 
To further assess whether shield-1 dependent regulation could be achieved for DNPfHsp70-1, 
cell lines expressing dd-ecDHFR-DNPfHsp70-1 (fig 3.9a) were cultured without or with 
increasing concentrations of TMP ranging upto 15.0µM for 72 hours. Post-treatment with or 
without TMP, free parasites were isolated by saponin lysis. Following several washes of the 
parasite pellets, soluble protein extracts were obtained by cell lysis (described under section 
2.2). Samples were analysed by SDS-PAGE and western blot to determine the effect of TMP 
on the stabilization of the fusion proteins.  
 
In the absence of the TMP, the fusion protein could be detected with anti-PfHsp70-1 antibody 
at the correct molecular mass of ~ 95kDa indicating inefficiency of dd-ecDHFR to mediate 
degradation (fig 3.9b). Further we wanted to find out whether addition of TMP has any effect 
on the stabilisation of protein level. Therefore, parasites were treated with increasing 
concentrations of TMP ranging from 5.0 - 15.0µM for 72 hours. No further increase in the 
level of fusion proteins were seen from the whole cell extract by western blot with anti-
PfHsp70-1 antibody (fig 3.9b). In addition, a possible degradation product of the fusion 
protein could be detected at ~ 80kDa. Noteworthy, the endogenous wild type PfHsp70-1 level 
was found to be higher than compared to that of the dominant negative fusion proteins in all 
the lanes (fig 3.9b). The cells expressing DNPfHsp70-1 exhibited normal developmental 
stages indicating the absence of any dominant negative effect in the parasites. Western blot 
with anti-glycophorin A antibody served as loading control (fig 3.9c). 
 
Therefore, from this experiment it could be concluded that dd-ecDHFR mediated degradation 
and TMP dependent regulation of DNPfHsp70-1 fusion protein was also not possible. At the 
same time, the level of dominant negative fusion protein was lower than that of the 
endogenous wild type protein. Hence the expression of the dominant negative PfHsp70-1 did 
not affect normal growth and development of the parasite. Therefore, we further attempted to 
try this system to regulate eplisomal expression of GFP as a control. 
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Figure 3.9 Analysis of dd-ecDHFR mediated destabilisation and the effect of Shield-1 on further 
suppression of the destabilisation of DNPfHsp70-1 fusion protein.  
(a) Schematic representation of dd-ecDHFR-DNPfHsp70-1 fusion protein. The dominant negative PfHsp70-1 
shown in dark orange with gradient and contains an E187K mutation. The dd-ecDHFR domain is shown in grey 
and is fused to the N- terminus of the candidate protein. The HA tag is shown in blue at the extreme N-terminus 
of the fusion protein (b) Western blot analysis from the whole extract of cells expressing PfHsp70-1 N-
terminally tagged to dd-ecDHFR that grew with or without TMP for 72 hours. Without TMP the fusion protein 
could be detected at the correct molecular mass of ~95 kDa with anti-PfHsp70-1 antibody. Maintenance of the 
same parasite line with TMP ranging upto 15.0µM did not yield any increase in the level of the fusion proteins. 
An additional band at ~80kDa indicates to possible degradation product. Endogenous wild type PfHsp70-1 was 
detected at least with tow time stronger signal intensity compared to that of the dominant negative fusion 
proteins in all the lanes (+/- TMP). (c) Glycophorin level was assessed as loading control with anti-glycophorin 
A antibody, and indicted equal loading of samples in all the lanes (+/- TMP). 1x107 parasite cell equivalents 
were used for all the western blot analysis. Similar results were obtained in three independent experiments.  
 
3.2.1.4 Control GFP could not be destabilised by N-terminal fusion of dd-
ecDHFR and addition of TMP did not yield any further increase in the 
level of fusion protein in the intraerythocytic stages of P. falciparum 
 
Since we failed to achieve a TMP dependent regulation of both the wild type and dominant 
negative version of the PfHsp70-1 we wanted to validate the system using a GFP control. 
Parasite line expressing GFP tagged to dd-ecDHFR on the N-terminus (fig 3.10a) was used to 
study dd-ecDHFR mediated destabilization of candidate protein. At the same time, the effect 
of TMP on the suppression of destabilization was also tested.  
 
For this purpose cell lines expressing dd-ecDHFR-GFP were cultured without or with 
increasing concentrations of TMP ranging upto 15.0µM for 72 hours in a similar way as 
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followed for the candidate proteins studied earlier. Post-treatment with or without TMP, free 
parasites were isolated by saponin lysis. Following several washes of the parasite pellets, 
soluble protein extracts from the parasite were obtained by cell lysis (described under section 
2.2). Samples were analysed by SDS-PAGE and western blot to determine the effect of TMP 
on the stabilization of the GFP fusion proteins.  
 
In the absence of the TMP fusion protein could be detected with anti-HA antibody at the 
expected molecular mass of ~ 49kDa. This showed that dd-ecDHFR could not lead to 
degradation of the GFP fusion protein (fig 3.10b). Further we wanted to verify whether 
addition of TMP has any effect on the stabilisation of GFP level. Therefore parasites were 
treated with increasing concentrations of TMP ranging from 5.0 - 15.0µM for 72 hours. No 
further increase in the level of fusion proteins were seen from the whole cell extract by 
western blot with anti-HA antibody (fig 3.10b). Western blot with anti-glycophorin A 
antibody served as loading control (fig 3.10c). 
 
Hence, it could be concluded that dd-ecDHFR could not mediate the degradation of control 
GFP fusion protein. At the same time the level of GFP could not be regulated in a TMP 
dependent manner.  
 
In previous studies it has been reported that C-terminal fusion of ec-DHFR has stronger 
destabilisation effect (Rakhit et al., 2011). Therefore we further wanted to obtain TMP 
dependent regulation of parasite Hsp40 homologue (PF3D7_0213100), where the ec-DHFR 
is fused to the C-terminus.   
 
Figure 3.10 Analysis of dd-ecDHFR mediated destabilisation and the effect of Shield-1 on further 
suppression of the destabilisation of GFP fusion protein  
(a) Schematic representation of dd-ecDHFR-GFP fusion protein. The GFP is shown in green. The dd-ecDHFR 
domain is shown in grey and is fused to the N-terminus of the GFP. The HA tag is shown in blue at the extreme 
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N-terminus of the fusion protein (b) Western blot analysis from the whole extract of cells expressing GFP 
tagged to dd-ecDHFR on the N-terminus, that grew with or without TMP for 72 hours. Without TMP the fusion 
protein could be detected at the correct molar mass of ~49 kDa with anti-HA antibody. Maintenance of the same 
parasite line with TMP ranging from 5.0 -15.0µM did not yield any increase in the level of the fusion proteins as 
protein bands were detected with same signal intensity. (c) Glycophorin level was assessed as loading control 
with anti- glycophorin A antibody, and indicted equal loading of samples in all the lanes (+/- TMP). 1x107 cell 
equivalents were used for all the western blot analysis. Similar results were obtained in three independent 
experiments. 
3.2.2 Dominant negative system coupled with dd-ecDHFR to 
establish conditional knockdown of PfHsp40 in intraerythrocytic 
P. falciparum 
3.2.2.1 Generation of cell lines expressing WT/DN PfHsp40 and GFP, C- 
terminally fused to dd-ecDHFR  
 
Plasmids coding for PfHsp40 (PF3D7_0213100), DNPfHsp40 and GFP fused to the dd-
ecDHFR on the C-terminus, were generated as explained under section 2.2. The transfection 
of these plasmids was carried out into 3D7 (PM1 KO) parasite line as used earlier for the 
transfection of dd-ecDHFR-PfHsp70-1 coding plasmids. Post transfection, cells were 
cultured under drug pressure (BSD) for 2-3 weeks for selection of plasmid-carrying parasites. 
3.2.2.2 Wild type PfHsp40 could not be destabilised by C-terminal fusion of 
dd-ecDHFR and addition of TMP did not yield further increase in the level 
of fusion protein in the intraerythocytic stages of P. falciparum 
 
Cell lines expressing PfHsp40-dd-ecDHFR (fig 3.11a) were cultured without or with 
increasing concentrations of TMP ranging upto 15.0µM for 72 hours. Post treatment, with or 
without TMP free parasites were isolated by saponin lysis. Following several washes of the 
parasite pellet, soluble protein extracts were obtained by cell lysis (described under section 
2.2). Samples were analysed by SDS-PAGE and western blot to determine the effect of TMP 
on the stabilization of the fusion proteins.  
 
In the absence of the TMP fusion protein could be detected with anti-HA antibody at the 
correct molecular mass of ~ 59kDa (fig 3.11b). This indicated that the dd-ecDHFR was not 
efficient in mediating the degradation of wild type PfHsp40 when fused to the C-terminus. 
Further, we wanted to determine whether addition of TMP had any effect on the fusion 
protein level. Therefore, parasites were treated with increasing concentrations of TMP 
ranging from 5.0 - 15.0µM for 72 hours. Unfortunately, no increase in the level of fusion 
proteins was seen from the whole cell extract by western blot with anti-HA antibody (fig 
3 Results       96 
! !
3.11b). The endogenous PfHsp40 level could not be determined and compared due to 
unavailability of a specific anti-PfHsp40 antibody. Western blot with anti-glycophorin A 
antibody served as loading control (fig 3.11c). 
 
Therefore, from this experiment we could conclude that inspite of previous reports, C-
terminus tagging of dd-ecDHFR could not lead to the destabilisation of PfHsp40. In addition, 
TMP dependent regulation of the episomal WTPfHsp40 protein level was not possible. 
Hence, we further wanted to try this system for the dominant negative version of the PfHsp40 
and to assess whether ec-DHFR mediated degradation was achievable and could be regulated 
by TMP.  
 
 
 
Figure 3.11 Analysis of dd-ecDHFR mediated destabilisation and the effect of TMP on further 
suppression of the destabilisation of WTPfHsp40 fusion protein.  
(a) Schematic representation of WTPfHsp40-dd-ecDHFR fusion protein. The WTPfHsp40 is shown in olive 
green. The dd-ecDHFR domain is shown in grey and is fused to the C-terminus of the candidate protein. The 
HA tag is shown in blue at the extreme N-terminus of the fusion protein (b) Western blot analysis from the 
whole extract of cells expressing WTPfHsp40, C-terminally tagged to dd-ecDHFR maintained with or without 
TMP for 72 hours. Without TMP the fusion protein could be detected at the correct molecular mass of ~59kDa 
with anti-HA antibody. Maintenance of the same parasite line with TMP ranging upto 15.0µM does not show 
any increase in the level of the fusion protein. (c) Glycophorin level was assessed as loading control with anti-
glycophorin A antibody, and indicted equal loading of samples in all the lanes (+/- TMP). 1x107 cell equivalents 
were used for all the western blot analysis. Similar results were obtained in three independent experiments.  
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 3.4.2.3 Dominant negative PfHsp40 could not be destabilised by C-
terminal fusion of dd-ecDHFR and addition of TMP did not yield further 
increase in the level of fusion protein in the intraerythocytic stage of P. 
falciparum 
 
Cell lines expressing DNPfHsp40-dd-ecDHFR (fig 3.12a) were cultured without or with 
increasing concentrations of TMP ranging upto 15.0µM for 72 hours. Post treatment with or 
without TMP free parasites were isolated by saponin lysis. Following several washes of the 
parasite pellets, soluble protein extracts were obtained by cell lysis (described under section 
2.2). Samples were analysed by SDS-PAGE and western blot to determine the effect of TMP 
on the stabilization of the fusion protein.  
 
In the absence of the TMP fusion protein could be detected with anti-HA antibody at the 
correct molecular mass of ~ 59 kDa that (fig 3.12b). This indicated that the dd-ecDHFR was 
not efficient in mediating the degradation of the dominant negative version of PfHsp40 when 
fused to the C-terminus. Further, we wanted to determine whether addition of TMP has any 
effect on the protein level. Therefore, parasites were treated with increasing concentrations of 
TMP ranging from 5.0 - 15.0µM for 72 hours. No increase in the level of fusion proteins was 
seen from the whole cell extract by western blot with anti-HA antibody (fig 3.12b). Although, 
the endogenous PfHsp40 level could not be determined and compared due to unavailability of 
a specific anti-PfHsp40 antibody, the parasites exhibited normal developmental stages 
indicating the absence of any dominant negative effect in the parasites. Western blot with 
anti-glycophorin A antibody served as loading control (fig 3.12c). 
 
Therefore, we could conclude that similar to the WTPfHsp40, C-terminus tagging of dd-
ecDHFR to the DNPfHsp40 also could not lead to the destabilisation of the fusion proteins. 
At the same time, TMP dependent regulation of the DNPfHsp40 protein level was not 
possible. In addition, expression of a dominant negative version of the endogenous PfHsp40 
did not affect the normal growth and developmental cycle of the parasite. Therefore, we 
further attempted to test the applicability of the system towards the regulation of the level of 
control GFP. 
 
 
3 Results       98 
! !
 
 
Figure 3.12 Analysis of dd-ecDHFR mediated destabilisation and the effect of Shield-1 on further 
suppression of the destabilisation of DNPfHsp40 fusion protein  
(a) Schematic representation of DNPfHsp40-dd-ecDHFR fusion protein. The DNPfHsp40 is shown in olive 
green with gradient containing a D34N mutation. The dd-ecDHFR domain is shown in grey and is fused to the 
C-terminus of the candidate protein. The HA tag is shown in blue at the extreme N-terminus of the fusion 
protein (b) Western blot analysis from the whole extract of parasites expressing DNPfHsp40, C-terminally 
tagged to dd-ecDHFR, maintained with or without TMP for 72 hours. Without TMP the fusion protein could be 
detected at the expected molecular mass of ~59kDa with anti-HA antibody. Maintenance of the same parasite 
line with TMP ranging upto 15.0µM did not yield any increase in the level of the fusion proteins. (c) 
Glycophorin level was assessed as loading control with anti-glycophorin A antibody, and indicted equal loading 
of samples in all the lanes (+/- TMP). 1x107 cell equivalents were used for all the western blot analysis. Similar 
results were obtained in three independent experiments. 
3.4.2.4 Control GFP could be efficiently destabilised by C-terminal fusion 
of dd-ecDHFR and addition of TMP yielded a robust dose dependent 
stabilisation of fusion protein in the intraerythocytic stages of P. falciparum 
 
Since we failed to achieve a TMP dependent regulation of both the wild type and dominant 
negative version of the PfHsp40 when tagged to the C-terminus, we wanted to validate the 
system using a GFP control. Parasite line expressing GFP tagged to dd-ecDHFR on the C- 
terminus (fig 3.13a) was used to study dd-ecDHFR mediated destabilization and degradation. 
At the same time, the effect of TMP on the suppression of destabilization was tested.  
 
For this reason, cell lines expressing GFP-dd-ecDHFR were cultured without or with 
increasing concentrations of TMP ranging upto 15.0µM for 72 hours in a similar way as 
explained for the candidate proteins studied earlier. Post treatment with or without TMP free 
parasites were isolated by saponin lysis. Following several washes of the parasite pellets, 
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soluble protein extracts were obtained by cell lysis (described under section 2.2). Samples 
were analysed by SDS-PAGE and western blot to determine the effect of TMP on the 
stabilization of the fusion protein.  
 
In the absence of the TMP, GFP fusion protein was efficiently degraded leaving behind 
residual amount that could barely be detected with anti-HA antibody (fig 3.13b). Further we 
wanted to verify whether addition of TMP had any effect on the stabilisation. Therefore, 
parasites were treated with increasing concentrations of TMP ranging from 5.0 - 15.0µM for 
72 hours. This resulted in a robust increase in the level of episomal fusion protein. At the 
same time the regulation conferred by TMP was clearly dose dependent. The fusion protein 
could barely be detected in the absence of TMP and the level reached to the maximum at a 
TMP concentration of 15.0µM (fig 3.13b). Western blot with anti-glycophorin A antibody 
served as loading control (fig 3.13c). 
 
 
Figure 3.13 Analysis of dd-ecDHFR mediated destabilisation and the effect of TMP on further 
suppression of the destabilisation of GFP fusion protein.  
(a) Schematic representation of GFP-dd-ecDHFR fusion protein. The GFP is shown in green. The dd-ecDHFR 
domain is shown in grey and is fused to the C-terminus of the candidate protein. The HA tag is shown in blue at 
the extreme N-terminus of the fusion protein (b) Western blot analysis from the whole extract of cells 
expressing GFP, C-terminally tagged to dd-ecDHFR and maintained with or without TMP for 72 hours. Without 
TMP the fusion protein could barely be detected at the correct size of ~49kDa with anti-HA antibody. 
Maintenance of the same parasite line with TMP ranging from 5.0 µM upto 15.0 µM shows a dose dependent 
increase in the level of the fusion proteins (c) Glycophorin level was assessed as loading control with anti-
glycophorin A antibody, and indicted equal loading of samples in all the lanes (+/- TMP). 1x107 cell equivalents 
were used for all the western blot analysis. Similar results were obtained in three independent experiments. 
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After confirming the TMP dependent regulation of GFP-dd-ecDHFR by western blot we 
wanted carry out a secondary verification of the observation. Hence, live parasites expressing 
GFP-dd-ecDHFR, were treated with or without TMP (15.0µM) for 24 hours as mentioned 
above. Post treatment live parasites were visualized under the fluorescence microscope as 
explained under section 2.2. Consistent with the data form SDS-PAGE, the residual GFP 
signal could barely be detected from parasite line cultured in the absence of TMP (fig 3.14a). 
Whereas, robust and significant increase in the cytoplasmic GFP level was observed in the 
parasite cultured in the presence of 15.0µM TMP (fig 3.14b) indicating efficient stabilization. 
 
 
 
Figure 3.14 Fluorescent microscopy of live parasites treated without or with TMP.  
(a) TMP untreated parasites labelled with hoechst showing barely detectable residual GFP signal in the 
cytoplasm. (b) 15.0 µM TMP treated parasites labelled with hoechst showing strong recovery of GFP signal in 
the cytoplasm.  
Therefore, from this experiment it could be concluded that unlike the N-terminal fusion, C 
terminal fusion of dd-ecDHFR to the GFP leads to almost complete degradation of the fusion 
protein. Furthermore the stability can be efficiently reverted in a dose dependent manner by 
the addition of TMP.  
 
To conclude, we could not establish a dose dependent regulation of almost all episomally 
expressed dd-ecDHFR tagged candidate proteins. The level of control GFP fused to dd-
ecDHFR on the C-terminus could only be regulated by TMP amongst all proteins studied 
(table 3).  
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Construct Regulation by TMP 
HA- dd-ecDHFR- PfWTHsp70-1 ✗ 
HA- dd-ecDHFR- PfDNHsp70-1 ✗ 
HA- dd-ecDHFR- GFP ✗ 
HA- WTPfHsp40 - dd-ecDHFR ✗ 
HA- WTPfHsp40 - dd-ecDHFR ✗ 
HA- GFP - dd-ecDHFR ✔ 
 
Table 3. Summary of all the candidate and control proteins studied and their regulation conferred by 
TMP
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4. Discussion 
 
Plasmodium falciparum is the causative agent of the most lethal form of malaria resulting in 
death of millions of people worldwide. Growing resistance of the parasite against effective 
and available drugs is the biggest concern towards the treatment and successful eradication of 
the disease. Therefore, further understanding of essential genes and their mode of action at 
different stages of the parasite life cycle will strengthen our knowledge of the parasite 
biology. This in turn holds enormous potential for the development of efficacious 
antimalarial drugs and vaccines.   
 
Unfortunately, the experimental validation of the function of essential gene in blood stage 
Plasmodium falciparum is posed with several challenges (Meissner et al., 2007). Plasmodium 
falciparum haploid genome during intraerythrocytic stage has only allowed mutagenesis to be 
carried out only for non-essential genes (Maier et al., 2008, Cowman and Crabb, 2006). For 
example, erythrocyte invasion of the parasite has typically been studied via the classical 
reverse genetics methods. Since invasion of erythrocyte by the parasite involves multiple 
pathways and ligands, none of which are completely essential (Cowman and Crabb, 2006) 
mutation of one of the ligands does not prove to be lethal for the parasite. Essential genes 
required during the different stages of life cycle other than the blood stage could be 
successfully studied by introducing a mutation in the gene at the blood stage (where it is not 
expressed) and then passing it through the mosquito and liver stage (where it is expressed) to 
establish phenotype (Ishino et al., 2005, van Dijk et al., 2005, van Dijk et al., 2001). 
Nevertheless it is the blood stage where the manifestation of the disease occurs, giving rise to 
the symptoms of malaria. Till date the function of several essential proteins during the blood 
stage has been severely hampered due to various reasons.   
 
In modern experimental biology the function of an essential gene is often determined by 
perturbation of the gene of interest with several methods following the observation and 
analysis of the resulting phenotype. This is often achieved by RNA interference (RNAi) that 
has become a widely acceptable and favourable approach to determine the function of 
putative proteins and pathways (Medema, 2004, Banaszynski et al., 2006). Among parasitic 
protozoa RNAi is extensively used with success in Trypanosoma brucei to assess the function 
of several proteins and their pathways. From direct experimentation it is becoming prominent 
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that the RNAi pathway is also likely to be functional in T. gondii, E. histolytica and G. 
intestinalis and Leishmania (Ullu et al., 2004, Kolev et al., 2011, McCarthy et al., 2013).  
 
Extensively used gene silencing approaches including RNAi are yet to be validated in 
Plasmodium (Agop-Nersesian et al., 2008). Specifically RNAi appears to be of limited use 
since Plasmodium does not code for many essential protein for the RNAi approach to be 
functional (Baum et al., 2009). 
On the other hand, one by one gene knockout approach has often been exploited to assess the 
functionality of such genes in blood stage malaria parasite but, yielded more general 
information on the protein function (Cowman and Crabb, 2006). Since the intraerythrocytic 
stage of Plasmodium is haploid, gene knockout by homologous recombination proved to be 
simple and straightforward. But, if the gene is essential for the parasite and indispensible for 
the blood stage growth knockout of such gene could prove to be lethal. Therefore, to 
overcome this challenge there has been huge amount of studies to develop genetic tools that 
can conditionally downregulate the expression level of the gene or can lead to mutagenesis 
(Collins et al., 2013, Meissner et al., 2007).  
One such technique known as Tetracyline inducible gene expression or TetR has been used to 
study essential genes in Plasmodium. Commonly used tetracycline sensitive transactivator 
does not activate minimal promoter in apicomplexan parasite like Plasmodium falciparum 
(Meissner et al., 2001, Collins et al., 2013). An artificial transactivation domain (TATi), 
fused to TetR has been used in distant apicomplexan Toxoplasma gondii with great success to 
obtain conditional knockout (Meissner et al., 2002). This system has been applied with some 
success in Plasmodium to achieve regulatable expression of genes (Meissner et al., 2005, 
Gilson et al., 2008). 
Site-specific recombination event using Cre recombinase is widely used and Cre was found 
to be active and working in Plasmodium falciparum (O'Neill et al., 2011). But, unfortunately 
this system cannot be regulated in a robust manner. The most noteworthy disadvantage is 
that, this system is irreversible and hence, cannot be applied for the study of essential genes. 
In this approach the excision of the gene using Cre recombinase would have lethal effect on 
the growth of the parasite making it impossible to pursue further study.  
For the limitations mentioned above we employed an alternative strategy to analyse the 
importance of heat shock protein, PfHsp70-1 and PfHsp40 which we predicted to have an 
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essential role in the intraerythrocyitc stage of the parasite. Functional assesment of an 
essential gene is often carried out by the overexpression of a catalytically dead dominant 
negative version of the endogenous protein. This method involves introducing a mutation into 
the protein of interest that results in the abolishment of its function and at the same time 
inhibits the function of the wild type endogenous protein. The phenotypic consequences 
resulting from such expression of the dominant negative version not only helps to determine 
the importance of the gene of interest but also shed light on the pathways where the protein 
might be involved. The functions of a number of proteins have been determined using this 
approach. But, this method is most effective for elucidating the function of proteins that 
requires forming multimers in the cell to be functional for example, Heat shock proteins 
(Hsps) in our case. Dominant negative studies using mutant proteins have already been used 
as a successful tool to determine the function of a number of protein families including 
oncogenes, growth factor receptors, hormone receptors etc (Sheppard, 1994). This system has 
been already applied successfully to determine the function of several proteins in Toxoplasma 
gondii (Herm-Gotz et al., 2007), and blood stage Plasmodium falciparum  (Russo et al., 
2010).  
 
To determine the essential role of the PfHsp70-1 and PfHsp40 we generated and transfected 
expression constructs expressing either dominant negative version or wild type form (control) 
of the candidate proteins episomally under the control of a crt promoter. crt promoter ensures 
the expression of the fusion proteins throughout all the stages of asexual life cycle. We 
further coupled this approach with destabilisation domain strategy. This is a recently 
developed conditional genetic tool to control gene expression in an exogenous manner. This 
is a system where we fused the candidate proteins to the C- or N-terminus with 
destabilisation domains (either FKBP derived L106P or ecDHFR) (Armstrong and Goldberg, 
2007, Herm-Gotz et al., 2007, Iwamoto et al., 2010). Generally, such domain leads to the 
degradation of the entire fusion protein by the proteasome. But, the reversible binding of the 
synthetic ligands (shield-1 or TMP) should stabilize the protein, allowing it to carry out its 
biological function. Thus, a dose dependent regulation of protein level by this method should 
be possible. This approach has already been applied with some success to study the function 
of essential proteins in Leishmania, Toxoplasma gondii and Plasmodium falciparum 
(Madeira da Silva et al., 2009, Armstrong and Goldberg, 2007, Dvorin et al., 2010, Gershlick, 
1990, Herm-Gotz et al., 2007). 
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4.1. dd-FKBP mediated degradation of episomally 
expressed fusion protein? !
During this study our observations have confirmed several limitations of the dd-FKBP 
system to efficiently regulate the level of episomally expressed fusion protein. Therefore, 
such limitations hindered the conditional knockdown of the candidate proteins. 
We expressed both the dominant negative PfHsp70-1 and PfHsp40 tagged to dd-FKBP 
domain under the control of crt promoter. We expected an episomal overexpression of the 
dominant negative PfHsp70-1 in the parasite line. In normal condition, the dd-FKBP should 
lead to the destabilization of the entire fusion protein resulting in proteasome mediated rapid 
degradation, leaving none or insignificant amount of fusion protein behind. Similar 
observation was also expected for dominant negative PfHsp40-dd-FKBP fusion. It was 
reported previously that dd-FKBP fusion protein is completely degraded in the absence of the 
stabilizing ligand and therefore certified the applicability of this system for studying the 
function of native plasmodial proteins (Armstrong and Goldberg, 2007, Herm-Gotz et al., 
2007). In fact, L106P mutant of dd-FKBP, used for our study was claimed to be one of the 
most potent (Destabilisation domain) DDs identified during initial screening (Chu et al., 
2008). 
Since, PfHsp70-1has been predicted to interact with PfHsp90 or PfHOP and many other 
substrate proteins via the long C-terminus EEVD motif, we tagged both the wild type and 
dominant negative PfHsp70-1 on the N-terminus with the dd-FKBP domain to avoid 
interrupting the native interaction of the PfHsp70-1 in the cell (Gitau et al., 2012, Banumathy 
et al., 2003, Banerjee et al., 2012) . Whereas, the PfHsp40 was tagged at the C-terminus of 
the destabilisation domain to avoid interfering with the possible HPD mediated interaction 
with partner PfHsp70-1 (Fan et al., 2003). According to previous publications, dd-FKBP 
domain when fused to the N-terminus of the PfHsp70-1 should establish stronger rapid 
degradation kinetics. It was also mentioned that the efficiency of L106P mutant of dd-FKBP 
to degrade YFP and other fusion proteins from the N-terminus was much higher compared to 
that from the C-terminus (Chu et al., 2008, Banaszynski et al., 2006). But in contrast, during 
our study we could detect significant amount of wild type and dominant negative PfHsp70-1 
fusion protein in the absence of the shield-1 (fig.3.1b, 3.1d, fig.3.2b, 3.2c and fig.3.3b, 3.3c). 
Similar observation was also made for PfHsp40 expressing transgenic lines where strong 
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protein level was detected from the cells in the absence of the shield-1 (fig.3.4b, 3.4d, and 
3.5b, 3.6b).  
Several possible interpretations can be put forward to explain the contrasting observation in 
our work. Firstly, the rapid degradation kinetics of this system has been reported in several 
literatures. But, at the same time such a system failed to efficiently degrade some candidate 
proteins. Therefore, the success of this strategy remains greatly protein dependent 
(Armstrong and Goldberg, 2007, Herm-Gotz et al., 2007). Although destabilisation domain 
has been used to test the function of several essential proteins this was the first attempt to tag 
parasite Hsps. Secondly, Hsps play an important role in stabilisation of unfolded precursor 
polypeptide, the maintenance of protein homeostasis in the cell in unfavourable conditions, 
and represent an important class of protein family for parasites. Therefore, destabilisation and 
degradation of such an important cytosolic protein might prove to be more challenging (Bell 
et al., 2011, Hartl et al., 1992). Our data reflects that the destabilization of Hsps in 
Plasmodium is not efficient compared to previous studies with other candidate proteins. In a 
recent study it was suggested that detection of fusion protein in the absence of shield-1 might 
be a direct impact of the less active protein degradation in Plasmodium (de Azevedo et al., 
2012). PfHsp70-1 is one of the most abundant and essential proteins constitutively expressed 
in the parasite. As suggested by de Azevedo et al., (2012) at an optimum level the 
proteasome might not be capable of complete degradation of the fusion protein as it might be 
burdened with a pool of fusion proteins and other proteins from the cell. Hence, a significant 
amount of the fusion protein is left behind.  In our study, study we synchronised transfected 
3D7 parasite line expressing the WT or DN PfHsp70-1/ PfHsp40 to ring stage and then 
maintained them with or without shield-1. Since the crt promoter mediated episomal 
expression of the protein is constitutive, the residual amount of PfHsp70-1 (fig.3.2b, 3.2c and 
fig.3.3b, 3.3c) and PfHsp40 (fig. 3.5b and 3.6b) escaping proteosomal degradation might 
have been accumulated which was detected with western blot from the whole parasite lysate.  
While we are assuming that a significant amount of protein was either not destabilised or 
escaped proteasomal degradation, we cannot rule out the possibility of the dd-FKBP domain 
having no effect altogether on the destabilisation of the tagged protein. In such an event the 
amount of protein detected from the whole parasite lysate with western blot at a particular 
time point is not a part but the whole pool of fusion protein expressed episomally by the 
plasmid. Since we know that destabilisation domain mediated degradation of the fusion 
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protein is proteasome dependent, therefore blocking the proteasome by several proteasome 
inhibitor should compromise the dd-FKBP mediated degradation. This will shed light on very 
important data whether or not dd-FKBP is engaged in the degradation of the fusion protein to 
any extent (Gantt et al., 1998, Czesny et al., 2009, Kreidenweiss et al., 2008). If the dd-FKBP 
domain is involved to some extent in directing the tagged fusion protein to proteasome 
mediated degradation, the inhibition of the protesome should lead to the blockage of the 
degradation which should be reflected by an increase in the level of fusion protein in the cell. 
At the same time we expect to see further increase in the reporter level after adding shield-1. 
In addition, one of the initial experiments carried out during our study could provide some 
information about the involvement of dd-FKBP in degradation of the candidate proteins. We 
generated several control plasmids where we replaced the dd-FKBP domain with GFP (fig. 
S2 and S3). We loaded equal amount of parasite equivalence from both transgenic line 
expressing the same candidate proteins tagged to either dd-FKBP or GFP. In SDS PAGE we 
did not see any noticeable difference in the level of the fusion protein expression without 
shield-1 between two transgenic lines. If the dd-FKBP was involved in mediating degradation 
of the fusion protein, we would have expected to see a lower level of fusion protein detected 
from the transgenic parasite line where candidate protein was fused to dd-FKBP compared to 
the one where protein was tagged to GFP. Since we do not see any significant difference in 
the level of fusion protein we can argue that dd-FKBP might not be efficiently involved in 
mediating degradation. But, these experiments also have some drawbacks. Firstly, since the 
fusion protein under the control of dd-FKBP and GFP were collected from two separate 
parasite line, therefore the level of the fusion protein was not really comparable because the 
rate of expression of the episomal plasmid in the two different transgenic lines might differ. 
Secondly, equal level of fusion protein indicates that protein might not be efficiently 
degraded by the proteasome, but the dd-FKBP domain might be still destabilising the fusion 
protein. This can be further clarified using a proteosome inhibitor as explained earlier.   
Although the destabilization domain confers instability to the protein when tagged to either N 
or C-terminus, N-terminal tagging establishes more destabilizing effect when compared to 
that of C-terminal fusion. This might indicate that the degradation machinery of the cell can 
recognize the protein domain more efficiently when the dd-FKBP is fused to the N –terminus 
(Chu et al., 2008). Since in all our plasmids we had a 3x hemagglutinin (HA) tag fused to the 
extreme N-terminus of the fusion protein we speculate whether this interrupts the dd-FKBP 
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mediated destabilization finally leading to degradation. In our study, PfHsp70-1 (WT/DN) 
expressing plasmids have the HA tag at the N-terminus followed by the FKBP domain and 
then the candidate protein at the C-terminus (fig.2.2a and fig.2.2b) unlike published data 
where the dd-FKBP domain is present at the extreme N- or C-terminus of the fusion protein 
(Armstrong and Goldberg, 2007, de Azevedo et al., 2012). Therefore, the position of the dd-
FKBP might have affected efficient destabilization. But we do not see dd-FKBP dependent 
degradation of the fusion protein for the PfHsp40 fusion constructs where the dd-FKBP tag is 
present at the extreme C-terminus of the fusion protein (fig.2.3a and fig.2.3b). Therefore, it 
rules out the possibility that the presence of HA tag is responsible for the inefficiency of the 
dd-FKBP domain to direct degradation. As we did not see any significant degradation of the 
fusion protein by tagging it to dd-FKBP, one can assume that the destabilization effect of the 
dd-FKBP might be strengthened by tagging several destabilization domains to the N- or C- 
terminus of the candidate proteins. But it has already been shown by Chu et al., (2008) that 
fusion of a series of destabilizing domains on either end of the protein of interest decreases 
rather than increasing the effectiveness of the system (Chu et al., 2008). To conclude, it has 
been shown by a recent systematic analysis of the FKBP derived DD domains by Azevedo et 
al., (2012) that regulation offered by DD domain is generally low in Plasmodium (de 
Azevedo et al., 2012). 
4.2. Dominant negative variants of Plasmodium Hsps do 
not establish negative phenotypes in ligand dependent 
manner? !
The destabilization domain strategy attracted us to exploit the system to investigate protein 
function due to its claimed applicability to specifically block the native in vivo function of a 
protein in a reversible fashion. This aim can be achieved by two possible approaches: 1) 
conditional knockdown of the endogenous protein leading to the expression of the 
endogenous protein in relatively low non function level; or 2) small molecule regulated 
episomal over expression of a dominant negative variant of the endogenous protein that can 
interfere and inhibit the function of native protein by targeting and occupying its ligand and 
substrates in the cell. We adapted the later approach for our study.  
As already discussed we wanted to determine the essential role of the two abundantly 
expressed cytosolic heat shock proteins in Plasmodium; Pfhsp70-1 and PfHsp40. Dominant 
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negative mutation in the PfHsp70-1 was generated by substituting an important amino acid 
(E) in the ATPase domain (refer to section 2.2.1.1.4.1 and fig. S1). This was based on a 
similar mutational analysis in E. coli DnaK (Buchberger et al., 1994). As mentioned earlier, 
the E187K mutation is predicted to interfere with the interdomain movement of the PfHsp70-
1 required for the coupling of the ATPase activity with the substrate binding that is important 
for proteolytic activity of the protein. On the other hand, PfHsp40 was mutated in the 
signature J domain. D34N mutation in the highly conserved HPD motif (refer to section 
2.2.1.1.4.2) should disrupt the interaction of PfHsp40 with PfHsp70-1 (provided they interact 
and function together in the cell) leading to the development of a dominant negative 
phenotype. But in contrast to our predictions, episomal expression of both the dominant 
negative versions of the PfHsp70-1 and PfHsp40 under the control of crt promoter (fig.3.3b 
and 3.6b) does not affect the normal phenotype, growth or the progression of the 
development stages of the transgenic parasites. There could be several possible reasons that 
could contribute to our inability to establish a dominant negative effect in the parasite lines. 
In the three following sections possible interpretations will be discussed in detail.  
4.2.1. Shield-1 mediated suppression of destabilisation is not 
sufficient  !
The point behind using the destabilisation domain approach was that the protein level can be 
regulated by adding a small ligand known as shield-1 to the cell. In a previous study, using 
mammalian cells, and apicomplexan like Toxoplasma and Plasmodium dd-FKBP tagged 
proteins could be efficiently regulated by the addition of shield-1 (Chu et al., 2008, Herm-
Gotz et al., 2007, Armstrong and Goldberg, 2007). In an ideal situation one would expect to 
see no or negligible amount of protein in the absence of the shield-1 that should increase by 
several folds upon addition of shield-1. But, during this study a significant amount of fusion 
proteins (both dominant negative and wild type) was detected even in the absence of the 
shield-1 as explained earlier. Now if we consider that dd-FKBP mediated degradation of 
fusion protein is active, then we must have seen some increase in the level of fusion protein 
in the cell after the addition of shield-1. The only observation that is in agreement with this 
expectation came for the experiment with the wild type PfHsp70-1 fused to dd-FKBP (refer 
to fig.3.3.b and fig.3.2.c). The fusion protein could be stabilised to some level by the addition 
of 1.0 µM shield-1. Firstly there was only one fold increase in the level of the fusion protein 
and secondly the level of the endogenous PfHsp70-1 was higher by several folds than that of 
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the fusion protein. We did not expect to see a dominant negative effect in this transgenic line 
since the parasites were expressing the wild type fusion protein. But, the most disappointing 
observations were made in the parasite line expressing either of DNPfHsp70-1, WTPfHsp40 
and DNPfHsp40 (fig.3.3b, 3.3c, fig.3.5b, and fig.3.6b simultaneously). Treatment of the 
transfectant lines with as high as 1.5µM shield-1 for 72 hours did not yield any further 
increase in the level of the fusion protein. There was no effect on the normal phenotype of the 
cell expressing either of dominant negative PfHsp70-1 or PfHsp40. We need to consider that 
in our experimental model we have kept the endogenous protein intact therefore upon 
addition of shield-1 we needed to obtain a level of the dominant negative version that could 
override the function of the endogenous protein. But, if we compare the level of endogenous 
with that of the dominant negative fusion protein after the addition of shield-1 we observed 
that the level of episomally expressed dominant negative protein is lower than that of the 
endogenous one (fig.3.3b). In previous studies it has been shown that only 0.5µM shield-1 
could supress the destabilisation of fusion protein in Plasmodium (Armstrong and Goldberg, 
2007). If we consider that the fusion protein was unstable, the inability to supress the 
destabilisation could be an outcome of highly strong destabilisation of the fusion protein. In 
fact, experiments with different FKBP derived dd domain was carried out by de Azevedo et 
al., (2012). In this study from transient and stable transfectants it was shown that the entire 
FKBP derived dd domain including L106P was quite sufficient in the destabilization. But the 
drawback is that none of these dd could be stabilized efficiently by the addition of as high as 
1.0µM shield-1. Therefore, the reporter activity could not be reverted. This confirmed that the 
instability of the several dd domains could not be supressed by adding the ligand. The authors 
also commented that the efficiency of destabilisation and the robust range of induction in 
Plasmodium are much lower in comparison to other cell types. While 1.0µM shield-1 could 
increase protein level to 20 fold in other cell types, only 4-5 fold increase in the protein level 
was observed in Plasmodium. In the same study it was also shown that longer induction with 
shield-1 does not have any significant effect. Higher shield-1 concentration was tried too with 
no improvement. While increasing the shield-1 concentration it needs to be considered that 
shield-1 is toxic for the parasite. Although shield-1 concentration at or higher than 1.0 µM 
does not affect the growth yet it delays the development of the parasite. This needs to be 
considered while interpreting the resulting phenotype. Therefore, shield-1 concentration 
cannot be increased further to supress stabilization as it could prove to be lethal for the 
parasite (de Azevedo et al., 2012). At the same time a rapamycin sensitive FKBP homologue 
of Plasmodium is constitutively expressed (Kumar et al., 2005) but whether it is sensitive to 
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rapamycin derivative shield-1 is not known (de Azevedo et al., 2012). As shield-1 is sensitive 
to repeated freeze and thaw so before each experiment we freshly diluted shield-1 stock in the 
cell culture media to obtain desirable concentrations. To rule out the possibility that shield-1 
has lost its effectiveness we used it to supress the destabilisation of control T. gondii MLC1. 
Incubation with only 0.5 µM shield-1 for 24 hours induced robust suppression of 
destabilisation of the dd-FKBP-MycTgMLC1, resulting in several fold increase in the level 
of fusion protein (fig.3.7b and fig.3.7c). 
4.2.2. N- or C-terminal tagging render the fusion proteins non 
functional 
 
In modern biology, we often use N- or C-terminal tags for various purposes. Protein tags are 
peptide sequences that are fused either to the N- or C-terminus of the protein of interests. 
Tags are used for several purposes like purification, detection, trafficking in the cell, and 
localization etc. One criterion that needs to be considered is that all proteins do not tolerate 
N- or C- terminal tagging. During our work we have fused dd-FKBP tag either to the N- or 
C-terminus depending on the protein. In addition, we have also fused the HA tag on the 
protein of interest for the purpose of detection. Since we could not achieve a dominant 
negative effect in the parasite line by episomal expression of the dominant negative alleles of 
PfHsp70-1 and PfHsp40, we speculate whether this could be due to the compromised 
function of the protein of interests in vivo due to tagging with the HA and dd-FKBP. As 
already discussed earlier, the whole idea of using dominant negative approach is the episomal 
expression of a catalytically dead protein. This competitively occupies the interaction partner 
for endogenous protein rendering the protein functionally silent. Although the proteins are 
catalytically dead in this approach yet the overall native structure of the episomally expressed 
fusion protein needs to be conserved in order to allow them to interact and block the ligands 
of the endogenous protein. As we could not obtain overexpression of the endogenous protein 
to a certain level for establishing dominant negative phenotype, we cannot rule out the 
possibility of the proteins not behaving as ‘dominant negative’ at all in the cell. For both the 
PfHsp70-1 and PfHsp40 we do not know whether the tagging of the protein with the dd-
FKBP affects their overall folding into native functional structure and therefore hinders 
binding to the native substrate. In fact this would explain why expression of a certain amount 
of dominant negative Pfhsp70-1 and PfHsp40 do not have even slightest effect on the normal 
growth and phenotype of the parasite. The mutations have been constructed in PfHsp70-1 and 
4 Discussion       112 
! !
PfHsp40 in agreement with previous work that should render the proteins ‘dominant 
negative’ (Buchberger et al., 1994, Hennessy et al., 2005) (refer to section 2.2.1.1.4!and!7.2). 
But, we do not know whether the fusion of the 15kDa destabilisation domain onto the protein 
adversely affects the overall native folding of the protein and therefore the fusion protein 
cannot compete with the endogenous version. Hence, significant alteration of the native 
folding of the fusion protein might compromise its interaction with the endogenous ligands 
that would in turn dissatisfy the purpose of the study. But in two independent studies from 
our group, the endogenous copies of PfHsp40 and also episomal PfHsp70x could be tagged to 
GFP without an effect on the protein function (Kulzer et al., 2010, Kulzer et al., 2012). One 
of the PfHsp40s is likely to be essential therefore the tagging cannot have affected the protein 
function. Inspite of the conservation of several amino acids, between members of PfHsp70 
and PfHsp40s, we do not know whether there are some significant differences in folding 
among individual homologues. As a result, the function of one might be affected by tagging 
whereas the other is unaffected. For the same reason, we constructed control plasmids 
expressing the candidate proteins tagged to both GFP and HA in order to avoid an influence 
of the tag on protein function.  
 
Nevertheless, this problem has already been reported as one of the important drawbacks of 
using this system. Recently it was reported by Herm-Götz et al., (2007) that some proteins 
are no longer functional when tagged to the dd-FKBP domain, (Herm-Gotz et al., 2007, 
Armstrong and Goldberg, 2007). The point, that parasite proteins might not tolerate the 
fusion of dd-FKBP domain, has been raised by study in Plasmodium as well (Armstrong and 
Goldberg, 2007, de Koning-Ward and Gilson, 2009). Chu et al., (2008) has addressed this 
challenge and therefore tested the efficiency of dd-FKBP to confer destabilization of the 
fusion protein when spliced into the middle of a protein. They tethered the L106P using long 
linkers between certain amino acids of yellow fluorescent protein (YFP) that tolerate 
insertion of additional peptide keeping the overall folding topology intact. This fusion protein 
showed robust strong destabilization kinetics that could further be reverted very efficiently by 
the addition of shield-1 (Chu et al., 2008). Therefore, an alternative approach would be to 
introduce the destabilisation domain inside PfHsp70-1 and PfHsp40. Since these proteins 
achieve their function via several domains present throughout the protein, finding a site 
where these will tolerate additional peptide insertion without affecting the function and 
overall folding of the protein, could be challenging.  
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4.2.3. Episomal expression driven by crt promoter does not lead to 
sufficient overexpression of fusion proteins 
 
Although we could detect wild type and dominant negative fusion protein expressed 
episomally under crt promoter, the level of expression was much lower compared to the 
endogenous protein (fig.3.2b and fig.3.3b). Since the whole idea of this approach was to 
override the function of the endogenous protein by dominant negative alleles in a competitive 
manner, the success partly lies in the sufficient overexpression of the dominant negative 
version. Till date, this system has been applied in different organisms with success but in all 
these cases the protein has been placed under the control of a strong constitutive promoter or 
native promoter of the gene. For example in Toxoplasma gondii, functional analysis of 
essential parasite protein was carried out using this approach where the fusion protein was 
either placed under the control of strong constitutive p5RT70 promoter or stable transfection 
was carried out using the plasmid coding for dominant negative protein (Herm-Gotz et al., 
2007). In a similar study, in Plasmodium falciparum, episomal expression of the protein of 
interest fused to dd-FKBP was driven from a strong hsp86 promoter. In addition to that the 
plasmid was transfected into a clone lacking the endogenous gene (Armstrong and Goldberg, 
2007). This makes the assessment of the function of the protein much simpler in comparison 
to our work where the wild type gene coding for the endogenous protein has been kept intact. 
Since in our work the endogenous PfHsp70-1 and PfHsp40 are present intact to carry out 
their function unlike in the work of Amstrong et al., (2007) where episomal overexpression 
of the dominant negative versions by several fold under a native or strong constitutive 
promoter is a ‘must’ for the success of the strategy. Another study in Plasmodium showed 
that the protein of interests fused to destabilisation domain were either expressed under 
strong Pfhsp86 promoter or integrated into the endogenous locus (de Azevedo et al., 2012).  
 
In our study, we attempted to clone the PfHsp70-1 native promoter in front of the 3XHA-dd-
FKBP-PfHsp70-1 fusion protein by replacing the crt promoter of the transfection plasmid 
(refer to section 2.2.2.5). By this we wanted to assess whether the expression of the fusion 
protein under its native promoter is much higher in comparison to the much weaker crt 
promoter. At the same time we could compare the level of the endogenous PfHsp70-1 and 
episomally expressed PfHsp70-1 fusion protein under native promoter. Unfortunately, due to 
low transfection efficiency in Plasmodium we could not generate any successful transgenic 
parasite line. 
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In order to bypass this challenges associated with poor expression of the fusion protein 
another straightforward possible approach would be to integrate the destabilization domain 
by either single or double crossover recombination at the 3’ end of the endogenous coding 
region. In this manner the protein of interest is expressed as a fusion protein tagged to 
destabilization domain at its C-terminus. At the same time the gene is maintained under the 
control of the endogenous promoter. Plasmodium falciparum protein kinase (Dvorin et al., 
2010) and calpain (Russo et al., 2009) have been reported to be conditionally knocked down 
with this approach of C-terminal tagging of the destabilization domain. But, among several 
proteins studied only these two essential proteins could be successfully tagged by this 
method. The reason behind low success rate could be explained by two possible reasons. 
Firstly, the protein might become nonfunctional by the C-terminal tagging of the 
destabilization domain therefore cannot carry out essential function for the survival of the 
organism. Secondly, the small ligand (shield-1) might not be effective to suppress the 
destabilization, reverting back the function of the protein necessary for the cellular function 
(de Azevedo et al., 2012). Even if the protein accepts C-terminal destabilization domain 
tagging the success of achieving a knockdown of the protein might be obstructed. This is 
because the leakiness of the destabilization domain cannot lead to complete degradation of 
the target protein to establish a detectable phenotype. This challenge can be possibly 
overcome by using other triple mutant of the dd-FKBP derived destabilization domains 
DD24 (E31G-R71G-K105E) or DD29 (D79G-P93S-D100R) (Chu et al., 2008) that have 
much stronger destabilization effect in comparison to that of dd-FKBP (L106P) used in our 
study (refer to section.4.3.1). DD29 (DDTM) has been successfully used to generate 
conditional knockdown of Plasmodium falciparum calcium dependent protein kinase domain 
(Dvorin et al., 2010).  
4.2. Alternative ecDHFR-derived dd failed to regulate 
protein level in the parasite by ligand TMP !
Being unable to control protein level tagged to the FKBP derived destabilization domain we 
further attempted to use another E. coli dihydrofolate reductase (ecDHFR) derived 
destabilization domain recently characterized by Iwamoto et al., (2010). This domain was 
engineered to successfully confer its instability to the fused protein. Therefore the previously 
used dd-FKBP and dd-ecDHFR function in similar fashion. But, as claimed by the authors, 
dd-ecDHFR had several improved properties compared to the previous dd-FKBP (Iwamoto et 
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al., 2010). Therefore, by using dd-ecDHFR we aimed to overcome several drawbacks of the 
dd-FKBP system. Firstly, it was reported that dd-ecDHFR is much more efficient in 
destabilising the level of the fusion protein when tagged to the C-terminus of the protein of 
interest unlike the L106P dd-FKBP where negligible protein was detected in absence of the 
ligand (Chu et al., 2008, Iwamoto et al., 2010). We expected that the level of PfHsp40 could 
be more efficiently regulated when tagged to the dd-ecDHFR at the C-terminus (fig. 3.11a 
and fig. 3.12a). Secondly, trimethoprim (TMP), the stabilizing ligand of the dd-ecDHFR is 
commercially available, inexpensive, and does not have any effect on the growth or normal 
developmental cycle of the TMP resistant parasite when used at a concentration as high as 
15.0 µM. On the other hand, dd-FKBP delays the growth cycle of the parasite when used at a 
concentration higher than 1.0 µM (de Azevedo et al., 2012).  
Unfortunately, the tagging of the dd-ecDHFR also failed to regulate protein level when 
expressed episomally. All the wild type and dominant negative PfHsp70-1 and control GFP 
when fused to the dd-ecDHFR at the N-terminus (fig. 3.8a, 3.9a and 3.10a) resulted in a 
significant amount of fusion protein in the absence of TMP (fig.3.8b, 3.9b and 3.10b). 
Further, there was no upregulation in the level of protein on increasing the concentration of 
TMP upto 15.0 µM (fig.3.8b, 3.9b and 3.10b). This observation suggested that dd-ecDHFR is 
also not efficient to regulate parasite heat shock proteins and the GFP level. At the same time 
since the level of the endogenous protein were much higher than the dominant negative 
PfHsp70-1, we could not obtain a dominant negative effect in the parasite (fig 3.9b). In 
addition, the failure to establish a dominant negative effect in the parasite by expressing 
DNPfHsp70-1 can be due to several reasons that is, either inefficient stabilisation by TMP, 
the loss of native interaction by N-terminal tagging and the expression under weak crt 
promoter as mentioned earlier (refer to section. 4.2.1, 4.2.2 and 4.2.3). As previously 
mentioned that C-terminal tagging of the dd-ecDHFR is claimed to be more effective in 
regulation, we thought that tagging of these candidate protein at the N-terminus (fig. 3.8a, 
3.9a, and 3.10a) might be the reason for poor regulation by this domain.  
If this reasoning is right, and the N-terminal tagging is less effective in regulating protein 
level, then we expected to see better regulation of the level of wild type and dominant 
negative PfHsp40 and GFP where the dd-ecDHFR was fused to the C-terminus (fig. 3.11a, 
3.12a and 3.13a). But, once again we did not witness any sign of regulation of the wild type 
and dominant negative PfHsp40 fusion protein level by dd-ecDHFR. In the absence of TMP, 
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high level of fusion proteins was detected. Increasing TMP concentration up to 15.0 µM for 
the PfHsp70-1 fusion protein did not show any visible increase in the protein level (fig. 3.11b 
and 3.12b). In contrast, on addition of TMP the GFP level was regulated in a robust and dose 
dependent manner. GFP fusion protein was barely detected in the absence of the TMP, while 
increasing concentration of TMP up to 15.0 µM resulted in clear dose dependent stabilization 
and increase in the protein level (fig. 3.13b). This observation is in agreement with previous 
studies carried out with dd-ecDHFR fused to YFP and GFP (Muralidharan et al., 2011, 
Iwamoto et al., 2010, Rakhit et al., 2011). On the other hand, our inability to regulate parasite 
protein level by this approach once again suggests that the success rate of the destabilisation 
domain approach in Plasmodium is low and tagging of essential plasmodium protein is highly 
challenging.  
4.2.1. Applicability of dd-ecDHFR domain is not universal and 
success is protein dependent  !
Although, the dd-ecDHFR domain has been gaining research attention as an alternative 
approach to FKBP derived destabilisation domain, the success rate depends on several factor 
and is purely dependent on the organism and protein to be studied.  This domain was first 
characterised and used to regulate the stability of several proteins in mammalian central 
nervous system to successfully regulate some transmembrane protein that was difficult to be 
controlled by the dd-FKBP (Iwamoto et al., 2010). Since then the dd-ecDHFR has been used 
to regulate the level of essential kinase in S. cerevisiae, where the authors wanted to evaluate 
the efficiency of dd-FKBP and dd-ecDHFR. The authors reported that the dd-ecDHFR tagged 
proteins were rapidly degraded and stabilization was obtained with the addition of TMP, 
whereas dd-FKBP was unstable under all conditions (Rakhit et al., 2011). Very recently the 
dd-ecDHFR has been used in Plasmodium falciparum to successfully generate conditional 
knockout of a proteasome lid subunit 6 (Rpn6) (Muralidharan et al., 2011). In this study the 
conditional knockdown of the Rpn6 could be efficiently obtained in a TMP dependent 
manner and therefore the author claimed the applicability of the dd-ecDHFR to study 
essential genes in Plasmodium falciparum. Noteworthy, during this work dd-ecDHFR along 
with the reporter protein was fused to the 3’ end of the endogenous Rpn6 gene via single 
cross over homologous recombination. Hence, the success of this work greatly relied on the 
possibility to regulate the endogenous Rpn6 by dd-ecDHFR under the control of the native 
promoter (Muralidharan et al., 2011). Unlike our study where we wanted to establish 
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dominant negative phenotype by episomal overexpression of the dominant negative protein 
fused to dd-ecDHFR under the control of weaker crt promoter instead of knocking out the 
gene of interests. At the same time to our knowledge Rpn6 is the only Plasmodium protein 
studied so far by this system with success. During our study, we were able to accomplish a 
clear dose dependent regulation of GFP, whereas several Plasmodium heat shock proteins 
(PfHsp70-1 and PfHsp40) could not be controlled under the same condition. Considering the 
fact that applicability of the destabilisation domain strategy in Plasmodium is much lower 
when compared to other organisms (de Azevedo et al., 2012), regulation of more essential 
plasmodial protein needs to be studied in order to claim the universal application of this 
system.  
To conclude, inspite of several reports of successful application of FKBP and ecDHFR 
derived destabilisation domain strategy in Plasmodium falciparum, the success of the 
approach is dependent on several factors. One major factor is to either integrate the 
destabilisation domain into the gene locus or to drive episomal expression of the wild type 
and dominant negative protein under strong hsp86 like promoter in a knockout cell line. 
Again, both of these factors could further be posed with several challenges. As mentioned 
earlier, integration into the gene locus might render the protein nonfunctional whereas, the 
endogenous or episomal destabilisation might be leaky. If we cannot regulate the protein 
level, this approach would not be of much help. Therefore, these factors need to be carefully 
considered and the right approach should be determined depending on individual protein 
candidate. Although, our attempt to study the essential role of PfHsp70-1 and PfHsp40 in the 
parasite by establishing a dominant negative phenotype using this approach failed, several 
combinations with other systems can be tried in future in order to ensure success of the 
method. In fact, to our knowledge conditional over expression of protein of interest to 
establish dominant negative phenotypes has not yet been published for P. falciparum (de 
Azevedo et al., 2012).  
4.3. Possible alternative future approaches that can be 
tested to ensure success  !
Several alternative strategies that can be tested either individually or in combination with the 
other, to generate conditional knock down of the essential proteins during asexual blood stage 
of Plasmodium falciparum will be discussed in the following sections. Nevertheless, it needs 
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to be seriously considered that none of these techniques are of a “gold standard” and 
therefore has advantages as well as drawbacks. Hence, a careful selection of the approach 
that is most suited for the protein of interest needs to be determined. 
4.3.1. Triple mutant of dd-FKBP conferring greater instability to 
protein of interest !
We used L106P mutant of dd-FKBP that failed to regulate the level of episomally expressed 
protein. The dd-ecDHFR domain also proved to be ineffective inspite of being successfully 
used for other proteins in rat, S. cerevisiae and Plasmodium falciparum. The L106P dd-FKBP 
was among the very first potent destabilisation domain identified during the initial screening 
carried out by Banaszynski et al., (2006) (Banaszynski et al., 2006). This dd-FKBP possesses 
only single point mutation (F36V). But, there were also several possible drawbacks of the 
L106P mutant. For example, the fusion protein was unstable when L106P was tagged to the 
C-terminus. At the same time this single mutant was not dominant to endogenous degrons 
(Banaszynski et al., 2006). Realising this drawbacks Chu et al., (2008) identified two 
addition triple mutant dd-FKBP known as either DD24 (E31G-R71G-K105E called FKBP) 
or DD29 (D79G-P93S-D100R). After comparing the efficiency of these two domains with 
L106P mutant, it was revealed that these were capable of conferring better instability to the 
fusion protein and obtained complete stabilization on addition of shield-1 in a dose dependent 
manner (Chu et al., 2008).  
DD29 has already been used in Plasmodium falciparum with great success for generating 
conditional knock down of a protein kinase and calpin to assess their importance during the 
blood stage (Dvorin et al., 2010, Russo et al., 2009). The applicability of DD24 to regulate 
the level of Plasmodium Ring-Infected Erythrocyte Surface Antigen (RESA) has also been 
tested in a recent study while doing systematic analysis of the efficacy of all destabilization 
domains (de Azevedo et al., 2012). The same study also showed that DD29 is the most 
efficient destabilisation domain, capable of reducing reporter protein level down to 6% in the 
absence of shield-1.  
During the course of our study, we have generated all the transfection plasmids for PfHsp70-
1, PfHsp40 and GFP by using triple mutant DD29, fused to either N- or C- terminus 
depending on the protein of interest (PfHsp70-1 or PfHsp40). In future we could express the 
protein of interest under strong hsp86 promoter instead of the weaker crt promoter as used 
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earlier (fig. 4.1). Therefore, we expect to override the level and function of the endogenous 
candidate Hsps by the overexpression of dominant negative version fused to more efficient 
destabilisation domain under the control of a much stronger promoter.  
 
Figure 4.1 Schematic illustration of a transfection plasmid for conditional episomal expression of the 
protein of interest.  
The coding region of the gene of interest (GOI) is fused to the dd triple mutant (DD29) either at the N-terminus 
(a) or C-terminus (b). Expression is driven under the control of a strong hsp86 promoter.  
Nevertheless this strategy might have few disadvantages. It has already been published that 
although the triple mutant of the dd-FKBP has stronger destabilizing ability the problem lies 
in poor suppression of destabilization by the addition of shield-1. Therefore, the expression 
and function of the fused protein cannot be efficiently reverted (de Azevedo et al., 2012). 
This is also in agreement with the study of Chu et al., (2008), where 3.0µM shield-1 was 
needed to obtain full stabilization (Chu et al., 2008). 
Considering the fact that the destabilisation domain is in some part greatly organism and 
protein dependent, in future the ability to regulate the episomal level of one of the candidate 
heat shock proteins need to be checked to assess the applicability of this system. This way 
one can save time and resources. Since, we claim that the system is partly protein dependent 
there is no real “control” as the outcome from the study of one candidate protein will not be 
of much help in deciphering the success of another.  
4.3.2. Application of a recently characterised tertracyline 
repressible transactivator system for Plasmodium falciparum !
An inducible gene expression system was characterized and established by Meissner et al., 
(2002) for Toxoplasma gondii. The transactivator domain contained a Tet repressor (TetRep) 
fused to a non-endogenous activating domain (TATi1) (Meissner et al., 2002). Since 
characterization, this domain has been severely adapted to study the function of several 
essential genes in T. gondii (Meissner et al., 2002, Huynh and Carruthers, 2006, Plattner et 
al., 2008, Buguliskis et al., 2010).  
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TATi2 identified from Toxoplasma qualified to be functional in Plasmodium yet when 
expressed from multicopy episomal plasmid (Meissner et al., 2005). But, it failed to generate 
conditional knockouts of essential gene in P. falciparum. This could be an outcome of the 
poor transactivation activity. Therefore, the best possible way would have been to design a 
transactivation system depending on the transcriptional activation pathway of the parasite 
(Pino et al., 2012). 
 
Very recently highly efficient transactivator domains have been identified and characterized 
for their utility in Plasmodium berghei and Plasmodium falciparum. This robust Tet-
repressible transactivator system has been efficiently and successfully applied to study the 
function of essential gene in Plasmodium berghei when integrated into the genome by 
homologous recombination. Nevertheless, it has also been shown that TRAD4 (one out of the 
few identified transactivator domains) was highly efficient in mediating the derivative 
anhydrotetracycline (ATc) dependent conditional expression of reporter protein when 
expressed from an episomal plasmid in human malaria parasite. The mode of function of this 
system is based on ‘Tet on and off’ system. In the absence of the tetracycline derivative 
anhydrotetracycline (ATc) transactivator interact with the tet operator (TetO) sequence via 
the Tet repressor (TetR) and initiate transcription. Whereas when ATc is added, there is a 
dramatic reduction in the affinity of the TetR for the TetO that results in switching off the 
transcription (Bujard, 1999). Therefore, using this system we could try to achieve the 
conditional episomal expression of our candidate Hsps by ATc dependent episomal 
expression of the candidate protein (Fig. 4.2). 
 
Figure 4.2 Schematic illustration of a transfection plasmid for conditional episomal expression of the 
protein of interest.  
TRAD4 is placed under the control of a PfMSP2 promoter. The gene of interest (GOI) is under the control of a 
tet transactivator-responsive promoter. This promoter contains seven tet operator sites. Adapted from (Pino et 
al., 2012). 
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This system is much more leak proof, where a tight regulation of protein expression is 
possible compared to that offered by destabilization domain. On the other hand, it is a 
reversible system compared to Di-Cre recombinase system reported recently for P. 
falciparum (Pino et al., 2012, Collins et al., 2013). But, the disadvantage is that this system is 
not yet fully optimised for use in Plasmodium falciparum. And, copy numbers of plasmid 
under same conditions greatly vary between individual parasites. Therefore, it needs to be 
investigated whether TRAD4 is functional and effective when integrated into the genome for 
obtaining more homogenous and reproducible response to ATc (Pino et al., 2012).  
4.3.3. Integration of the destabilisation domain to the 3’ end of the 
endogenous coding region !
If we find DD29 mutant of dd-FKBP to be much stronger and robust in achieving conditional 
expression of protein level upon addition of shield-1, another straightforward strategy would 
be to genetically fuse this domain to the C-terminus of the coding region of the gene. This 
approach has previously been tried successfully in two individual studies to elucidate the 
essential role of protein kinase and calpin in intraythrocytic stage of P. falciparum (Dvorin et 
al., 2010, Russo et al., 2009). Therefore, after the validation of the effectiveness of the DD29 
mutant we can try to integrate it to the C-terminus of the candidate Hsps by homologous 
recombination. This way the expression level of the endogenous protein could directly be 
controlled by the addition or withdrawal of shield-1. In absence of the shield the level of 
expressed protein should be significantly reduced resulting in a conditional knockdown and 
therefore the resulting phenotype could further be analysed (fig. 4.3).  
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Figure 4.3 Schematic illustration of homologous recombination event at C-terminal end of an endogenous 
coding region.  
a. Targeting plasmid to integrate the gene of interest fused to the destabilization domain (DD) at the 3’ end of 
the endogenous coding region. b. Structure of the gene locus containing the gene to be targeted (GOI). c. 
Integrated GOI fused to DD at the C-terminus coding region of the endogenous locus resulting from 
homologous recombination. Adapted from (Dvorin et al., 2010), (supplementary documents). 
This method has the advantage of directly regulating the expression level of endogenous 
proteins. But at the same time this strategy has several disadvantages and uncertainties. As 
previously mentioned, at the very first stage it needs to be assured whether there is complete 
stabilisation of the protein level by the addition of shield-1 as it has already been noticed that 
the destabilisation cannot be efficiently supressed upon shield-1 addition (de Azevedo et al., 
2012). Since the endogenous protein is directly tagged to the destabilisation domain, 
stabilisation ensuring essential protein function for parasite survival is mandatory. Secondly, 
the shield-1 is highly expensive therefore the application of this strategy that need the 
parasite to be maintained all the time under shield-1, demands huge financial investment. 
Thirdly, since the parasites are selected and always maintained under shield-1, they might 
become non responsive after its removal (Pino, 2013). There have been several reports where 
the fusion of the destabilisation domain to the N- or C-terminus interferes with the protein 
function rendering the protein non-functional (Herm-Gotz et al., 2007). Therefore the last and 
most importantly, the tagging to the C-terminus of the endogenous coding region should be 
able to tolerate fusion.  
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In recent years there has been a significant increase in the amount of diverse technologies to 
target essential gene during intraerythrocytic life stage of Plasmodium falciparum. 
Noteworthy, inspite of these progresses only less than ten genes have been successfully 
studied by either of these approaches. This indeed reflects the challenges and difficulties 
involved in obtaining knockdown of essential gene during blood stage malaria parasite. As 
mentioned earlier all the possible approaches explained herein along with other available 
ones have huge drawbacks. Therefore, identification of a reliable strategy to generate 
reversible conditional knockdown of essential genes will be a significant step forward. 
Needless to say, this will help in further investigation and validation of potential vaccine and 
drug targets to reduce the global burden of malaria.  
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5a. Summary 
 
The apicomplexan malaria parasite, Plasmodium falciparum is capable of invading red blood 
cells and causes the most virulent form of malaria. The life cycle of P. falciparum involves 
the migration from the poikilothermic mosquito vector to warm-blooded human host and vice 
versa. Such transition introduces radical differences between the cellular environments where 
the parasite resides, imposing physiological stress. The diverse environmental insults in 
addition to the febrile fever episodes imparts challenge on the proteostasis, resulting in the 
evolutionary selection of a diverse network of molecular chaperones. In fact, some molecular 
chaperones are essential for the survival of Plasmodium. Due to the developing resistance of 
Plasmodium against currently available drugs, heat shock proteins have received extensive 
research attention as antimalarial targets in recent years.  
Plasmodium codes for one Hsp90 homologue and a constitutively expressed heat inducible 
cytosolic Hsp70 known as PfHsp70-1. In general, Hsp70 interacts with co-chaperone Hsp40 
initiating the protein folding machinery that finally interacts with Hsp90 to maintain 
proteostasis in a cell. PfHsp90 has been found to be essential for the intraerythrocytic 
development of P. falciparum. Although there have been some in vitro studies on the biology 
of PfHsp70-1, the information on the in vivo essential function of PfHsp70-1 and its 
interaction with PfHsp40 is limited.  
In this study, we wanted to identify the in vivo biological importance of PfHsp70-1 and one 
of its predicted co-chaperones, PfHsp40 by the overexpression of the dominant negative 
alleles tagged to recently characterised destabilisation domain (dd) to regulate protein level. 
We expressed a dominant negative PfHsp70-1 possessing a point mutation (E187K), severely 
affecting normal domain movement important for its function. PfHsp40 was mutated in the 
conserved HPD motif (D34N) necessary for establishing interaction with PfHsp70-1. 
Unfortunately, we could not obtain sufficient overexpression of the episomal dominant 
negative versions to override the function of the endogenous proteins in a competitive 
manner. The cellular levels of endogenous proteins were higher by several folds compared to 
that of the episomally expressed dominant negative alleles. The destabilisation strategy has 
been reported to be successful for studying certain plasmodial proteins. But in contrast, 
during our work the level of almost none of the candidate chaperones could be controlled by 
either FKBP or E. coli DHFR derived destabilisation domains in a ligand dependent fashion. 
Although, the level of wild type PfHsp70-1 could be regulated by this strategy, the dominant 
negative version with only one amino acid substitution made it non responsive to dd tagging 
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and further ligand treatment. At the same time, the level of control proteins could be 
efficiently regulated by stabilising ligands. Recently, success of destabilization domain 
strategy for conditional knockdown of several genes has been reported.  But in contrast, our 
observations in this study unravel the possible drawbacks. We assume that the success of 
such an approach is greatly protein dependent. Based on the several reports initially this 
approach appeared to be the most beneficial system. But, the failure to successfully 
implement this strategy demands careful consideration in selecting an alternative future 
approach to study the function of essential genes in Plasmodium. 
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5b. Zusammenfassung 
Der apikomplexe Parasit Plasmodium falciparum ist in der Lage, Erythrozyten zu invadieren 
und verursacht die virulenteste Form der Malaria. Der Lebenszyklus von P. falciparum 
umfasst den Übergang vom poikilothermen Moskito Vektor zum warmblütigen, 
menschlichen Wirt und zurück. Ein solcher Wechsel bedeutet gleichzeitig einen radikalen 
Wechsel der zellulären Umgebung, in welcher der Parasit sich befindet und letzten Endes 
physiologischen Stress. Die unterschiedlichen Stressfaktoren durch die Umgebung stellen 
zusätzlich zu den Fieberepisoden eine Herausforderung bezüglich der Proteostase dar, was 
zur evolutionären Selektion eines Netzwerks unterschiedlicher molekularer Chaperone 
geführt hat. Tatsächlich sind einige dieser molekularen Chaperone für das Überleben von 
Plasmodium unabdinglich. Aufgrund der immer weiter fortschreitenden Ausbildung von 
Resistenzen gegenüber den verfügbaren Medikamenten kam den Hitzeschock Proteinen 
(Hsp) große Beachtung bezüglich der möglichen Verwendung als Angriffspunkte für neue 
Antimalaria Therapien zu. 
Plasmodium kodiert für ein Hsp90 Homolog sowie ein konstitutiv exprimiertes, 
hitzeinduziertes zytosolisches Hsp70 namens PfHsp70-1. Grundsätzlich interagiert Hsp70 mit 
dem Co-Chaperon Hsp40 und initiiert die durch die Interaktion mit Hsp90 vervollständigte 
Proteinfaltungsmaschinerie, welche die Proteostase in der Zelle aufrechterhält. PfHsp90 hat 
sich als essentiell für die intraerythrozytäre Entwicklung von P. falciparum erwiesen. 
Obwohl bezüglich der Biologie von PfHsp70-1 einige in vitro Studien durchgeführt wurden, 
existiert wenig Information bezüglich der essentiellen Funktion der Interaktion von PfHsp70-
1 und PfHsp40  in vivo. 
Im Zuge der hier vorliegenden Arbeit sollte in vivo die biologische Bedeutung von PfHsp70-
1 und einem seiner vorhergesagten Co-Chaperonen, PfHsp40, untersucht werden. Dazu sollte 
mit Hilfe von Überexpression der dominant negativen Allele, welche an die kürzlich 
charakterisierte Destabilisierungsdomäne (dd) gebunden wurden, der intrazelluläre 
Proteinlevel reguliert werden. Dabei wurde eine dominant negative Mutante von PfHsp70-1 
exprimiert, welche eine Punktmutation (E187K) trägt, die die für die normale Funktion des 
Proteins wichtige Beweglichkeit der Domänen stark beeinflusst. PfHsp40 wurde im 
konservierten HPD Motiv (D34N) mutiert, welches wichtig für die Ausbildung der 
Interaktion mit PfHsp70-1 ist. Eine ausreichende Überexpression der episomalen dominant 
negativen Versionen, welche notwendig ist, um die Funktion der endogenen Proteine 
kompetitiv auszuschalten, war nicht möglich. Hierbei lagen die zellulären Level der 
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endogenen Proteine um viele Stufen höher als die der episomal exprimierten dominant 
negativen Allele. In der Literatur wurde der Destabilisierungsansatz als erfolgreich bei der 
Untersuchung vieler Plasmodienproteine beschrieben. Im Gegensatz dazu konnte im Zuge 
dieser Arbeit bei nahezu keinem der ausgewählten Chaperone der Proteinlevel durch die 
Liganden FKBP oder DHFR (eine aus  E. coli genutzte Destabilisierungsdomäne) kontrolliert 
werden. Obwohl der Level von Wildtyp PfHsp70-1 über diese Strategie reguliert werden 
konnte, war die dominant negative Version des Proteins mit einer mutierten Aminosäure 
gegenüber dem dd-Tag und Zugabe des Liganden resistent. Gleichzeitig war es möglich, die 
als Kontrolle fungierenden Proteine effektiv durch die stabilisierenden Liganden zu 
regulieren. 
Kürzlich konnte die erfolgreiche Nutzung des Destabilisierungsdomänen Ansatzes für 
konditionelle Knock-Outs verschiedener Gene gezeigt werden. Die in der vorliegenden 
Arbeit dargestellten Ergebnisse weisen im Gegensatz dazu aber auch auf die möglichen 
Nachteile dieser Technik hin. Wir vermuten dabei, dass der Erfolg dieses Ansatzes stark vom 
jeweiligen Protein abhängig ist. Die Wahl dieses Ansatzes bei der vorliegenden Arbeit 
basierte auf verschiedenen Veröffentlichungen, welche auf eine erfolgreiche mögliche 
Nutzung hindeuteten. Die Tatsache jedoch, dass es nicht möglich war, diese Strategie 
erfolgreich zu implementieren, verlangt ein vorsichtiges Vorgehen bei der Wahl zukünftiger 
Ansätze zur Untersuchung der Funktion essentieller Gene.!!!!!!!
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7. Supplementary Data 
7.1 List of sequence 
7.1.1 Coding sequence for PfHsp70-1 (PF3D7_0818900) 
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ATGGCTAGTGCAAAA GGTTCAAAACCAAAT TTACCAGAATCCAAT ATCGCTATTGGAATT GATTTAGGTACTACT 
 M  A  S  A  K   G  S  K  P  N   L  P  E  S  N   I  A  I  G  I   D  L  G  T  T  
TATTCTTGTGTTGGT GTATGGAGAAATGAA AATGTAGATATTATT GCTAATGACCAAGGT AATAGAACAACCCCA 
 Y  S  C  V  G   V  W  R  N  E   N  V  D  I  I   A  N  D  Q  G   N  R  T  T  P  
TCTTATGTTGCTTTC ACCGATACCGAAAGA TTAATTGGAGATGCT GCTAAAAACCAAGTA GCTAGGAATCCAGAA 
 S  Y  V  A  F   T  D  T  E  R   L  I  G  D  A   A  K  N  Q  V   A  R  N  P  E  
AATACAGTATTTGAT GCTAAGAGATTAATT GGTAGAAAATTTACA GAATCATCAGTACAA AGTGATATGAAACAT 
 N  T  V  F  D   A  K  R  L  I   G  R  K  F  T   E  S  S  V  Q   S  D  M  K  H  
TGGCCATTCACTGTT AAATCAGGTGTTGAT GAGAAACCAATGATT GAAGTTACCTATCAA GGAGAAAAGAAATTA 
 W  P  F  T  V   K  S  G  V  D   E  K  P  M  I   E  V  T  Y  Q   G  E  K  K  L  
TTCCATCCAGAAGAA ATTTCTTCTATGGTA TTACAAAAAATGAAA GAAAATGCTGAAGCA TTTTTAGGAAAATCT 
 F  H  P  E  E   I  S  S  M  V   L  Q  K  M  K   E  N  A  E  A   F  L  G  K  S  
ATAAAGAATGCTGTC ATTACCGTTCCAGCT TATTTTAACGATTCA CAAAGACAAGCTACT AAAGATGCTGGTACA 
 I  K  N  A  V   I  T  V  P  A   Y  F  N  D  S   Q  R  Q  A  T   K  D  A  G  T  
ATTGCAGGATTAAAT GTTATGAGAATTATT AATGAACCTACTGCA GCTGCTATTGCATAT GGTTTACACAAAAAA 
 I  A  G  L  N   V  M  R  I  I   N  E  P  T  A   A  A  I  A  Y   G  L  H  K  K  
GGAAAAGGTGAAAAG AACATTTTAATTTTC GACTTAGGAGGAGGT ACATTTGATGTATCA TTATTAACTATTGAA 
 G  K  G  E  K   N  I  L  I  F   D  L  G  G  G   T  F  D  V  S   L  L  T  I  E  
GATGGTATTTTTGAA GTAAAAGCTACTGCT GGTGATACTCATTTA GGTGGTGAAGATTTC GATAACAGATTAGTA 
 D  G  I  F  E   V  K  A  T  A   G  D  T  H  L   G  G  E  D  F   D  N  R  L  V  
AATTTCTGTGTTGAA GATTTCAAAAGAAAA AACAGAGGTAAAGAT TTATCAAAAAATAGT AGAGCCTTAAGAAGA 
 N  F  C  V  E   D  F  K  R  K   N  R  G  K  D   L  S  K  N  S   R  A  L  R  R  
TTAAGAACACAATGT GAAAGAGCAAAACGT ACTTTATCATCATCT ACACAAGCTACAATT GAAATAGATTCCTTA 
 L  R  T  Q  C   E  R  A  K  R   T  L  S  S  S   T  Q  A  T  I   E  I  D  S  L  
TTTGAAGGTATTGAT TACAGTGTTACTGTA AGTAGAGCAAGATTT GAAGAATTATGTATC GACTATTTCCGTGAT 
 F  E  G  I  D   Y  S  V  T  V   S  R  A  R  F   E  E  L  C  I   D  Y  F  R  D  
ACTTTAATTCCAGTA GAAAAAGTTTTAAAA GATGCTATGATGGAT AAAAAAAGTGTACAT GAAGTTGTTTTAGTT 
 T  L  I  P  V   E  K  V  L  K   D  A  M  M  D   K  K  S  V  H   E  V  V  L  V  
GGTGGTTCTACAAGA ATTCCAAAAATCCAA ACTTTAATAAAAGAA TTCTTTAATGGTAAA GAAGCATGCAGATCA 
 G  G  S  T  R   I  P  K  I  Q   T  L  I  K  E   F  F  N  G  K   E  A  C  R  S  
ATTAACCCAGATGAA GCTGTTGCATATGGT GCAGCTGTACAAGCA GCCATTTTATCTGGT GACCAATCAAATGCT 
 I  N  P  D  E   A  V  A  Y  G   A  A  V  Q  A   A  I  L  S  G   D  Q  S  N  A  
GTCCAAGATTTATTA TTATTAGATGTTTGC TCCTTATCATTAGGT TTAGAAACTGCTGGT GGTGTTATGACCAAA 
 V  Q  D  L  L   L  L  D  V  C   S  L  S  L  G   L  E  T  A  G   G  V  M  T  K  
TTAATTGAAAGAAAC ACAACCATACCTGCT AAAAAGAGTCAAATC TTTACTACTTATGCT GATAACCAACCAGGT 
 L  I  E  R  N   T  T  I  P  A   K  K  S  Q  I   F  T  T  Y  A   D  N  Q  P  G  
GTCTTAATTCAAGTA TATGAAGGTGAAAGA GCCTTAACCAAAGAT AACAATTTATTAGGA AAATTTCACTTAGAT 
 V  L  I  Q  V   Y  E  G  E  R   A  L  T  K  D   N  N  L  L  G   K  F  H  L  D  
GGTATTCCACCTGCA CCAAGAAAGGTACCA CAAATCGAAGTTACA TTCGATATCGATGCT AACGGTATCTTAAAC 
 G  I  P  P  A   P  R  K  V  P   Q  I  E  V  T   F  D  I  D  A   N  G  I  L  N  
GTTACGGCTGTAGAA AAATCCACTGGTAAA CAAAACCATATTACA ATTACCAACGACAAA GGAAGATTATCTCAA 
 V  T  A  V  E   K  S  T  G  K   Q  N  H  I  T   I  T  N  D  K   G  R  L  S  Q  
GATGAAATTGATCGT ATGGTTAATGATGCT GAAAAATACAAAGCA GAAGATGAAGAAAAC AGAAAAAGAATCGAA 
 D  E  I  D  R   M  V  N  D  A   E  K  Y  K  A   E  D  E  E  N   R  K  R  I  E  
GCAAGAAACAGCCTT GAAAATTACTGCTAT GGAGTTAAAAGCTCA TTAGAAGACCAAAAA ATTAAAGAAAAATTA 
 A  R  N  S  L   E  N  Y  C  Y   G  V  K  S  S   L  E  D  Q  K   I  K  E  K  L  
CAACCAGCTGAAATT GAAACATGTATGAAA ACTATTACAACCATA CTTGAATGGTTAGAA AAAAACCAACTTGCT 
 Q  P  A  E  I   E  T  C  M  K   T  I  T  T  I   L  E  W  L  E   K  N  Q  L  A  
GGAAAAGATGAATAT GAAGCCAAACAAAAA GAAGCAGAATCGGTT TGTGCTCCAATTATG TCTAAAATCTATCAA 
 G  K  D  E  Y   E  A  K  Q  K   E  A  E  S  V   C  A  P  I  M   S  K  I  Y  Q  
GATGCTGCTGGTGCA GCCGGTGGTATGCCA GGAGGTATGCCCGGT GGAATGCCCGGTGGA ATGCCAGGTGGTATG 
 D  A  A  G  A   A  G  G  M  P   G  G  M  P  G   G  M  P  G  G   M  P  G  G  M  
AATTTCCCAGGAGGT ATGCCCGGAGCAGGA ATGCCAGGAAATGCC CCAGCTGGAAGTGGA CCAACAGTTGAAGAA 
 N  F  P  G  G   M  P  G  A  G   M  P  G  N  A   P  A  G  S  G   P  T  V  E  E  
GTTGATTAA 
 V  D  *  
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7.1.2 Coding sequence for PfHsp40 (PF3D7_0213100) 
 
 
1 
1 
76 
26 
151 
51 
226 
76 
301 
101 
376 
126 
451 
151 
526 
176 
601 
201 
676 
226 
751 
251 
826 
276 
901 
301 
976 
326 
ATGGGGAAGGATTAT TATTCAATATTAGGT GTTAGTAGAGACTGT ACAACAAATGATTTA AAAAAAGCGTATAGG 
 M  G  K  D  Y   Y  S  I  L  G   V  S  R  D  C   T  T  N  D  L   K  K  A  Y  R  
AAGCTAGCCATGATG TGGCATCCTGATAAA CATAATGACGAGAAA TCAAAAAAAGAAGCA GAAGAAAAATTTAAG 
 K  L  A  M  M   W  H  P  D  K   H  N  D  E  K   S  K  K  E  A   E  E  K  F  K  
AATATTGCTGAAGCA TATGATGTTTTAGCA GATGAGGAAAAAAGG AAAATTTATGATACA TATGGAGAAGAAGGA 
 N  I  A  E  A   Y  D  V  L  A   D  E  E  K  R   K  I  Y  D  T   Y  G  E  E  G  
TTAAAAGGTTCAATA CCAACAGGTGGAAAT ACATATGTCTATAGT GGTGTTGATCCTTCA GAATTATTTAGTAGA 
 L  K  G  S  I   P  T  G  G  N   T  Y  V  Y  S   G  V  D  P  S   E  L  F  S  R  
ATATTTGGTTCGGAT GGACAATTTTCTTTT ACCTCAACTTTTGAT GAGGACTTTTCTCCC TTTTCCACTTTTGTC 
 I  F  G  S  D   G  Q  F  S  F   T  S  T  F  D   E  D  F  S  P   F  S  T  F  V  
AACATGACTTCTAGA AAATCTAGACCATCC ACAACAACAAATATT AATACGAACAATTAT AACAAACCAGCCACA 
 N  M  T  S  R   K  S  R  P  S   T  T  T  N  I   N  T  N  N  Y   N  K  P  A  T  
TACGAGGTGCCTCTT TCTTTATCCCTAGAA GAATTGTACAGTGGT TGTAAGAAAAAATTA AAAATAACGAGAAAG 
 Y  E  V  P  L   S  L  S  L  E   E  L  Y  S  G   C  K  K  K  L   K  I  T  R  K  
AGATTTATGGGTACA AAAAGTTATGAAGAT GATAATTATGTAACA ATCGATGTAAAGGCA GGATGGAAAGATGGC 
 R  F  M  G  T   K  S  Y  E  D   D  N  Y  V  T   I  D  V  K  A   G  W  K  D  G  
ACAAAAATAACTTTT TATGGAGAAGGGGAT CAATTATCTCCTATG GCACAACCAGGAGAT TTAGTTTTTAAAGTA 
 T  K  I  T  F   Y  G  E  G  D   Q  L  S  P  M   A  Q  P  G  D   L  V  F  K  V  
AAAACCAAAACACAT GATAGATTCCTAAGA GACGCTAATCATTTA ATATATAAATGTCCT GTACCTTTAGATAAA 
 K  T  K  T  H   D  R  F  L  R   D  A  N  H  L   I  Y  K  C  P   V  P  L  D  K  
GCTTTAACAGGATTC CAATTTATTGTTAAA TCATTAGATAATAGA GATATTAATGTAAGG GTAGATGATATTGTT 
 A  L  T  G  F   Q  F  I  V  K   S  L  D  N  R   D  I  N  V  R   V  D  D  I  V  
ACTCCTAAATCAAGG AAAATTGTAGCAAAA GAAGGTATGCCTTCT TCCAAATACCCAAGC ATGAAAGGGGATCTC 
 T  P  K  S  R   K  I  V  A  K   E  G  M  P  S   S  K  Y  P  S   M  K  G  D  L  
ATTGTAGAATTTGAT ATTGTCTTTCCAAAA AGTTTAACCAGTGAA AAAAAAAAAATTATA AGAGAAACATTGGCA 
 I  V  E  F  D   I  V  F  P  K   S  L  T  S  E   K  K  K  I  I   R  E  T  L  A  
AATACATTCTAA 
 N  T  F  *  
 
 
7.1.3 Coding sequence for dd-FKBP !
ATGACTGCAGGAGTGCAGGTGGAAACCATCTCCCCAGGAGACGGGCGCACCTTC
CCCAAGCGCGGCCAGACCTGTGTGGTGCACTACACCGGGATGCTTGAAGATGGA
AAGAAAGTCGATTCCTCCCGGGACAGAAACAAGCCCTTTAAGTTTATGCTAGGC
AAGCAGGAGGTGATCCGAGGCTGGGAAGAAGGGGTTGCCCAGATGAGTGTGGG
TCAGAGAGCCAAACTGACTATATCTCCAGATTATGCCTATGGTGCCACTGGGCAC
CCAGGCATCATCCCACCACATGCCACTCTCGTCTTCGATGTGGAGCTTCTAAAAC
CGGAATAA 
 
7.1.4 Coding sequence for dd-ecDHFR 
 
ATCAGTCTGATTGCGGCGTTAGCGGTAGATCACGTTATCGGCATGGAAACCGTCA
TGCCGTGGAACCTGCCTGCCGATCTCGCCTGGTTTAAACGCAACACCTTAAATAA
ACCCGTGATTATGGGCCCCATACCTGGGAATCAATCGGTCGTCCGTTGCCAGGAC
GCAAAAATATTATCCTCAGCAGTCAACGAGTACGGACGATCGCGTAACGTGGGT
GAAGTCGGTGGATGAAGCCATCGCGGCGTGTGGTGACGTACCAGAAATCATGGT
TATTGGCGGCGGTCGCGTTTATGAACAGTTCTTGCCAAAAGCGCAAAATGTATCT
GACGCATATCGACGCAGAAGTGGAAGGCGACACCCATTTCCCGGATTACGAGCC
GGATGACTGGGAATCGGTATTCAGCGAATTCCACGATGCTGATGCGCAGAACTC
TCACAGCTATTGC 
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7.1.5 Coding sequence for DD29 
 
ATGGGAGTGCAGGTGGAAACCATCTCCCCAGGAGACGGGCGCACCTTCCCCAAG
GCCAGACCTGCGTGGTGCACTACACCGGGATGCTTGAAGATGGAAAGAAAGTTG
ATTCCTCCCGGGACAGAAACAAGCCCTTTAAGTTTATGCTAGGCAAGCAGGAGT
GATCCGAGGCTGGGAAGAAGGGGTTGCCCAGATGAGTGTGGGTCAGAGGCCAA
ACTGACTATATCTCCAGGTTATGCCTATGGTGCCACTGGGCACCCAGGCATCATC
CCATCACATGCCACTCTCGTCTTCCGTGTGGAGCTTCTAAAACTGGAATGA 
 
7.1.6 Coding sequence for 3XHA 
 
ATGTACCCGTACGACGTCCCGGACTACGCTGGCTATCCCTATGATGTGCCCGATT
ATGCGTATCCTTACGATGTTCCAGATTATGCCGAGCTC 
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7.2 Amino acid sequence alignments of  P. 
falciparum Hsp70-1 with E. coli DnaK 
 
 
 
DnaK           -------------MGKIIGIDLGTTNSCVAIMDGTTPRVLENAEGDRTTPSIIAYTQDGE 47 
PfHsp70-1      MASAKGSKPNLPESNIAIGIDLGTTYSCVGVWRNENVDIIANDQGNRTTPSYVAFTD-TE 59 
                                ******** ***.:    .  :: * :*:***** :*:*:  * 
 
DnaK           TLVGQPAKRQAVTNPQNTLFAIKRLIGRRFQDEEVQRDVSIMPFKIIAADNGDAWVEVK- 106 
PfHsp70-1      RLIGDAAKNQVARNPENTVFDAKRLIGRKFTESSVQSDMKHWPFTVKSGVDEKPMIEVTY 119 
                *:*: **.*.. **:**:*  ******:* :..** *:.  **.: :. : .  :**.  
 
DnaK           ---GQKMAPPQISAEVLKKMKKTAEDYLGEPVTEAVITVPAYFNDAQRQATKDAGRIAGL 163 
PfHsp70-1      QGEKKLFHPEEISSMVLQKMKENAEAFLGKSIKNAVITVPAYFNDSQRQATKDAGTIAGL 179 
                   : : * :**: **:***:.** :**: :.:***********:********* **** 
 
DnaK           EVKRIINEPTAAALAYGLD-KGTGNRTIAVYDLGGGTFDISIIEIDEVDGEKTFEVLATN 222 
PfHsp70-1      NVMRIINEPTAAAIAYGLHKKGKGEKNILIFDLGGGTFDVSLLTIED----GIFEVKATA 235 
               :* **********:****. **.*::.* ::********:*:: *::      *** **  
 
DnaK           GDTHLGGEDFDSRLINYLVEEFKK-DQGIDLRNDPLAMQRLKEAAEKAKIELSSAQQTDV 281 
PfHsp70-1      GDTHLGGEDFDNRLVNFCVEDFKRKNRGKDLSKNSRALRRLRTQCERAKRTLSSSTQATI 295 
               ***********.**:*: **:**: ::* ** ::  *::**:  .*:**  ***: *: : 
 
DnaK           NLPYITADATGPKHMNIKVTRAKLESLVEDLVNRSIEPLKVALQDAGLSVSDIDDVILVG 341 
PfHsp70-1      EIDSLFE----GIDYSVTVSRARFEELCIDYFRDTLIPVEKVLKDAMMDKKSVHEVVLVG 351 
               ::  :        . .:.*:**::*.*  * .. :: *:: .*:** :. ..:.:*:*** 
 
DnaK           GQTRMPMVQKKVAEFF-GKEPRKDVNPDEAVAIGAAVQGGVLTGD----VKDVLLLDVTP 396 
PfHsp70-1      GSTRIPKIQTLIKEFFNGKEACRSINPDEAVAYGAAVQAAILSGDQSNAVQDLLLLDVCS 411 
               *.**:* :*. : *** ***  :.:******* *****..:*:**    *:*:*****   
 
DnaK           LSLGIETMGGVMTTLIAKNTTIPTKHSQVFSTAEDNQSAVTIHVLQGERKRAADNKSLGQ 456 
PfHsp70-1      LSLGLETAGGVMTKLIERNTTIPAKKSQIFTTYADNQPGVLIQVYEGERALTKDNNLLGK 471 
               ****:** *****.** :*****:*:**:*:*  *** .* *:* :***  : **: **: 
 
DnaK           FNLDGINPAPRGMPQIEVTFDIDADGILHVSAKDKNSGKEQKITIKASSG-LNEDEIQKM 515 
PfHsp70-1      FHLDGIPPAPRKVPQIEVTFDIDANGILNVTAVEKSTGKQNHITITNDKGRLSQDEIDRM 531 
               *.**** **** :***********:***.*:* :*.:**:::***. ..* *.:***::* 
 
DnaK           VRDAEANAEADRKFEELVQTRNQGDHLLHSTRKQVEEAG--DK-LPADDKTAIESALTAL 572 
PfHsp70-1      VNDAEKYKAEDEENRKRIEARNSLENYCYGVKSSLEDQKIKEKLQPAEIETCMKTITTIL 591 
               *.***     *.: .: :::**. :.  :..:..:*:    :*  **: :*.:::  * * 
 
DnaK           ET----ALKGEDKAAIEAKMQELAQVSQKLMEIAQQQHAQQQTAGADASANNAKDDD--- 625 
PfHsp70-1      EWLEKNQLAGKDE--YEAKQKEAESVCAPIMSKIYQD-----AAGAAGGMPGGMPGGMPG 644 
               *      * *:*:   *** :*  .*.  :*.   *:     :*** ..   .        
 
DnaK           -----------------------VVDAEFEEVKDKK 638 
PfHsp70-1      GMPGGMNFPGGMPGAGMPGNAPAGSGPTVEEVD--- 677 
                                           .***.    !
Figure S.1 Amino acid sequence alignments of P. falciparum Hsp70-1 with E. coli DnaK.  
Based on the DnaK sequence E171 residue, important for the coupling of ATPase activity with substrate 
binding has been shown in PfHsp70-1 at the corresponding amino acid position 187 (Shown in red).  
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7.3 Episomal expression of WT/DN PfHsp70-1 and 
PfHsp40 where N- or C- terminus dd-FKBP is replaced 
with control GFP 
 
7.3.1 Episomal expression of WT/DN PfHsp70-1 fused to GFP on 
the N-terminus 
 
 
 
 !
Figure S.2 Episomal expression of WT/DN PfHsp70-1 fused to GFP on the N-terminus.  
(a) Schematic illustration of GFP-WTPfHsp70-1 fusion protein where the dd-FKBP is replaced with GFP. (b) 
Western blot analysis from the whole cell extract of cells expressing WTPfHsp70-1 N-terminally tagged to 
GFP. The fusion protein could be detected at the correct size of ~102 kDa with anti-HA antibody. (c) Schematic 
illustration of GFP-DNPfHsp70-1 fusion protein where the dd-FKBP is replaced with GFP. (b) Western blot 
analysis from the whole cell extract of cells expressing DNPfHsp70-1 N-terminally tagged to GFP. The fusion 
protein could be detected at the correct size of ~102kDa with anti-HA antibody. 1x107 cell equivalents were 
used for all the western blot analysis.  
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7.3.2 Episomal expression of WT/DN PfHsp40 fused to GFP on 
the C-terminus !
!
 
Figure S.3 Episomal expression of WT/DN PfHsp40 fused to GFP on the C-terminus.  
(a) Schematic illustration of GFP-WTPfHsp40 fusion protein where the dd-FKBP is replaced with GFP. (b) 
Western blot analysis from the whole cell extract of cells expressing WT PfHsp40 C-terminally tagged to GFP. 
The fusion protein could be detected at the correct size of ~67kDa with anti-HA antibody. (c) Schematic 
illustration of GFP-DNPfHsp70-1 fusion protein where the dd-FKBP is replaced with GFP. (d) Western blot 
analysis from the whole cell extract of cells expressing DNPfHsp40 C-terminally tagged to GFP. The fusion 
protein could be detected at the correct size of ~67kDa with anti-HA antibody. 1x107 cell equivalents were used 
for all the western blot analysis. !!!
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